 
 
 
A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to Assess the Clinical Efficacy 
of ISIS 721744, a Second -Generation Ligand -Conjugated Antisense Inhibitor of Prekallikrein, in 
Patients With Hereditary Angioedema.  
 
[STUDY_ID_REMOVED]  
 
5 May 2020  
  
 
IONIS PHARMACEUTICALS, IN C. 
 
 
ISIS 721744 -CS2 
 
A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study 
to Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients 
with Hereditary Angioedema  
 
Protocol Amendment 3 – 5 May 2020  
 
EudraCT No:  2019 -001044-22 
 
Trial Sponsor:  Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court  
Carlsbad, CA 92010  
Telephone Numbe r:  760-603-4665 
Fax Number:  760 -603-2625 
Key Sponsor Contact:   
 
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court  
Carlsbad, CA 92010  
 
 
  

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
2 ISIS 721744 -CS2 
Protocol Amendment 3 
EudraCT No:  2019 -001044-22 
 
Clinical Phase:  2a  
 
A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study 
to Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated Antisense Inhibitor of Prekallikrein , in Patients 
with Hereditary Angioedema  
 
Protocol History:  
Original Protocol:   3 May 2019  
Amendment 1:    21 October 2019  
Amendment 2:    29 January 2020  
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
Carlsbad, CA  92010  
 
 
 
 
  
 
 
Confidentiality Statement  
This document contains confidential information of Ionis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the Independent Ethics 
Committee, Institutional Review Board, or authorized regulatory agencies.  This information 
cannot be used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc.  

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
3 Protocol Signature Page  
 
Protocol Number:  ISIS 721744 -CS2 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to 
Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients with 
Hereditary Angioedema  
Amendment:   Amendment 3 
Date:   5 May 2020  
 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “A 
Randomize d, Double -Blind, Placebo -Controlled, Phase 2a Study to Assess the Clinical Efficacy 
of ISIS 721744, a Second -Generation Ligand -Conjugated Antisense Inhibitor of Prekallikrein, in 
Patients with Hereditary Angioedema,” dated 5 May 2020 , and agree to conduct the study as 
described herein.  
I agree to comply with the International Conference on Harmonisation Tripartite Guideline on 
Good Clinical Practice.  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
4 TABLE OF CONTENTS  
PROTOCOL AMENDMENT  ................................ ................................ ................................ .........8 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ..............12 
STUDY DESIGN AND TRE ATMENT SCHEMA  ................................ ................................ ......21 
STUDY GLOSSARY  ................................ ................................ ................................ .................... 22 
1. OBJECTIVES AND ENDPO INTS ................................ ................................ ............24 
1.1. Objectives  ................................ ................................ ................................ ................... 24 
1.1.1.  Primary Obj ective ................................ ................................ ................................ .......24 
1.1.2.  Secondary Objectives  ................................ ................................ ................................ .24 
1.1.3.  Exploratory Objectives  ................................ ................................ ............................... 24 
1.2. Study Endpoints  ................................ ................................ ................................ ..........24 
1.2.1.  Primary Endpoints  ................................ ................................ ................................ ......24 
1.2.2.  Secondary Endpoints  ................................ ................................ ................................ ..24 
1.2.3.  Safety Endpoints  ................................ ................................ ................................ .........25 
1.2.4.  Exploratory Endpoints  ................................ ................................ ................................ 25 
2. BACKGROUND AND RATIO NALE ................................ ................................ .......25 
2.1. Overview of Disease  ................................ ................................ ................................ ...25 
2.2. Therapeutic Rationale  ................................ ................................ ................................ .26 
2.3. ISIS 721744 ................................ ................................ ................................ ................ 26 
  
  
2.3.3.  Preclinical Experience  ................................ ................................ ................................ 28 
2.3.4. Clinical Experience  ................................ ................................ ................................ .....28 
2.4. Rationale for Dose and Schedule of Administration  ................................ .................. 29 
2.5. Benefit-Risk Assessment  ................................ ................................ ............................ 29 
2.5.1.  Benefit Assessment  ................................ ................................ ................................ .....29 
2.5.2.  Risk Assessment  ................................ ................................ ................................ .........29 
2.5.3.  Overall Assessment of Benefit:Risk  ................................ ................................ ...........30 
3. EXPERIMENTAL PLAN  ................................ ................................ .......................... 30 
3.1. Study Design ................................ ................................ ................................ ...............30 
3.2. Number of Study Centers  ................................ ................................ ........................... 31 
3.3. Number of Patients  ................................ ................................ ................................ .....31 
3.4. Overall Study Duration and Follow -up ................................ ................................ ......31 
3.4.1.  Screening  ................................ ................................ ................................ .................... 31 
3.4.2.  Treatment Period  ................................ ................................ ................................ ........31 
3.4.3.  Post-Treatment Period  ................................ ................................ ................................ 32 
3.5. End-of-Study ................................ ................................ ................................ ...............32 
3.6. Data and Safety Monitoring Board  ................................ ................................ .............32 
4. PATIENT ENROLLMENT  ................................ ................................ ........................ 32 
4.1. Screening  ................................ ................................ ................................ .................... 32 

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
5 4.2. Randomization  ................................ ................................ ................................ ............33 
4.3. Replacement of Patients  ................................ ................................ ............................. 33 
4.4. Unblinding of Treatment Assignment  ................................ ................................ ........33 
5. PATIENT ELIGIBILITY  ................................ ................................ ........................... 34 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........34 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......35 
6. STUDY PROCEDURES  ................................ ................................ ............................ 36 
6.1. Study Schedule ................................ ................................ ................................ ...........36 
6.1.1.  Screening  ................................ ................................ ................................ .................... 37 
6.1.2.  Treatment Period  ................................ ................................ ................................ ........37 
6.1.3.  Post-Treatment Period  ................................ ................................ ................................ 38 
6.2. Study Assessments ................................ ................................ ................................ ......39 
6.2.1.  Collection of Hereditary Angioedema Attack Details  ................................ ................ 39 
6.2.2.  Patient-Reported Outcomes  ................................ ................................ ........................ 40 
6.2.2.1.  Angioedema Quality of Life Questionnaire  ................................ ............................... 40 
6.2.2.2.  Angioedema Activity Score  ................................ ................................ ........................ 40 
6.2.3.  Laboratory Assessments  ................................ ................................ ............................. 41 
6.3. Restriction on the Lifestyle of Patients  ................................ ................................ .......41 
6.3.1.  Contraception Requirements  ................................ ................................ ...................... 41 
7. STUDY DRUG  ................................ ................................ ................................ ...........42 
7.1. Study Drug Description  ................................ ................................ .............................. 42 
7.2. Packaging and Labeling  ................................ ................................ .............................. 42 
7.3. Study Drug Accountability  ................................ ................................ ......................... 42 
8. TREATMENT OF PATIENT S ................................ ................................ .................. 43 
8.1. Study Drug Administration ................................ ................................ ......................... 43 
8.2. Other Protocol -Required Drugs  ................................ ................................ .................. 43 
8.3. Other Protocol -Required Treatment Procedures  ................................ ........................ 43 
8.4. Treatment Precautions  ................................ ................................ ................................ 43 
8.5. Safety Monitoring Rules  ................................ ................................ ............................. 43 
8.5.1.  Safety Monitoring Rules for Liver Chemistry Tests  ................................ .................. 44 
8.5.2.  Safety Monitoring Rules for Platelet Count Results ................................ ................... 44 
8.5.3.  Safety Monitoring Rules for Renal Function Test Results  ................................ .........45 
8.5.4.  Safety Monitoring for Minor Bleedin g Events ................................ ........................... 45 
8.6. Stopping Rules  ................................ ................................ ................................ ............45 
8.6.1.  Stopping Rules for Liver Chemistry Elevations  ................................ ......................... 45 
8.6.2.  Stopping Rules for Platelet Count Results  ................................ ................................ ..46 
8.6.3.  Temporary Stopping Rules for Renal Function Test Results ................................ .....48 
8.7. Adjustment of Dose and/or Treatment Schedule  ................................ ........................ 48 
8.8. Discontinuation of Study Drug  ................................ ................................ ................... 48 
8.9. Withdrawal of Patients from the Stu dy Procedures  ................................ .................... 49 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
6 8.10.  Concomitant Therapy and Procedures  ................................ ................................ ........49 
8.10.1.  Concomitant Therapy  ................................ ................................ ................................ .49 
8.10.2. Concomitant Procedures  ................................ ................................ ............................. 50 
8.11.  Treatment Compliance  ................................ ................................ ................................ 50 
9. SERIOUS AND NON -SERIOUS ADVERSE EVENT RE PORTING  ..................... 50 
9.1. Sponsor Review of Safety Information  ................................ ................................ ......50 
9.2. Regulatory Requirements  ................................ ................................ ........................... 50 
9.3. Definitions  ................................ ................................ ................................ .................. 51 
9.3.1.  Adverse Event ................................ ................................ ................................ .............51 
9.3.2.  Adverse Drug Reaction and Unexpected Suspected Adverse Drug Reaction  ............51 
9.3.3.  Serious Adverse Event  ................................ ................................ ................................ 52 
9.3.4. Adverse Events of Special Interest  ................................ ................................ .............52 
9.4. Monitoring and Recording Adverse Events  ................................ ............................... 52 
9.4.1.  Serious Adverse Events  ................................ ................................ .............................. 53 
9.4.2. Non-Serious Adverse Events  ................................ ................................ ...................... 53 
9.4.3.  Evaluation of Adverse Events (Serious and Non -Serious) ................................ .........53 
9.4.3.1.  Relationship to the Study Drug ................................ ................................ ................... 53 
9.4.3.2.  Severity ................................ ................................ ................................ ....................... 54 
9.4.3.3.  Action Taken with Study Drug  ................................ ................................ ................... 54 
9.4.3.4.  Treatment Given for Adverse Event  ................................ ................................ ...........54 
9.4.3.5.  Outcome of the Adverse Event  ................................ ................................ ................... 54 
9.4.3.6.  Follow-up of Adverse Event  ................................ ................................ ....................... 55 
9.5. Procedures for Handling Special Situations  ................................ ............................... 56 
9.5.1.  Abnormalities of Laboratory Tests  ................................ ................................ .............56 
9.5.2.  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ................ 56 
9.5.3.  Dosing Errors  ................................ ................................ ................................ ..............56 
9.5.4.  Contraception and Pregnancy  ................................ ................................ ..................... 57 
10. STATISTICAL CONSIDER ATIONS ................................ ................................ .......57 
10.1.  Sample Size Considerations  ................................ ................................ ....................... 58 
10.2.  Populations  ................................ ................................ ................................ ................. 58 
10.3.  Definition of Baseline  ................................ ................................ ................................ .58 
10.4.  Data and Safety Monitoring Board  ................................ ................................ .............58 
10.5.  Interim Analysis  ................................ ................................ ................................ ..........59 
10.6.  Planned Methods of Analysis  ................................ ................................ ..................... 59 
10.6.1.  Demographic and Baseline Characteristics  ................................ ................................ 59 
10.6.2.  Safety Analysis  ................................ ................................ ................................ ...........59 
10.6.3.  Efficacy Analysis  ................................ ................................ ................................ ........59 
10.6.3.1. Primary Efficacy Analysis  ................................ ................................ .......................... 60 
10.6.3.2.  Secondary Efficacy Analysis  ................................ ................................ ...................... 60 
10.6.3.3.  Exploratory Efficacy Analysis  ................................ ................................ .................... 60 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
7 10.6.4.  Pharmacokinetic Analysis  ................................ ................................ .......................... 60 
11. INVESTIGATOR’S REGUL ATORY OBLIGATIONS  ................................ ...........61 
11.1.  Informed Consent  ................................ ................................ ................................ .......61 
11.2.  Ethical Conduct of the Study  ................................ ................................ ...................... 61 
11.3.  Independent  Ethics Committee/Institutional Review Board  ................................ ......61 
11.4.  Patient Confidentiality  ................................ ................................ ................................ 62 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ................................ ..............62 
12.1.  Protocol Amendments  ................................ ................................ ................................ 62 
12.2.  Study Termination  ................................ ................................ ................................ ......63 
12.3.  Study Documentation and Storage  ................................ ................................ .............63 
12.4.  Study Monitoring  ................................ ................................ ................................ ........63 
12.5.  Language  ................................ ................................ ................................ ..................... 64 
12.6.  Compensation for Injury  ................................ ................................ ............................. 64 
13. REFERENCES  ................................ ................................ ................................ ...........65 
14. APPENDICES  ................................ ................................ ................................ ............66 
APPENDIX  A. SCHEDULE OF PROCEDUR ES ................................ ................................ .....67 
APPENDIX  B. LIST OF LABORATORY A NALYTES  ................................ .......................... 72 
APPENDIX  C. PHARMACOKINETIC SAMP LING SCHEDULE  ................................ .........74 
APPENDIX  D. GRADING SCALE FOR AD VERSE EVENTS RELATIN G TO 
LABORATORY ABNORMALI TIES ................................ .............................. 76 
 
 
LIST OF TABLES  
Table 1: Study Drug Characteristics  ................................ ................................ ......................... 42 
Table 2: Actions in Patients with Low Platelet Count  ................................ .............................. 47 
 
 
LIST OF  FIGURES  
Figure 1: Design of GalNAc 3-Conjugated Chimeric 2ʹ -MOE Phosphorothioate 
Oligonucleotides (MOE -Gapmer) ................................ ................................ ..............27 
 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
8 PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 721744 -CS2 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to 
Assess the Clinical Efficacy of ISIS 721744, a Second-Generation 
Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients 
with Hereditary Angioedema  
Amendment Number:  3 
Amendment Date:  5 May 2020  
 
The following modification s to Protocol  ISIS 721744 -CS2 Amendment 2, dated 29 January 
2020, have been made.  
1) To adjust the length of time patients must not have received lanadelumab , prior to 
screening for ISIS 721744 -CS2, from 6 months to 10 weeks  (i.e., 5 times the ~14-day 
half life for lanadelumab) .  
2) To decrease the burden of site visits where feasible for patients, Study Drug 
administration, assessements and procedures may be conducted by either a Home 
Healthcare professional  (if available) or the Study Center, as arranged by the Study 
Center personnel, for visits as noted in Appendix  A. 
3) To decrease the burden of PK sampling for patients, only a subgroup of approximately 
6 patients (rather than all patients) will have blood draws of pre -dose, 1, 2, 4, and 6 hours 
post-dose on Day 1 and Day 85.  This, along with a pre -dose and a 2 hour post -dose 
blood collection on Day 1 and Day 85 in all patients, will provide enough information to 
determine PK parameters.  
Minor changes (not included in the lis t of changes below) have been made throughout the 
protocol to correct errors and/or to improve the overall clarity of the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
9 The following table provid es a summary list of major changes to the protocol : 
Protocol Section  Description of Change  Rationale  
PROTOCOL 
SYNOPSIS  
Study Population 
Exclusion Criteria  
 
Section 5.2.11.b 
Exclusion Criteria  Deletions in strikeout and additions in bold:  
11.b  Chronic prophylaxis with  Llanadelumab within 
10 weeks 6 months prior to Screening  To adjust the length of time 
patients must not have received 
lanadelumab, prior to screening 
for ISIS 721744 -CS2, to 
5 times the ~14 day half life for 
lanadelumab.  
PROTOCOL 
SYNOPSIS  
Study Visit Schedule 
and Procedures  
 
Section 6.1.2  
Treatment Period  Deletions in strikeout and additions in bold:  
The first dose of Study Drug will be administered at the 
Study Center on Day  1.  ISIS 721744 Study Drug  will be 
administered as a SC injection in the abdomen, thigh, or 
outer area of the upper arm by qualified personnel at the 
Study Center or Home Healthcare professional  (if 
available  and after dosing inst ructions and training are 
provided by qualified site personnel ).  The first dose of 
Study Drug will be administered at the Study Center on 
Day 1.  Study visits Center person nel (or Home 
Healthcare if available), will complete  procedures   per 
the Schedule of Procedures in  Appendix A . will be 
performed during the Treatment Period at Week  1 
(Administration 1), Week 3 (safety monitoring), Week 5 
(Administration 2), Week 9 (Administration  3), and Week 
13 (Administration  4); Home healthcare provided to 
decrease the burden of site 
visits, where feasible, for 
patients. 
Section 6.1.3 
Post-Treatment 
Period Additions in bold:  
Each patient will  be followed for safety assessments for up 
to 13 weeks after the last dose of Study Drug.  During the 
Post-Treatment Period, patients will return to the Study 
Center (or have Home Healthcare (if available), as 
arranged by the Study Center personnel, per th e 
Schedule of Procedures in Appendix A)  for visits at 
Weeks 17, 21, and 26/ET for safety and clinical laboratory 
evaluations and for blood sampling for PK/PD analyses.   Home healthcare provided to 
decrease the burden of site 
visits, where feasible, for 
patients. 
Section 8.1 
Study Drug 
Administration  Additions in bold:  
Study Drug (ISIS 721744 or placebo) will be administered 
as a single -SC injection once every 4  weeks by blinded 
study staff during on -site visits a t the Study Centers or by 
Home Healthcare professional  (if available  and after 
dosing inst ructions and training are provided by 
qualified site personnel ).   Home healthcare provided to 
decrease the burden of site 
visits, where feasible, for 
patients. 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
10 Protocol Section  Description of Change  Rationale  
Section 10.6.4 
Pharmacokinetics 
Analysis Deletions in strikeout and a dditions in bold : 
The plasma PK of ISIS 721744 will be assessed following 
SC administration.  For all patients, pre -dose (trough) and 
post-treatment plasma ISIS 721744 concentrations will 
be determined and summarized using descriptive 
statistics.  Plasma terminal elimination half -life will also 
be calculated using the Post-Treatment follow up 
ISIS 721744 plasma concentrations, if data permits. For 
patients in the PK sub group, n Non-compartmental PK 
analysis of ISIS 721744 will be carried out on each 
individual patient dataset.   Added paragraph to define how 
PK data will be analyzed and 
described  
STUDY 
GLOSSARY  
 
Section 10.6.4 
Pharmacokinetics 
Analysis Additions in bold:  
Additional details regarding the PK analysis along with  
immunogenicity ( IM) analysis will be described in the 
SAP. Added “along with IM 
analysis” to clarify that 
immunogenicity analysis will 
be performed  
Appendix  A 
Footnote  Added: 
17 Assessments and procedures may be conducted by either 
a Home Healthcare professional (if available), or the 
Study Center as arranged by the Study Center personnel.  
Physical Exam will be labeled Body Assessment if 
conducted by Home Healthcare professional.   Study drug 
administration by Home Healthcare professional may be 
done only after study drug for home use is available  Home healthcare provided to 
decrease the burden of site 
visits, where feasible, for 
patients 
Appendix  A 
Footnote  Additions in bold:  
b Pre-dose, 1, 2, 4, and 6 hours post -dose (PK Subgroup) 
or Pre-dose and 2 -hours post -dose Added to note changes in PK 
schedule 
Appendix  A  Removed:  
Week 3 pregnancy test  Pregnancy test only needed 
every 4 weeks  
Appendix  B  Removed  
Thyroid Panel  
TSH 
Free T4 
Free T3 Thyroid panel is not a per 
protocol assessment  
Appendix  C  Added: 
PK samples on Day 1 and Day 85 will be collected pre -dose, 
and 1, 2, 4, and 6 hours post -dose in PK subgroup only 
(approximately 6 patients) while pre -dose and 2 hours post -
dose samples  on Day 1 and Day 85  will be collected for all 
other patients. The rest of the sampling schedule will be the 
same for both sets of pateints ( see table below ): Added to describe PK sampling  
ISIS 721744-CS2 CONFIDENTIAL Amendment 3 
Protocol 5 May 2020 
11 Protocol 
Section Description of Change Rationale 
Appendix C Addions in bold: 
Day 1 Day 15 Day 29 Day 57 Day 85 Day 113 Day 141 Day 176 
All Patients Blood: Pre-dose, 2 hours post-dose Blood Anytime Blood: Pre-dose Blood: Pre-dose Blood: Pre-dose, 2 hours post-dose Blood Anytime Blood Anytime Blood Anytime 
PK Subgroup Blood:  Pre-dose, 
1, 2, 4, 
and 6 hours post-dose Blood: Anytime Blood: Pre-dose Blood: Pre-dose Blood:  Pre-dose, 
1, 2, 4, 
and 6 hours post-dose Blood:  Anytime Blood: Anytime Blood: Anytime 
To decrease the burden of PK sampling for patients, only a subgroup of approximately 
6 patients (rather 
than all patients) will have blood draws of pre-dose, 1, 2, 4, and 
6 hours post-
dose on Day 1 and Day 85. 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
12 PROTOCOL SYNOPSIS  
Protocol Title  A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to Assess the 
Clinical Efficacy of ISIS  721744, a Second -Generation Ligand -Conjugated Antisense 
Inhibitor of Prekallikrein, in Patients with Hereditary Angioedema  
Study Phase  2a 
Indication  Hereditary angioedema (HAE)  
Primary 
Objective  The primary objective of the study is to evaluate the clinical efficacy of antisense 
inhibitor of prekallikrein (ISIS  721744) in patients with HAE type 1 (HAE -1), HAE 
type 2 (HAE -2), or HAE with normal C1 -inhibitor (C1 -INH). 
Secondary 
Objectives  The secondary objectives of the study are to evaluate safety and tolerability of 
ISIS 721744 in patients with HAE -1/HAE-2 or HAE with normal C1 -INH (HAE -nC1-
INH) and to evaluate the effect of ISIS  721744 on plasma prekallikrein (PKK) and 
other relevant biomarkers.   
Exploratory 
Objectives  The exploratory objectives of the study are to  evaluate pharmacokinetics (PK) of 
ISIS 721744 (as a total full -length antisense oligonucleotide (ASO), including fully 
conjugated, partially conjugated, and unconjugated ISIS  721744) over time and to 
assess potential PK/pharmacodynamic (PD) correlations o n relevant biomarkers and 
clinical outcomes, as appropriate.   
Study Design  The study will be randomized, double -blind, and placebo -controlled in Part  A and will 
be open-label in Part B.  
Number of 
Patients Approximately 24 patients with HAE are planned t o be enrolled in the study:  
approximately 18 patients with HAE -1/HAE-2 are planned to be enrolled in Part A of 
the study, and, in parallel, approximately 6  patients with HAE -nC1-INH are planned to 
be enrolled in Part B of the study.  Due to the rarity of HAE-nC1-INH, enrollment in 
Part B may be ended early if Study Centers are unable to enroll sufficient patients with 
HAE-nC1-INH; this will not impact completion of Part  A. 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
13 PROTOCOL SYNOPSIS CONTINUED  
Study 
Population  Inclusion Criteria  
1. Patients must provide written informed consent (signed and dated) and any 
authorizations required by local law and be able to comply with all study 
requirements for the duration of the study.  
2. Patients must be aged ≥  18 years at the time of informed consent.  
3. Patients must have a documented diagnosis of HAE -1/HAE-2 (for inclusion in 
Part A) or HAE -nC1-INH (for inclusion in Part B) as defined below:  
a. Documented diagnosis of HAE -1/HAE-2 based upon ALL of the following:  
i. Documented clinical history consistent with HAE (su bcutaneous [SC] or 
mucosal, non -pruritic swelling episodes without accompanying urticaria) 
(Maurer et al. 2018 ). 
ii. Diagnostic testing results that confirm HAE -1/HAE-2:  C1-INH functional 
level < 40% normal level.  Patients with a functional level of  40% to 50% 
of normal can be enrolled if their complement factor C4 (C4) level is 
below the lower limit of normal (LLN) or if a known pathogenic mutation 
in the SERPING1  gene has been demonstrated.  
iii. At least 1 of the following:  age at reported HAE onset ≤ 30 years; a 
family history consistent with HAE -1/HAE-2; or complement component 
1q within the normal range.  
b. Documented diagnosis of HAE -nC1-INH based upon documented clinical 
history consistent with HAE (SC or mucosal, non -pruritic swelling episodes 
without accompanying urticaria) (Maurer et al. 2018 ) AND any 1 of the 
following:  
i. A clinical diagnosis of bradykinin  (BK)-mediated angioedema as 
confirmed with threshold -stimulated kallikrein activity and 
Investigator -confirmed response to acute use of a BK targeted treatment 
(icatibant or ecallantide -). 
ii. One (1) of the established mutations (c.1032C>A, Thr309Lys; 
c.1032C>G, Thr309Arg; c.971_1018+24del72*; or c.892_909dup) in the 
factor XII gene.  
iii. The established mutation in the plasminogen gene (c.988A >G, 
p.Lys330Glu).  
iv. The established mutation in the angiopoietin -1 gene (c.355G>T, 
p.A119S).  
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
14 PROTOCOL SYNOPSIS CONTINUED  
Study 
Population 
Continued  Inclusion Criteria Continued  
4. Patients must:  
a. Experience a minimum of 2 HAE attacks (assessed by the Angioedema 
Activity Score [AAS] and confirmed by the Investigator) during the 
Screening Period.  
b. Complete the AAS questionnaire on a daily basis (minimum of 4  daily 
assessments per week) for the duration of the Screening Period.  
5. Patients must have acc ess to, and the ability to use, ≥  1 acute medication(s) (e.g., 
plasma-derived or recombinant C1 -INH concentrate or a BK2 -receptor antagonist) 
to treat angioedema attacks.  
6. Female patients must be non -pregnant (and not planning a pregnancy during the 
study) and non -lactating, and be either:  
a. Surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, 
or bilateral oophorectomy).  
b. Post-menopausal (defined as 12 months of spontaneous amenorrhea in females 
> 55 years of age or, in females ≤  55 years of age, 12  months of spontaneous 
amenorrhea without an alternative medical cause and follicle-stimulating 
hormone [FSH] levels in the post -menopausal range for the laboratory 
involved).  
c. Abstinent (only acceptable as true abstinence, i.e., when in line with the 
preferred and usual lifestyle of the patient; periodic abstinence [e.g., calendar, 
ovulation, symptothermal, or post -ovulation methods], declaration of 
abstinence for the duration of the study, or withdrawal are not acceptable 
methods of contraception).  
d. If engaged in sexual relations of childbearing potential, agree to use highly 
effective contraceptive methods (refer to Section  6.3.1) from the time of 
signing the informed consent form (ICF) until at least 24  weeks after the last 
dose of Study Drug (ISIS 721744 or placebo).  
7. Male patients must be surgically sterile or, if engaged in sexual relations with a 
female of childbearing potential, the patient must agree to use  a highly effective  
contraceptive method (refer to Section  6.3.1) from the time of signing the ICF until 
at least 24 weeks  after the last dose of Study Drug (ISIS  721744 or placebo).  
Exclusion Criteria  
1. Anticipated use of short -term prophylaxis for angioedema attacks for a pre -planned 
procedure during the S creening or Study Periods.  
2. Concurrent diagnosis of any other type of recurrent angioedema, including acquired 
or idiopathic angioedema.  
3. Anticipated change in the use of concurrent androgen prophylaxis used to treat 
angioedema attacks.  
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
15 PROTOCOL SYN OPSIS CONTINUED  
Study 
Population 
Continued  Exclusion Criteria Continued  
4. Any clinically significant abnormalities in screening laboratory values that would 
render a patient unsuitable for inclusion in the study.  The following values are 
exclusionary:  
a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
> 2.5 × upper limit of normal (ULN).  
b. Bilirubin >  1.5 × ULN unless due to Gilbert’s syndrome.  
c. Platelet count < LLN  
d. Estimated glomerular filtration rate (eGFR) <  60 mL/min (as determined by 
the Cockcroft Gault - Equation for creatinine clearance)  
e. aPTT > 1.5 × ULN 
5. Patients with a history of acquired coagulopathies or bleeding diathesis (e.g. , 
thrombocytopenia, disseminated intravascular coagulation, coagulopathy of liver 
disease, drug -induced platelet dysfunction, hyperfibrinolysis, acquired clotting 
factor inhibitors) and inherited bleeding disorders (e.g., hemophilia A, hemophilia 
B, other clotting factor deficiencies, qualitative platelet disorders, inherited 
thrombocytopenia, vascular abn ormalities).  
6. Any clinically significant renal or hepatic diseases.  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not 
be completed prior to dosing.  
8. Active infection with HIV, hepatitis C or hepatitis B diagnosed b y initial 
serological testing and confirmed with RNA testing, or prior treatment for hepatitis 
C.  Patients at Screening who test positive by serology, but negative by RNA may 
be allowed in consultation with the Sponsor Medical Monitor.  
9. Malignancy with in 5 years, except for basal or squamous cell carcinoma of the skin 
or carcinoma  in situ of the cervix that has been successfully treated.  
10. Treatment with another investigational drug or biological agent within 1  month or 
5 half-lives, whichever is long er, of Screening.  
11. Exposure to any of the following medications:  
a. Angiotensin -converting enzyme (ACE) inhibitors or any estrogen -containing 
medications with systemic absorption (such as oral contraceptive or hormonal 
replacement therapy) within 4  weeks prior to Screening.  
b. Chronic prophylaxis with lanadelumab within 10 weeks prior to Screening.  
c. Oligonucleotides (including small interfering RNA) within 4  months of 
Screening if single dose received, or within 12  months of Screening if 
multiple doses receive d. 
12. Any condition that, in the opinion of the Investigator, may compromise the 
patient’s safety or compliance, preclude successful conduct of the study, or 
interfere with the interpretation of results  
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
16 PROTOCOL SYNOPSIS CONTINUED  
Prohibited 
Concomitan t 
Medications  The following medications/procedures will not be permitted during the study:  
• Chronic prophylaxis for angioedema attacks, except for a stable dose of 
androgens.  Any use of lanadelumab will not be permitted.  
NOTE:  The use of acute medications (plasma -derived or recombinant C1 -INH 
concentrate or BK2 -receptor antagonist) to treat angioedema attacks is allowed as 
medically indicated.  
• ACE inhibitors or any estrogen -containing medications with systemic absorption 
(such as oral contraceptive or hormonal replacement therapy).  
• Any oligonucleotides (including small interfering RNA) other than ISIS  721744. 
• Plasmapheresis.  
• Any other investigational drug or device.  
Treatment 
Groups A total of approximately 24 patients in Part s A and B combined will be administered 
SC injections of ISIS  721744 80 mg or placebo every 4  weeks.  Patients will be 
allocated into Part A or Part B according to type of HAE, (i.e., either HAE -1/HAE-2 in 
Part A or HAE -nC1-INH in Part  B) as follows:  
• In Part A, approximately 18  patients with HAE -1/HAE-2 will be randomized to 
SC injections of ISIS  721744 80 mg or placebo in a 2:1  ratio 
(ISIS 721744:placebo).   
• In Part B, approximately 6 patients with HAE -nC1-INH will be administered 
open-label SC injections  of ISIS 721744 80 mg.  Due to the rarity of 
HAE-nC1-INH, enrollment in Part B may be ended early if Study Centers are 
unable to enroll sufficient patients; this will not impact the completion of Part  A. 
Study Drug 
Dosage and 
Administration  The Study Drug  (ISIS 721744 or placebo) is contained in 2 -mL stoppered glass vials.  
The Study Drug (ISIS 721744 or placebo) and its storage and preparation instructions 
will be provided by the Sponsor or designee.  The Study Drug (ISIS 721744 or 
placebo) must be stored  securely at 2  °C to 8 °C and be protected from light.  
During the Treatment Period, Study Drug (ISIS  721744 or placebo) will be 
administered as a single SC injection every 4 weeks .  
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
17 PROTOCOL SYNOPSIS CONTINUED  
Rationale for 
Dose and 
Schedule 
Selection  The dose level of 80  mg every 28 days was selected based on the safety, tolerability, 
PK, and PD data from the ISIS 721744 -CS1 study in healthy volunteers.  The Phase 1 
study evaluated doses of 20, 40, 60, and 80 mg ISIS 721744 administered once every 
4 weeks for a total of 12 weeks.  All dose levels were generally well -tolerated and 
induced a dose and exposure -dependent reduction in plasma PKK, a biomarker for BK 
and vascular permeability.  The highest dose level of 80 mg produced near -complete 
reduction of  plasma PKK levels (a mean reduction of 93.6% from Baseline on Day 99 
[2 weeks after the last dose]).  The estimated half -life (t½) from the Phase 1 PK data 
was approximately 4 to 5 weeks, supporting the once -every-28-day dosing regimen.  
Pharmacokinetic/P D analysis of the Phase 1 data suggested very minor differences in 
plasma PKK reductions at doses higher than 80 mg.  
Adjustment of 
Dose and/or 
Treatment 
Schedule  Down-titration of Study Drug (ISIS 721744 or placebo) will not be allowed during the 
study. 
Action taken with Study Drug (ISIS 721744 or placebo) due to an adverse event (AE) 
is characterized by 1 of the following:  
• None:  No changes made to Study Drug (ISIS 721744 or placebo) administration 
and dose.  
• Not Applicable:  AE reported during the Screening Period prior to Study Drug 
(ISIS 721744 or placebo) administration.  
• Permanently Discontinued:  Study Drug (ISIS 721744 or placebo) discontinued 
and not restarted.  
• Temporarily Interrupted, Restarted – Same Dose:  Dosing and/or dosing 
frequency tem porarily interrupted/changed or delayed due to the AE and restarted 
at the same dose.  
Study Visit 
Schedule and 
Procedures  The study will be conducted concurrently in 2 parts (Part A and Part B); patients will 
be allocated into Part  A or Part B according t o type of HAE (i.e., either HAE -1/HAE-2 
in Part A or HAE -nC1-INH in Part B).  Part A is randomized, double -blind, and 
placebo-controlled; and Part B is open -label.  The study visit schedule and procedures 
are nearly identical in Part A and Part  B, and thus  are presented together; any 
differences are indicated where applicable.  
Patients will be screened for eligibility criteria following written informed consent.   
During the Screening Period, the following assessments will be performed:  
demographics; medical history, including a detailed HAE history; prior and 
concomitant medications, including type of prophylaxis (if used) and type of acute 
treatment; HIV, hepatitis B, and hepatitis C screening; pregnancy testing for women of 
childbearing potential an d FSH testing for confirmation of menopause per inclusion 
criteria; quality of life as assessed by the angioedema quality of life (AE QoL) 
questionnaire; attack frequency, as assessed by the AAS daily during up to 
8 consecutive weeks, and confirmed by the Investigator; HAE attack assessment; 
physical examinations, including vital signs, body height, and weight; 
electrocardiograms (ECGs); AEs; PD blood sampling; inflammatory panel; and clinical 
laboratory assessments (chemistry, hematology, coagulation, and urinalysis).   
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
18 PROTOCOL SYNOPSIS CONTINUED  
Study Visit 
Schedule and 
Procedures 
Continued  Threshold stimulated kallikrein activity will be assessed only in patients who have 
HAE-nC1-INH without a factor XII mutation or the plasminogen or angiopoietin -1 
mutation.  Genetic testing will be performed only for patients who do not have HAE 
genetic di agnostic testing results prior to Screening.   
During the Screening Period, patients must experience a minimum of 2 HAE attacks 
(assessed by the AAS and confirmed by the Investigator) to be eligible for the study; 
patients will be instructed to report deta ils of any HAE attack to the study site within 
72 hours of the onset of the attack.  Throughout the Screening Period, site personnel 
will contact the patient once a week (at approximately 7 days after the last contact with 
the patient) in order to inquire about any attack that may have occurred.  If a patient 
experiences a third attack, the patient should be randomized as soon as possible, 
assuming all other screening activities have been completed and the patient meets all 
other eligibility requirements; i n such cases, the Screening Period may be shorter than 
8 weeks. 
During the course of the study, the use of acute medications (plasma derived or 
recombinant C1 INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to 
treat angioedema attacks is  allowed as medically indicated.  Patients can be treated 
with on demand therapy as determined by their treating physician.  
After a Screening Period of up to 8 weeks, those patients who had at least 
2 documented attacks (assessed by the AAS and confirmed b y the Investigator) during 
the Screening Period will be enrolled and/or randomized to receive ISIS 721744 80 mg 
or placebo (Part A) or open label ISIS 721744 80 mg (Part B) every 4 weeks for a total 
Treatment Period of 12 weeks.  
Study Drug will be administ ered as a SC injection in the abdomen, thigh, or outer area 
of the upper arm by qualified personnel at the Study Center or Home Healthcare 
professional (if available and after dosing instructions and training are provided by 
qualified site personnel).  The  first dose of Study Drug will be administered at the 
Study Center on Day 1.  Study Center person nel (or Home Healthcare if available), 
will complete procedures  per the Schedule of Procedures in Appendix  A.  After 
completion of the Week 13 visit, eligible patients may elect to enroll in the Open -Label 
Extension (OLE) Study (ISIS  721744-CS3), pending study approval by the IRB/IEC 
and the appropriate regulat ory authority, and will need to sign the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) approved informed consent.  Patients 
who complete Study Visit Week 17, and meet eligibility requirements, may start the 
treatment period in the CS3 s tudy anytime after the Week 17 visit and discontinue 
participation in the CS2 Post -Treatment Evaluation Period.  
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
19 PROTOCOL SYNOPSIS CONTINUED  
Study Visit 
Schedule and 
Procedures 
Continued  During the study, patients will be instructed to report details of any HAE attack to the 
study site within 72 hours of the onset of the attack.  During the Treatment and 
Post-Treatment Periods, the following data will be collected:  daily AAS and number 
of HAE attacks (assessed by the AAS and confirmed by the Investigator ); number of 
HAE attacks that required on -demand treatment; HAE attack details, including 
localization, severity, course, and details of any required treatment (i.e., frequency and 
dose); and vital signs.  Throughout the Treatment and Post -Treatment Period s, site 
personnel will contact the patient once a week (at approximately 7 days after the last 
contact with the patient) in order to inquire about any attack that may have occurred.  
In addition, at study visit  time points , site personnel will inquire abou t any new HAE 
attack information that was not provided through patient contact with the site.  See 
Section 6.2.1 for further information on the collection of data surrounding HAE 
attacks. 
Additionally, blood will be collected at every visit during the Treatment and 
Post-Treatment Periods to assess PD and coagulation parameters, including, but not 
limited to:  plasma  PKK, plasma proenzyme activation, cleaved high molecular weight 
kininogen (cHK) levels, D -dimer levels, activated partial thromboplastin time (aPTT), 
plasmin-antiplasmin complexes, C4 split products, and platelet counts.  Blood samples 
will also be collec ted regularly throughout the study for safety and PK/PD analyses.  
Additional assessments will be performed throughout the study as indicated in the 
Schedule of Procedures table in Appendix  A. 
Patients who discontinue treatment will remain in the study and attend the Early 
Termination (ET) Visit unless consent is withdrawn.  
Detailed information regarding the CS2 procedures is presented in Section  6 and 
Appendix  A.  Appendix B includes a list of laboratory analytes required for the study.  
Primary 
Endpoint  The primary endpoint is the time -normalized number of HAE attacks (per month) from 
Week 1 to Week  17. 
Secondary 
Endpoints  Secondary endpoints include the following:  
• The time-normalized number of HAE attacks (per month) from Week  5 to 
Week 17 
• The time-normalized number of moderate or severe HAE attacks (per month) 
from Week 5 to Week 17  
• The number of patients with a clinical response (defined as a ≥ 50%, ≥  70%, or 
≥ 90% reduction from Baseline in HAE attack rate) by Week  17 
• The number of HAE attacks requiring acute therapy from Week  5 to Week  17 
• cHK levels at Weeks 9 and 17  
• PKK activity at Weeks 9 and 17 
• Consumption of on -demand medication at Weeks 9 and 17  
• AE-QoL questionnaire score at Weeks  9 and 17 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
20 PROTOCOL SYNOPSIS CONTINUED  
Exploratory 
Endpoints  Exploratory endpoints include the following:  
• The number of HAE attack -free patients by Week 17  
• PK parameters, including, but not limited to:  maximum observed plasma 
concentration (C max), time to C max, area under the plasma concentration -time 
curve, and t ½  
• Potential exposure -response analysis using relevant exposure parameters and 
biomarkers  
Safety 
Endpoints  The safety and tolerability of ISIS 721744 will be assessed by determining the 
number, type, severity, and dose -relationship of AEs; vital signs; ECGs; and clinical 
laboratory parameters.  Safety results in patients dosed with ISIS  721744 will be 
compared to safety results in patients dosed with placebo.  
Statistical 
Considerations  The sample size of 18 patients with HAE -1/HAE-2 (12 patients administered 
SC injections of ISIS 721744 80 mg and 6 patients administered placebo) is from 
clinical con siderations for sufficient safety and tolerability evaluation.  The primary 
endpoint is the time -normalized number of HAE attacks (per month) from Week  1 to 
Week 17.  From historical data, the placebo group is estimated to have 6.8  HAE 
attacks per 4 -month period.  If the ISIS 721744 80 mg group is assumed to have 
2.8 HAE attacks per 4 -month period, then with a 0.05 significance level and Poisson 
model, the sample size of 18  patients will provide at least 90% power for the primary 
endpoint, considering a 10%  missing data or dropout rate for both active treatment 
and placebo.  There is no statistical rationale for the sample size of 6 patients with 
HAE-nC1-INH.   
An independent Data and Safety Monitoring Board (DSMB) will be established prior 
to the initiation  of the study.  The DSMB will be responsible for monitoring the 
overall safe conduct of the study.  Based on its ongoing assessment of the safety and 
tolerability of ISIS 721744, the DSMB will provide recommendations to the Sponsor 
for modifying, stopping,  or continuing the study as planned.  Details on the safety 
assessments, frequency of review, meeting schedules and controlled access to 
unblinded data are outlined in the DSMB Charter and Statistical Analysis Plan.  
Sponsor Ionis Pharmaceuticals, Inc.   
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
22 STUDY GLOSSARY  
Abbreviation  Definition  
2′-MOE 2′-O-(2-methoxyethyl)  
AAS Angioedema Activity Score  
ACE angiotensin -converting enzyme  
ADR adverse drug reaction  
AE(s) adverse event(s)  
AE-QoL angioedema quality of life  
AESI adverse event of special interest  
ALT alanine aminotransferase  
aPTT activated partial thromboplastin time  
ASO antisense oligonucleotide  
AST aspartate aminotransferase  
AUC area under the plasma concentration -time curve 
Bb complement factor Bb (activated complement split product)  
βhCG beta-subunit of human chorionic gonadotropin (pregnancy test)  
BK bradykinin  
BUN blood urea nitrogen  
C centigrade  
C1-INH C1-inhibitor 
C4 complement factor C4  
C5a complement factor C5a (activated complement split product)  
cHK cleaved high molecular weight kininogen  
Cmax maximum observed plasma concentration  
CTCAE Common Terminology Criteria for Adverse Events  
dL deciliter 
DNA deoxyribonucleic acid  
DSMB Data and Safety Monitoring Board  
ECG electrocardiogram  
eCRF electronic Case Report Form  
eGFR estimated glomerular filtration rate  
ET Early Termination  
FSH follicle-stimulating hormone  
GalNAc 3 N-acetyl galactosamine  
GCP Good Clinical Practice 
GGT gamma-glutamyl transferase  
HAE hereditary angioedema  
HAE-1 hereditary angioedema type 1  
HAE-2 hereditary angioedema type 2  
HAE-nC1-INH hereditary angioedema with normal C1 -inhibitor 
HIV human immunodeficiency virus  
HK high molecular weight kininogen  
hs-CRP C-reactive protein measured by high sensitivity assay  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
23 IgM immunoglobulin M  
IM imunogenicity  
INR international normalized ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ISIS 721744 antisense inhibitor of prekallikrein  
ITT Intent-to-Treat 
LCRIS local cutaneous reaction at injection site  
LLN lower limit of normal  
MCH mean corpuscular hemoglobin  
MCHC mean corpuscular hemoglobin concentration  
MCV mean corpuscular volume  
MedDRA™ Medical Dictionary for Regulatory Activities  
mRNA messenger ribonucleic acid  
NCS not clinically significant  
OLE open-label extension  
PD pharmacodynamic(s)  
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s)  
PKa plasma kallikrein  
PKK prekallikrein  
PP Per-Protocol 
PT prothrombin time  
RNA ribonucleic acid  
RNase H1  an ubiquitous endonuclease that specifically hydrolyzes the RNA strand in 
RNA/DNA hybrids  
SAE serious adverse event  
SAP Statistical Analysis Plan  
SC subcutaneous(ly)  
Study Day 1  defined as the first day Study Drug is administered to the patient  
Study Drug  ISIS 721744 or placebo  
SUSAR suspected unexpected serious adverse reaction  
t½ half-life  
T3 triiodothyronine  
T4 thyroxine  
TEAE treatment -emergent adverse event  
Tmax time to maximum observed plasma concentration  
TSH thyroid-stimulating hormone  
ULN upper limit of normal  
WBC white blood cell  
WOCBP woman/women of childbearing potential  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
24 1. OBJECTIVES AND ENDPO INTS 
1.1. Objectives  
1.1.1. Primary Objective  
The primary objective of the study is to evaluate the clinical efficacy of antisense inhibitor of 
prekallikrein (ISIS  721744) in patients with hereditary angioedema (HAE) type 1 (HAE -1), HAE 
type 2 (HAE -2), or HAE with normal C1 -inhibitor (C1 -INH). 
1.1.2. Secondary Objectives  
The secondary objectives of the study are to evaluate safety and tolerability of ISIS  721744 in 
patients with HAE -1/HAE-2 or HAE with normal C1 -INH (HAE -nC1-INH) and to evaluate the 
effect of ISIS 721744 on plasma prekallikrein (PKK) and other relevant biomarkers.  
1.1.3. Exploratory Objectives  
The exploratory objectives of the study are to evaluate pharmacokinetics (PK) of ISIS  721744 
(as a total full -length antisense oligonucleotide [ASO], includ ing fully conjugated, partially 
conjugated, and unconjugated ISIS 721744) over time and to assess potential 
PK/pharmacodynamic (PD) correlations on relevant biomarkers and clinical outcomes, as 
appropriate.  
1.2. Study Endpoints  
The definition of an HAE attack, including discrete attacks, is provided in Section  6.2.1. 
1.2.1. Primary Endpoints  
The primary endpoint is the time -normalized number of HAE attacks (per month) from Week  1 
to Week 17.  
1.2.2. Secondary Endpoints  
Secondary endpoints include the following:  
• The time-normalized number of HAE attacks (per month) from Week 5 to Week 17  
• The time-normalized number of moderate or severe HAE attacks (per month) from 
Week 5 to Week 17  
• The number of patients with a clinical response (defined as a ≥ 50%, ≥ 70%, or 
≥ 90% reducti on from Baseline in HAE attack rate) by Week 17  
• The number of HAE attacks requiring acute therapy from Week  5 to Week 17  
• Cleaved high molecular weight kininogen (cHK) levels at Weeks 9 and 17  
• PKK activity at Weeks 9 and 17  
• Consumption of on -demand medicati on at Weeks 9 and 17  
• Angioedema quality of life (AE -QoL) questionnaire score at Weeks 9 and 17  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
25 1.2.3. Safety Endpoints  
The safety and tolerability of ISIS 721744 will be assessed by determining the number, type, 
severity, and dose -relationship of adverse events ( AEs); vital signs; electrocardiograms (ECGs); 
and clinical laboratory parameters.  Safety results in patients dosed with ISIS 721744 will be 
compared to safety results in patients dosed with placebo.  
1.2.4. Exploratory Endpoints  
Exploratory endpoints include the following:  
• The number of HAE attack -free patients by Week 17  
• PK parameters, including, but not limited to:  maximum observed plasma 
concentration (C max), time to C max (Tmax), area under the plasma concentration -time 
curve (AUC), and half -life (t½) 
• Potential exposure response analysis using relevant exposure parameters and 
biomarkers  
2. BACKGROUND AND RATIO NALE 
2.1. Overview of Disease  
Hereditary angioedema is a rare genetic disorder that is characterized by disabling recurrent 
episodes of local skin swellings, pain ful abdominal attacks, and, occasionally, laryngeal attacks 
that can be life -threatening.  The disorder is classified in 3 subtypes.  Hereditary angioedema 
Type I (HAE-1) and Type II (HAE -2) are caused by an autosomal dominant mutation in the 
SERPING1  gene, resulting in either decreased levels of C1 -INH (HAE -1) or loss-of-function of 
this protein (HAE -2) (Bissler et al. 1997 ).  The third form of HAE is associated with normal 
levels and function of C1 -INH (HAE -nC1-INH).  This form is currently categorized as 
4 subtypes, with either specific genetic mutations in the factor XII gene, the plasminogen gene, 
or the angiopoietin -1 gene, or due to an unknown cause (Maurer et al. 2018 ).  Extensive 
evidence from in vitro and in vivo studies supports the key role of bradykinin (BK) in HAE 
attacks, although the data linking HAE -nC1-INH with BK are less strong (Zuraw and 
Christiansen 2016 ).  Diagnosing HAE -nC1-INH can be challenging given the large heterogeneity 
of this patient pop ulation, the lack of diagnostic tests, and the fact that specific genetic mutations 
account only partially for the occurrence of this type of HAE.  Recently, a threshold -stimulated 
kallikrein activity assay was shown to discriminate BK -mediated angioedema from histamine -
mediated angioedema (Lara‑Marquez et al. 2018 ).   
 
 
Treatment options for HAE include on -demand treatment of attacks and prophylaxis.  
On-demand options include supp lementation of C1 -INH (either plasma -derived or recombinant 
C1-INH concentrate) and inhibition of BK2 receptor activation (BK2 -receptor antagonist).  In 
addition, tranexamic acid may relieve symptoms in non -severe angioedema attacks.  
Prophylactic regimens  for HAE include plasma -derived C1 -INH concentrate (administered either 

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
26 intravenously or subcutaneously [SC]), attenuated androgens, antifibrinolytics and a recently 
Food and Drug Administration -approved monoclonal antibody directed against plasma kallikre in 
(PKa).  Kallikrein circulates in plasma as a zymogen (i.e., PKK) which is bound to one of its 
main substrates, high molecular weight kininogen (HK).  Prekallikrein is cleaved upon contact 
activation, forming the active protease PKa.  Plasma kallikrein c leaves HK in turn, thereby 
releasing BK and the split product cHK.  The binding of BK to the BK2 receptor leads to 
activation of various intracellular signaling pathways resulting in vasodilation, chemotaxis of 
neutrophils, and increased vascular permeabil ity and fluid efflux, which typically characterize an 
angioedema attack (Zuraw and  Christiansen 2016 ). 
2.2. Therapeutic Rationale  
 
Antisense technology is characterized by its 
high specificity in inhibiting a single -gene product, thereby diminishing the potential for 
off-target drug effects.   
 
 
    
 
The Phase 1 clinical data show that ISIS 721744 inhibits plasma PKK effectively in a 
dose-dependent manner without safety concerns.  
2.3. ISIS 721744 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
28 2.3.3. Preclinical Experience  
Detailed information concerning the pre clinical studies conducted with PKK ASO ISIS  546254, 
its 5ʹ-GalNAc 3-conjugated mixed backbone variant ISIS 721744, and mouse surrogate PKK 
ASOs can be found in the Investigator’s Brochure.  
 
Results also strongly support that 
GalNAc 3-conjugation of PKK ASO significantly increases the potency of ASO for inhibition of 
PKK hepatic mRNA and circulatory protein e xpression  
 
2.3.4. Clinical Experience  
ISIS 721744 has been evaluated in the clinical setting in a Phase 1 safety study 
(ISIS 721744-CS1).  All subjects have complete d study procedures and final safety and PD data 
are available.  A summary is included below.  Please refer to the Investigator’s Brochure for a 
detailed description of the preclinical pharmacology, nonclinical toxicology and PK, as well as a 
description of  previous clinical experience with other related 2′ -MOE phosphorothioate 
oligonucleotides.  
ISIS 721744 has been studied in 32 healthy volunteers in a double -blind, multiple -dose, 
dose-escalation study.  Of these, 24 subjects received multiple doses of ISIS  721744.  The 
32 subjects were randomized into 4 cohorts (6 subjects each) to receive once -every-4-week SC 
doses of ISIS  721744 20, 40, 60, or 80 mg, or placebo (8 subjects) for a total of 12  weeks (4 total 
doses).  All subjects received all planned doses of Study Drug (ISIS  721744 or placebo).  The 
duration of Study Drug exposure was 84 days for each subject.  
No serious adverse events (SAEs) were reported in the ISIS 721744 -CS1 study.  There were no 
early discontinuations from Study Drug or the study, and all subjects in the ISIS 721744 and 
placebo arms completed all study procedures.  Adverse events at the injection site (defined as 
any preferred term containing “injection site”) were the most commonly reported 
treatment -emergent adverse events (TEAEs) in the ISIS 721744 treatment arms; no injection 
site-related TEAEs were reported in the placebo arm.  There were no flu -like reactions or events 
of local cutaneous reaction at injection site (LCRIS) reported; LCRIS events were defined as 
(A) moderate or sever e injection site erythema, swelling, pruritus, pain, or tenderness that started 
on the day of injection and persisted for at least 2 days; or (B) any AE at the injection site, 
regardless of severity, that led to discontinuation of Study Drug, where AE at t he injection site 
was the principal reason for discontinuation.  No relationship between incidence of TEAEs and 
the dose administered was observed.  
Thirteen (13) AEs related to study treatment were reported for 4 (16.7%) subjects in the 
ISIS 721744 arm, an d for 1 subject (2 events; 12.5%) in the placebo arm.  One (1) subject each 
in the ISIS  721744 and placebo arm reported AEs of ECG T wave inversion (preferred term) that 
were assessed as related.  Nine (9) of the total 13 related events with ISIS 721744 co ncerned 
injection site -related events and were reported by 1 subject in the 80  mg arm.  Additional related 
events were tinnitus (1 subject, 1 event in the 60 mg arm), headache (1  subject, 1 event in the 
60 mg arm), and epistaxis (1 subject, 1 event in the 20 mg arm).  All TEAEs related to study 
treatment were mild in severity, and none were serious.  

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
29 ISIS 721744 resulted in a dose -dependent reduction of PKK concentration and plasma 
proenzyme activation.  The difference in absolute and percent change from Bas eline for 
ISIS 721744 vs. placebo was statistically significant for PKK concentration for 40, 60, and 
80 mg (p ≤ 0.043) starting at Day 15, the first evaluation, and for 20 mg starting at Day 29, and 
for plasma proenzyme activation for all doses (p ≤ 0.002 ) starting at Day 15.  The nadir was 
generally reached around Day 71, when the percent reduction with the 80 mg dose was -93.2% 
for PKK concentration and -99.6% for plasma proenzyme activation.  
The difference in absolute and percent change from Baseline in  cHK for ISIS 721744 vs. placebo 
was not statistically significant at any visit.  
Clinical data from other GalNAc 3-conjugated 2ʹ -MOE-gapmer oligonucleotides suggest that 
enhanced delivery of ISIS 721744 to hepatocytes vs. non -parenchymal cells will result in similar 
PD results as ISIS 546254 at 1/10th to 1/30th of the dose (Viney et al. 2016 ). 
2.4. Rationale for Dose and Schedule of Administration  
The dose level of 80  mg every 28 days was selected based on the safety, tolerability, PK, and PD 
data from the ISIS 721744 -CS1 study in heal thy volunteers.  The Phase 1 study evaluated doses 
of 20, 40, 60, and 80 mg ISIS 721744 administered once every 4 weeks for a total of 12 weeks.  
All dose levels were generally well -tolerated and induced a dose - and exposure -dependent 
reduction in plasma P KK, a biomarker for BK and vascular permeability.  The highest dose level 
of 80 mg produced near -complete reduction of plasma PKK levels (a mean reduction of 93.6% 
from Baseline on Day 99 [2 weeks after the last dose]).  The estimated t ½ from the Phase 1 P K 
data was approximately 4 to 5 weeks, supporting the once -every-28-day dosing regimen.  
Pharmacokinetic/PD analysis of the Phase 1 data suggested very minor differences in plasma 
PKK reductions at doses higher than 80 mg.  
2.5. Benefit-Risk Assessment  
2.5.1. Benefit Assessment  
The benefits of treatment of ISIS 721744 are currently unknown.  Due to its mechanism of 
action, ISIS 721744 has the potential to be efficacious for the treatment of patients with HAE.  
2.5.2. Risk Assessment  
The known potential risks to study participa nts associated with ISIS 721744 are elaborated on in 
the “Guidance to Investigator” section of the Investigator’s Brochure.  
There are no anticipated risks associated with reducing plasma PKK levels; however, a potential 
theoretical risk associated with PKK  inhibition would be prolongation of activated partial 
thromboplastin time (aPTT).  This risk is informed by 80 cases of PKK deficiency that have been 
described in the literature (Girolami et al. 2010 ).  In these individuals, there is a dis crepancy 
between an observed in vitro defect and an absence of bleeding.  Thus, it is believed that most 
cases go undetected or, if detected, go unreported.  Occasional bleeding or thrombosis has been 
reported in a few PKK deficient patients but these inst ances were due to the presence of 
associated risk factors.  Diagnosis is based on the prolongation of partial thromboplastin time 
and normal prothrombin time (PT) and thrombin time.  In these individuals, platelet and vascular 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
30 tests are normal and the long  partial thromboplastin time has shown to be fully corrected by the 
addition of normal plasma or normal serum.  
In monkeys, doses of ISIS 721744 of up to 30 mg/kg/wk for 13 weeks were well -tolerated with 
the exception of thrombocytopenia observed in 1 femal e at 12 mg/kg/wk and 1 male at 
30 mg/kg/wk.  The monkey dose of 6 mg/kg/wk provides an approximate 20 -fold margin relative 
to a human dose of 80 mg every 4 weeks and therefore there is sufficient therapeutic margin to 
assure the safe clinical use of ISIS 7 21744 at the proposed clinical dose and regimen.  
One (1) subject in the ISIS 721744 -CS1 study had a confirmed platelet nadir count between 
100 × 103/µL and the lower limit of normal (LLN) (140 × 103/µL).  The subject received 
ISIS 721744 at 20 mg and had a  platelet count of 139 × 103/µL on Study Day 99; all other 
reported values for this subject were within the reference range.  
Platelet counts will be monitored closely throughout the clinical study.  
More complete details can be found in the Investigator’s B rochure. 
2.5.3. Overall Assessment of Benefit:Risk  
No specific risks have been identified with ISIS 721744.  The AEs that occurred with the related 
drug ISIS 546254 were unrelated to reduction of PKK.  In addition, the conjugated nature of 
ISIS 721744 is anticipa ted to reduce systemic exposure even further.  Consequently, the platelet 
count reductions observed with the higher doses of the unconjugated molecule are not 
anticipated to occur at the dose tested in this study.  
Taking into account the measures taken to minimize risk to patients participating in this study, 
the potential risks identified in association with ISIS 721744 are justified by the anticipated 
benefits that may be afforded to patients with HAE.  
3. EXPERIMENTAL PLAN  
3.1. Study Design  
This Phase 2a study will be conducted at multiple Study Centers worldwide to assess the efficacy 
of ISIS 721744 in approximately 24 patients with HAE.  Part A of the study will be randomized, 
double-blind, and placebo -controlled; Part B of the study will be open -label. 
The study will be conducted concurrently in 2 parts (Part A and Part B); patients will be 
allocated into Part A or Part B according to type of HAE (i.e., either HAE -1/HAE-2 in Part A or 
HAE-nC1-INH in Part B).  Part A is randomized, double -blind, and placebo -controlled; and 
Part B is open -label.  The study visit schedule and procedures are nearly identical in Part A and 
Part B, and thus are presented together; any differences are indicated where applicable.  
In Part A, approximately 18 patients with HAE -1/HAE-2 will be randomized to SC injections of 
ISIS 721744 80 mg or placebo in a 2:1 ratio (ISIS 721744:placebo).  In Part B, approximately 
6 patients with HAE -nC1-INH will be administered open -label SC injections of ISIS  721744 
80 mg.  Due to the rarity of HAE -nC1-INH, enrollment in Part B may be ended early if Study 
Centers are unable to enroll sufficient patients; this will not impact the completion of Part A.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
31 Patients who discontinue treatment will remain in the study and attend the Early Termination 
(ET) Visit u nless consent is withdrawn.  
Detailed information regarding the study procedures is presented in Section  6 and Appendix  A.  
Appendix  B includes a list of laboratory analytes required for the study.  
3.2. Number of Study Centers  
This study will be conducted at multiple Study Centers worldwide.  
3.3. Number of Patients  
A total of approximately 24 patients in Parts A and B combined will be administered SC 
injections of ISIS 721744 80 mg or placebo every 4 weeks.  Patient s will be allocated into Part  A 
or Part B according to type of HAE, (i.e., either HAE -1/HAE-2 or HAE -nC1-INH):  
approximately 18  patients with HAE -1/HAE-2 are planned to be enrolled in Part A of the study, 
and, in parallel, approximately 6 patients with HA E-nC1-INH are planned to be enrolled in 
Part B of the study.  Due to the rarity of HAE -nC1-INH, enrollment in Part B may be ended 
early if Study Centers are unable to enroll sufficient patients with HAE -nC1-INH; this will not 
impact completion of Part A.  
3.4. Overall Study Duration and Follow -up 
The study will consist of Screening, Treatment, and Post -Treatment Periods.  Please refer to the 
Schedule of Procedures in Appendix  A. 
Patients may be required to attend additional visits for monitoring of AEs or abnormal 
investigation results.  The frequency of additional monitoring will be determined by the Sponsor 
Medical Monitor in consultation with the Investigator.  
The length of each patient’s participation in the study is approximately 8 months, which includes 
an up to 8 -week Screening Period, a 12 -week Treatment Period  (patients will receive fixed SC 
doses of Study Dru g every 4 weeks during 4  on-site study visits) , and a 4- to 13-week 
Post-Treatment Period  as determined by whether a patient enrolls in the ISIS 721744 -CS3 OLE 
study. 
3.4.1. Screening  
Patient eligibility for the study will be determined within 8 weeks (56 days) prior to study entry.  
3.4.2. Treatment Period  
Eligible patients will report to the Study Center for the first administration of Study Drug on 
Study Day  1 (Week 1 Visit) and will continue to receive Study Drug once every 4 weeks during 
the 12-week Treatment Period .  Patients will also return to the Study Center on Week 3 (or 
Home Healthcare (if available), as arranged by the Study Center personnel, per the Schedule of 
Procedures in Appendix  A) for a safety monitoring visit.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
32 3.4.3. Post-Treatment Period  
Patients are to return to the Study Center for post -treatment follow -up visits (or Home Healthcare 
(if available), as arranged by the Study Center personnel, per the Sched ule of Procedures in 
Appendix  A at Study Weeks 17, 21, and 26/ET.  Alternatively, patients who complete Study 
Visit Week 17, and meet eligibility require ments, may start the treatment period in the 
ISIS 721744-CS3 OLE study anytime after the Week 17 visit and discontinue participation in the 
CS2 Post-Treatment Evaluation Period.  Patients may be required to attend additional visits for 
monitoring of AEs or  abnormal investigation results.  The frequency of additional monitoring 
will be determined by the Sponsor Medical Monitor in consultation with the Investigator.   
The final study visit, for patients not enrolling in the OLE, will be the Week 26/ET Visit.   
3.5. End-of-Study 
The End-of-Study is defined as the date of the last visit of the last patient in the study.  
3.6. Data and Safety Monitoring Board  
A Data and Safety Monitoring Board (DSMB) will be assembled to review safety, tolerability, 
and efficacy (as needed)  data collected on ISIS  721744 during this study.  Based on its ongoing 
assessment of the safety and tolerability of ISIS  721744, the DSMB will provide 
recommendations to the Sponsor for modifying, stopping, or continuing the study as planned.  
Details on the safety assessments, frequency of review, meeting schedules, and controlled access 
to unblinded data are outlined in the DSMB Charter and Statistical Analysis Plan (SAP).  
4. PATIENT ENROLLMENT  
4.1. Screening  
Before patients may be enrolled into the study, the S ponsor or designee requires a copy of the 
Study Center’s written Independent Ethics Committee (IEC)/Institutional Review Board (IRB) 
approval of the protocol, informed consent form (ICF), and all other patient information and/or 
recruitment material.  
Patients must sign the consent form before any screening tests or assessments, prior to screening 
blood draws, are performed.  At the time of consent, the patient will be considered enrolled into 
the study and will be assigned a unique screening number before a ny study procedures, including 
screening procedures, are performed.  At the time of randomization, patients will be assigned a 
unique patient identification number.  This number will be used to identify the patient throughout 
the study and must be used on all study documentation related to that patient.  The screening 
number and patient identification number must remain constant throughout the entire study.   
In the event the patient is re -consented and re -screened, the patient must be given a new 
screening  number.  Screening numbers, once assigned, will not be re -used. 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
33 4.2. Randomization  
Patients will be allocated into Part A or Part B according to type of HAE (i.e., either 
HAE-1/HAE-2 in Part A or HAE -nC1-INH in Part B).  Only Part A will be randomized and 
placebo-controlled.   
Patients will be enrolled and/or randomized (Part A only)  at the Week 1 Visit, after all  screening 
assessments have been completed and after the Investigator has verified that they are eligible per 
the criteria in Sections  5.1 and 5.2.  No patient may begin treatment prior to randomiza tion 
(Part A only) and assignment of a unique patient identification number.   
In Part A, approximately 18  patients with HAE -1/HAE-2 will be randomized via the Interactive 
Response Technology (IRT) system to SC injections of ISIS 721744 80 mg or placebo in  a 
2:1 ratio (ISIS  721744:placebo).  In Part B, approximately 6 patients with HAE -nC1-INH will be 
enrolled via the IRT system to receive open -label SC injections of ISIS 721744 80 mg.  Due to 
the rarity of HAE -nC1-INH, enrollment in Part B may be ended ear ly if Study Centers are unable 
to enroll sufficient patients; this will not impact the completion of Part A.  
Randomization information will be concealed from the Investigators and patients until the end of 
the study, with the exception of an emergency situ ation involving a patient that requires 
unblinding of the treatment assignment.  
Both ISIS  721744 and placebo will be provided as injections for SC administration and will be 
identical in appearance.  
4.3. Replacement of Patients  
Patients who withdraw from the study will not be replaced.  
Patients whose randomization code has been broken will not be replaced.  
4.4. Unblinding of Treatment Assignment  
For Part A, the Sponsor and all patients, monitors, and Study Center personnel related to the 
study will be blinded throu ghout the study.  However, if a patient has suffered an SAE (as 
defined in Section  9.3.3), and/or when knowledge of the treatment assignment will impact  the 
clinical management of the patient, the Investigator will have the ability to unblind the treatment 
assignment for that patient via the IRT system.  
In the case of unblinding, the IRT system will send a blinded notification to the Sponsor or 
designee w ithin 24 hours to let them know that a patient was unblinded.  In addition, all 
suspected unexpected serious adverse reactions (SUSARs) will be unblinded by the Sponsor or 
designee for the purpose of regulatory reporting (see Section  9.2). 
Every reasonable attempt should be made to complete the ET study procedures and observations 
(see Appendix  A) prior to unblinding, as knowledge of the treatment arm could influence patient 
assessment.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
34 5. PATIENT ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following el igibility criteria 
within 8 weeks (56 days) of the Week 1 Visit (Study Day 1)  or at the time point specified in the 
eligibility criteria listed.  
5.1. Inclusion Criteria  
1. Patients must provide written informed consent (signed and dated) and any authorizations 
required by local law and be able to comply with all study requirements for the duration 
of the study.  
2. Patients must be aged ≥ 18 years at the time of informed consent.  
3. Patients must have a documented diagnosis of HAE -1/HAE-2 (for inclusion in Part  A) or 
HAE-nC1-INH (for inclusion in Part  B) as defined below:  
a. Documented diagnosis of HAE -1/HAE-2 based upon ALL of the following:  
i. Documented clinical history consistent with HAE (SC or mucosal, non -pruritic 
swelling episodes without accompanying urticaria) (Maurer et al. 2018 ). 
ii. Diagnostic testing results that confirm HAE -1/HAE-2:  C1-INH functional level 
< 40% normal level.  Patients with a functional level of 40% to 50% of normal 
can be enrolled if their complement factor C4 (C4) level is below the LLN or if a 
known pathogenic mutation in the SERPING1  gene has been demonstrated.  
iii. At least 1 of the following:  age at reported HAE onset ≤ 30 years; a family 
history consistent with HAE -1/HAE-2; or complement component 1q within the 
normal range.  
b. Documented diagnosis of HAE -nC1-INH based upon documented clinical history 
consistent with HAE (SC or mucosal, non -pruritic swelling episodes without 
accompanying urticaria) (Maurer et al. 2018 ) AND any 1 of the following:  
i. A clinical diagnosis of BK -mediated angioedema as confirmed with 
threshold-stimulated kallikrein activity and Investigator -confirmed resp onse to 
acute use of a BK targeted treatment (icatibant or ecallantide).  
ii. One (1) of the established mutations (c.1032C>A, Thr309Lys; c.1032C>G, 
Thr309Arg; c.971_1018+24del72*; or c.892_909dup) in the factor XII gene.  
iii. The established mutation in th e plasminogen gene (c.988A>G, p.Lys330Glu).  
iv. The established mutation in the angiopoietin -1 gene (c.355G>T, p.A119S).  
4. Patients must:  
a. Experience a minimum of 2 HAE attacks (assessed by the Angioedema Activity 
Score [AAS] and confirmed by the Investigator) during the Screening Period.  
b. Complete the AAS questionnaire on a daily basis (minimum of 4  daily assessments 
per week) for the duration of the Screening Period.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
35 5. Patients must have access to, and the ability to use, ≥ 1 acute medication(s) 
(e.g., plasma-derived or recombinant C1 -INH concentrate or a BK2 -receptor antagonist) 
to treat angioedema attacks.  
6. Female patients must be non -pregnant (and not planning a pregnancy during the study) 
and non-lactating, and be either:  
a. Surgically sterile (e. g., tubal occlusion, hysterectomy, bilateral salpingectomy, or 
bilateral oophorectomy).  
b. Post-menopausal (defined as 12 months of spontaneous amenorrhea in females 
> 55 years of age or, in females ≤ 55 years of age, 12 months of spontaneous 
amenorrhea wi thout an alternative medical cause and follicle-stimulating hormone 
[FSH] levels in the post -menopausal range for the laboratory involved).  
c. Abstinent (only acceptable as true abstinence, i.e., when in line with the preferred and 
usual lifestyle of the p atient; periodic abstinence [e.g., calendar, ovulation, 
symptothermal, or post -ovulation methods], declaration of abstinence for the duration 
of the study, or withdrawal are not acceptable methods of contraception).  
d. If engaged in sexual relations of chi ldbearing potential, agree to use highly effective 
contraceptive methods (refer to Section  6.3.1) from the time of signing the ICF until 
at least 24 wee ks after the last dose of Study Drug (ISIS 721744 or placebo).  
7. Male patients must be surgically sterile or, if engaged in sexual relations with a female of 
childbearing potential, the patient must agree to use a highly effective contraceptive 
method (refer  to Section  6.3.1) from the time of signing the ICF until at least 24 weeks 
after the last dose of Study Drug (ISIS 721744 or placebo).  
5.2. Exclusion Criteria 
1. Anticipated use of short -term prophylaxis for angioedema attacks for a pre -planned 
procedure during the Screening or Study Periods.  
2. Concurrent diagnosis of any other type of recurrent angioedema, including acquired or 
idiopathic angioedema.  
3. Anticipated change in the use of concurrent androgen prophylaxis used to treat 
angioedema attacks.  
4. Any clinically significant abnormalities in screening laboratory values that would render 
a patient unsuitable for inclusion in the study.  The following values ar e exclusionary:  
a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × upper 
limit of normal (ULN).  
b. Bilirubin > 1.5 × ULN unless due to Gilbert’s syndrome.  
c. Platelet count < LLN.  
d. Estimated glomerular filtration rate (eGFR) < 60 mL/min (as determined by the 
Cockcroft -Gault Equation for creatinine clearance).  
e. aPTT > 1.5 × ULN 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
36 5. Patients with a history of acquired coagulopathies or bleeding diathesis (e.g., 
thrombocytopenia, disseminated intravascular coagulation, coagulopathy o f liver disease, 
drug-induced platelet dysfunction, hyperfibrinolysis, acquired clotting factor inhibitors) 
and inherited bleeding disorders (e.g., hemophilia A, hemophilia B, other clotting factor 
deficiencies, qualitative platelet disorders, inherited th rombocytopenia, vascular 
abnormalities).  
6. Any clinically significant renal or hepatic diseases.  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to dosing.  
8. Active infection with HIV, hepatitis C or hepatitis B diagnosed by initial serological 
testing and confirmed with RNA testing, or prior treatment for hepatitis C.  Patients at 
Screening who test positive by serology, but negative by RNA may be allowed in 
consultation with the Sponsor Medical Monitor.  
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ of the cervix that has been successfully treated.  
10. Treatment with another investigational drug or biologic al agent within 1 month or 
5 half-lives, whichever is longer, of Screening.  
11. Exposure to any of the following medications:  
a. Angiotensin -converting enzyme (ACE) inhibitors or any estrogen -containing 
medications with systemic absorption (such as oral contra ceptive or hormonal 
replacement therapy) within 4 weeks prior to Screening.  
b. Chronic prophylaxis with lanadelumab within  10 weeks prior to Screening.  
c. Oligonucleotides (including small interfering RNA) within 4 months of Screening if 
single dose receiv ed, or within 12 months of Screening if multiple doses received.  
12. Any condition that, in the opinion of the Investigator, may compromise the patient’s 
safety or compliance, preclude successful conduct of the study, or interfere with the 
interpretation of re sults. 
6. STUDY PROCEDURES  
6.1. Study Schedule  
The study will be conducted concurrently in 2 parts (Part A and Part B); patients will be 
allocated into Part A or Part B according to type of HAE (i.e., either HAE -1/HAE-2 in Part A or 
HAE-nC1-INH in Part B).  Part A  is randomized, double -blind, and placebo -controlled; and 
Part B is open label.  The study visit schedule and procedures are nearly identical in Part A and 
Part B, and thus are presented together; any differences are indicated where applicable.  
All require d study procedures are outlined in Appendix  A. 
The safety of ISIS 721744 will be continually monitored throughout the study by the Investigator 
and the Sponsor Medical Monitor.  
The length of each patient’s participation from Screening to the last study visit is up to 
approximately 8 months (231 days).  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
37 6.1.1. Screening  
Written informed consent for the study will be obtained prior to the performance of any 
study-related procedures, including screening procedures.  A 56 -day period is provided for 
completing screening assessments and determining patient eligibility for the study.   
Safety labs may be retested for determination of patient eligibility at the Investigat or’s discretion.  
The Sponsor Medical Monitor will be available for consultation, if needed.  
After providing written informed consent, patients will be screened for eligibility criteria.  
During the Screening Period, the following assessments will be perfo rmed:  demographics; 
medical history, including a detailed HAE history; prior and concomitant medications, including 
type of prophylaxis (if used) and type of acute treatment; HIV, hepatitis B, and hepatitis  C 
screening; pregnancy testing for women of chil dbearing potential (WOCBP) and FSH testing for 
confirmation of menopause per inclusion criteria ; quality of life as assessed by the AE -QoL 
questionnaire; attack frequency, as assessed by the AAS daily during up to 8  consecutive weeks, 
and confirmed by the Investigator; HAE attack assessment; physical examinations, including 
vital signs, body height, and weight; ECGs; AEs; PD blood sampling; inflammatory panel; and 
clinical laboratory assessments (chemistry, hematology, coagulation, and urinalysis).  
Threshold-stimulated kallikrein activity will be assessed only in patients who have 
HAE-nC1-INH without a factor XII mutation or the plasminogen or angiopoietin -1 mutation.  
Genetic testing will be performed only for patients who do not have HAE genetic diagnostic  
testing results prior to Screening.  During the Screening Period, patients must experience a 
minimum of 2 HAE attacks (assessed by the AAS and confirmed by the Investigator) to be 
eligible for the study; patients will be instructed to report details of an y HAE attack to the study 
site within 72 hours of the onset of the attack.  Throughout the Screening Period, site personnel 
will contact the patient once a week (at approximately 7 days after the last contact with the 
patient) in order to inquire about any  attack that may have occurred.  If a patient experiences a 
third attack, the patient should be randomized as soon as possible, assuming all other screening 
activities have been completed and the patient meets all other eligibility requirements; in such 
cases, the Screening Period may be shorter than 8 weeks.  
During the course of the study, the use of acute medications (plasma -derived or recombinant 
C1-INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to treat angioedema 
attacks is allowed as medically indicated.  Patients can be treated with on -demand therapy as 
determined by their treating physician.  
6.1.2. Treatment Period  
After a Screening Period of up to 8 weeks, those patients who had at least 2 documented attacks 
(assessed by the AAS and confirmed by the Investigator) during the Screening Period and met all 
other eligibility criteria will be administered Study Drug (ISIS 721744 or placebo).  Patients in 
Part A will be randomized to receive ISIS  721744 80 mg or placebo every 4 weeks for a t otal 
Treatment Period of 12 weeks.  Patients in Part  B will all receive open -label ISIS  721744 80 mg 
every 4 weeks for a total Treatment Period of 12 weeks.   
Study Drug  will be administered as SC injections in the abdomen, thigh, or outer area of the 
upper arm by qualified personnel at the Study Center or by Home Healthcare professional  (if available  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
38 and after dosing inst ructions and training are provided by qualified site personnel ).  The first dose of 
Study Drug will be administered at the Study Center o n Study Day 1 (Week  1 Visit).  Study 
Center person nel (or Home Healthcare if available),  will complete procedures  per the Schedule 
of Procedures in Appendix  A.  A ± 2-day excursion from the scheduled visit date is permitted for 
all visits (excluding the Week  1 Visit on Study Day  1) during the Treatment Period.  
During the study, patients will be instr ucted to report details of any HAE attack to the study site 
within 72 hours of the onset of the attack.  During the Treatment Period, the following data will 
be collected:  daily AAS and number of HAE attacks (assessed by the AAS and confirmed by the 
Investigator); number of HAE attacks that required on -demand treatment; HAE attack details, 
including localization, severity, course, and details of any required treatment (i.e., frequency and 
dose); and vital signs.  Throughout the Treatment Period, site perso nnel will contact the patient 
once a week (at approximately 7 days after the last contact with the patient) in order to inquire 
about any attack that may have occurred.  In addition, at study visit  time points , site personnel 
will inquire about any new HAE  attack information that was not provided through patient contact 
with the site.  See Section  6.2.1 for further information on the collection of data sur rounding 
HAE attacks.  Additional assessments will be performed throughout the Treatment Period as 
indicated in the Schedule of Procedures table in Appendix  A. 
Additionally, blood will be collected to assess PD and coagulation parameters, including, but not 
limited to:  plasma PKK, plasma proenzyme activation, cHK levels, D -dimer levels, aPTT, 
plasmin-antiplasmin complexes, C4  split products, and platelet  counts.  Blood samples will also 
be collected regularly throughout the study for safety and PK/PD analyses.   
Patients who discontinue treatment will remain in the study and attend the ET Visit unless 
consent is withdrawn.  
Detailed information regarding t he study procedures is presented in Section  6 and Appendix  A.  
Appendix  B includes a list of laboratory analytes required for the study.   Detailed information 
regarding PK  subgroups and collection times is provided in Appendix  C. 
6.1.3. Post-Treatment Period  
Each patient will be followed for safety assessments for up to 13 weeks afte r the last dose of 
Study Drug.  During the Post -Treatment Period, patients will return to the Study Center (or have 
Home Healthcare (if available), as arranged by the Study Center personnel, per the Schedule of 
Procedures in Appendix  A) for visits at Weeks  17, 21, and 26/ET for safety and clinical 
laboratory evaluations and for blood sampling for PK/PD analyses.  A ± 2 -day excursion from 
the scheduled visi t date is permitted for the visits at Weeks  17 and 21, and a ± 3 -day excursion 
from the scheduled visit date is permitted for the visit at Week  26/ET.  Alternatively, after 
completion of the Week 13 visit, eligible patients may elect to enroll in the ISIS 721744-CS3 
OLE study, pending study approval by the IRB/IEC and the appropriate regulatory authority, and 
will need to sign the Institutional Review Board/Independent Ethics Committee (IRB/IEC) 
approved informed consent.  Patients who complete Study Visit Week 17, and meet eligibility 
requirements, may start the treatment period in the CS3 study anytime after the Week 17 visit 
and discontinue participation in the CS2 Post -Treatment Evaluation Period.  
During the Post -Treatment Period, the following data will  be collected:  daily AAS and number 
of HAE attacks (assessed by the AAS and confirmed by the Investigator); number of HAE 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
39 attacks that required on -demand treatment; HAE attack details, including localization, severity, 
course, and details of any required treatment (i.e., frequency and dose); and vital signs.  
Throughout the Post -Treatment Period, site personnel will contact the patient once a week (at 
approximately 7 days after the last contact with the patient) in order to inquire about any attack 
that may have occurred.  In addition, during study visits, site personnel will inquire about any 
new HAE attack information that was not provided through patient contact with the site.  See 
Section 6.2.1 for further information on the collection of data surrounding HAE attacks.  
Additionally, blood will be collected to assess PD and coagulation parameters, including, but not 
limited to:  plasma PKK, plasma proenzyme activation, cHK levels, D -dimer levels, aPTT, 
plasmin-antiplasmin complexes, C4 split products, and platelet counts.  Blood samples will also 
be collected regularly throughout the study for safety and PK/PD analyses.  Additional 
assessments will be performed throughout the Post -Treatment Period as indicated in the 
Schedule of Procedures table in Appendix  A. 
Patients who withdraw early from the s tudy during the Treatment Period will be required to 
complete their End -of-Study evaluations following procedures listed for the Week 26/ET Visit; 
see Appendix  A.   
6.2. Study Assessments  
6.2.1. Collection of Hereditary Angioedema Attack Details  
Historical HAE attack information will be collected at Screening.  During the study, patients will 
be instructed to report details of any HAE attack to the study site within 7 2 hours of the onset of 
the attack.  Throughout the Screening, Treatment, and Post -Treatment Periods, site personnel 
will contact the patient once a week (at approximately 7 days after the last contact with the 
patient) in order to inquire about any attack  that may have occurred.  In addition, during study 
visits, site personnel will inquire about any new HAE attack information that was not provided 
through patient contact with the site.  
During the Screening, Treatment, and Post -Treatment Periods, detailed information on each 
HAE attack will be collected, and the number of HAE attacks that required on -demand 
treatment, and the details of any on -demand treatment used (frequency and dosing), will be 
assessed.  For each HAE attack, the following data will be co llected:  
• Date/time of symptom onset  
• Description of symptoms  
• Location and description of symptoms:  
− Peripheral angioedema:  cutaneous swelling involving an extremity, face, neck, 
torso, and/or genitourinary region  
− Abdominal angioedema:  abdominal pain, with  or without abdominal distension, 
nausea, vomiting, or diarrhea  
− Laryngeal angioedema:  stridor, dyspnea, difficulty speaking, difficulty 
swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
40 • HAE attack severity:  
− Mild:  transien t or mild discomfort  
− Moderate:  mild to moderate limitation in activity, some assistance needed  
− Severe:  marked limitation in activity, assistance required  
• Need for assistance, medical intervention, emergency room visit, or hospitalization  
• Medications to treat the attack  
• HAE attack course, including if the HAE attack(s) in question was a typical attack for 
the patient, or if there was an alternative diagnosis  
• Date/time symptoms resolved  
An HAE attack will be defined as an event with signs or symptoms consi stent with an attack in at 
least 1 of the locations noted above.  A discrete attack will be counted if there is an at least 
24-hour symptom -free period between attacks.  
6.2.2. Patient-Reported Outcomes  
6.2.2.1. Angioedema Quality of Life Questionnaire  
Quality of life will  be assessed by the AE -QoL questionnaire during Screening and at Weeks  1, 
9, 17, and 26/ET.   
The AE-QoL questionnaire is a validated tool to assess symptom -specific health -related quality 
of life impairment in patients suffering from recurrent angioedema (Weller et al. 2013 ).  The 
AE-QoL is a self -administered questionnaire that can be completed in less than 5 minutes; it 
comprises 17 questions across 4 domains:  functioning, fatigue/mood, fears/s hame, and food.  
The AE-QoL can be used to calculate scores for the 4 individual domains, and can also be used 
to determine a total score.   The AE-QoL will be completed by the patient.  
6.2.2.2. Angioedema Activity Score  
Patients will be instructed on the use of the  AAS questionnaire during Screening and will record 
their HAE attacks using the AAS questionnaire during the Screening Period to confirm study 
eligibility.  The AAS questionnaire will be completed by patients on a daily basis (minimum of 
4 daily assessment s per week) for the duration of the study.   
During the Screening Period, patients must experience a minimum of 2 HAE attacks (assessed 
by the AAS and confirmed by the Investigator) to be eligible for the study.  
Enrolled patients will continue to record HA E attacks using the AAS questionnaire throughout 
the Treatment and Post -Treatment Periods.  
The AAS is a validated patient -reported outcome instrument to assess disease activity in patients 
with recurrent angioedema.  The AAS was designed as a diary -type tool, and is easy to 
administer and fast to complete.  Using the AAS questionnaire, patients score each of 5 key 
symptom-related factors from 0 to 3, resulting in a total daily score of 0 to 15.  Daily AAS can be 
summed to provide scores every 7  days, every 4 weeks, and every 12 weeks (Weller et al. 2013 ). 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
41 6.2.3. Laboratory Assessments  
Laboratory analyte samples will be collected throughout the study.  A list of these analytes is 
contained in Appendix  B.   
If the platelet value, serum creatinine, or liver enzyme tests are uninterpretable (e.g., due to 
clumping, hemolysis, or quantity not sufficient) or missing, a repeat blood specimen should be 
re-drawn as soon as po ssible (ideally within 7 days)  either in clinic or by Home Healthcare or 
local laboratory . 
6.3. Restriction on the Lifestyle of Patients  
6.3.1. Contraception Requirements  
All male patients and WOCBP must refrain from sperm/egg donation and either be abstinent † or 
use highly effective contraception from the time of signing the ICF until at least 24 weeks after 
their last dose of Study Drug.   
For male patients engaged in sexual relations with a WOCBP, if their female partner is using 
highly effective contracepti on from the time of the patient signing the informed consent until  
24 weeks after the patient’s last dose of study treatment, then it is not required for the male 
patient to also use a highly effective contraceptive method.  
For the purposes of this study, a WOCBP is defined as any female who has experienced 
menarche, and who does not meet 1 of the following conditions:  
• Post-menopausal:  12 months of spontaneous amenorrhea in females > 55 years of 
age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an 
alternative medical cause and FSH levels in the post -menopausal range for the 
laboratory involved  
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy  
• Post-hysterectomy  
For the purposes of the study, highly effective contraception is defined as follows:  
For male patients:  
• Highly effective male contraception includes a vasectomy with neg ative semen 
analysis at follow -up, or the non -pregnant female partner of childbearing potential 
uses a highly effective contraceptive method (defined below).  
• Male patients with partners that are pregnant must use condoms as contraception to 
ensure that the  fetus is not exposed to the Study Drug.  
Note: A female condom and a male condom should not be used together as friction 
between the two can result in either or both products failing.  
For female patients and female partners of male patients, highly effecti ve contraception methods 
comprise 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
42 • Surgical sterilization (i.e., bilateral tubal occlusion); progestogen -only hormonal 
contraception associated with inhibition of ovulation; intrauterine contraception 
device or intrauterine hormone -releasing system.  
†Note: Abstinence (i.e., refraining from heterosexual intercourse throughout the duration of 
study participation) is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, or post -ovulation methods), declaration of abstinence for the 
duration of the study, or withdrawal are not acceptable methods of contraception.  
7. STUDY DRUG  
7.1. Study Drug Description  
Study Drug (ISIS 721744 or placebo) charac teristics are listed in Table 1. 
 
 
 
 
During the Treatment Period, Study Drug (ISIS 721744 or placebo) will be administered as a 
single-SC injection every 4 weeks .  
Table 1: Study Drug Characteristics  
Study Drug  ISIS 721744 Placebo 
Strength 100 mg/mL  Not Applicable  
Volume/Formulation  0.8 mL solution per vial  0.8 mL solution per vial  
Route of Administration  SC SC 
 
7.2. Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug (ISIS 721744 or placebo) 
labeled in accordance with specific country regulatory requirements.  
7.3. Study Drug Accountability  
The study staff is required to document the receipt, dispensing, and return/destruction of Study 
Drug (ISIS  721744 or placebo) supplies provided by the Sponsor according to Sponsor 
instruction and in accordance with institutional policy.  

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
43 8. TREATMENT OF PATIENT S 
8.1. Study Drug Administration  
Study Drug (ISIS 721744 or placebo) will be administered as a single -SC injection once every 
4 weeks by blinded study staff during on -site visits at the Study Centers  or by Home Healthcare 
professional  (if available  and after dosing inst ructions and training are provided by qualified site 
personnel ).  Vials of Study Drug (ISIS  721744 or placebo) are for single use only.  
Please refer to the Study Drug Manual provided by the Sponsor or designee for more detailed  
instructions for Study Drug (ISIS  721744 or placebo) preparation and administration.  
8.2. Other Protocol -Required Drugs  
Patients must have access to, and the ability to use, ≥ 1 acute medication(s) (e.g., plasma -derived 
or recombinant  C1-INH concentrate or a BK2 -receptor antagonist) to treat angioedema attacks.  
During the course of the study, the use of acute medications (plasma -derived or recombinant 
C1-INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to treat angio edema 
attacks is allowed as medically indicated.  Patients can be treated with on -demand therapy as 
determined by their treating physician.  
8.3. Other Protocol -Required Treatment Procedures  
There are no other protocol -required treatment procedures.   
8.4. Treatment Precautions  
There are no specific treatment precautions required.   
8.5. Safety Monitoring Rules  
Please refer also to the “Guidance for Investigator” section of the Investigator’s Brochure.  
For the purposes of safety monitoring, Baseline is defined as the average of the pre -dose Study 
Day 1 value and the last value prior to Study Day 1.   
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations.  
Confirmation Guidance :  At any time during the study (Treatment or Post -Treatment Periods), 
the initial clinical laboratory results meeting the safety monit oring criteria presented below must 
be confirmed by performing measurements (ideally in the same laboratory that performed the 
initial measurement) on new specimens.  All new specimen collections should take place as soon 
as possible (ideally within 3 days  of the initial collection).  For stopping rules, if the initial 
laboratory result is observed during the Treatment Period, the results from the retest must be 
available prior to administering the next dose of Study Drug (ISIS  721744 or placebo).  
Re-dosing Guidance :  Patients with initial laboratory test values that reach a stopping rule must 
not be re-dosed until the retest results are available.  In general, patients who do not meet the 
stopping rules based upon retest may continue dosing.  However, the I nvestigator and the 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
44 Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether 
additional close monitoring of the patient is appropriate.  If any of the stopping criteria described 
below (refer to Section  8.6) are met, the patient will be permanently discontinued from further 
treatment with Study Drug (ISIS  721744 or placebo), evaluated fully as outlined below and in 
consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be 
followed up in accordance with Section  8.8 of the protocol.   
8.5.1. Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the draft guidance for industry, “Drug -Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by the U.S.  Department of Health and Human 
Services, Food and Drug A dministration, July 2009.  For a definition of Baseline, please refer to 
guidance in Section  8.5 above. 
In the event of an ALT or AST measurement that i s > 3 × ULN (or the greater of 2 × baseline 
value or 3 × ULN if the baseline value was > ULN) at any time during the study (Treatment or 
Post-Treatment Period), the initial measurement(s) should be confirmed as described above.  
Additional, confirmatory measurements should also be performed if ALT or AST levels  increase 
to 5 × ULN. 
Frequency of Repeat Measurements :  Patients with confirmed ALT or AST levels > 3 × ULN (or 
the greater of 2 × baseline value or 3 × ULN if the baseline value was > ULN) should have their 
liver chemistry tests (ALT, AST, alkaline phosp hatase, international normalized ratio [INR], and 
total bilirubin) retested at least once -weekly until ALT and AST levels become ≤ 1.2 × ULN or 
1.2 × baseline value if the baseline value was > ULN.  
Further Investigation into Liver Chemistry Elevations :  For patients with confirmed ALT or AST 
levels > 3 × ULN (or the greater of 2 × baseline value or 3 × ULN if the baseline value was 
> ULN), the following evaluations should be performed:  
• Obtain a more detailed history of symptoms and prior and concurrent dise ases 
• Obtain further history for concomitant drug use (including non -prescription 
medications, herbal and dietary supplement preparations), alcohol use, recreational 
drug use, and special diets  
• Obtain a history for exposure to environmental chemical agents and travel  
• Perform serology for viral hepatitis (hepatitis A virus immunoglobulin M ([IgM], 
hepatitis B surface antigen, hepatitis C virus antibody, cytomegalovirus IgM, and 
Epstein-Barr Virus antibody panel)  
• Perform serology for autoimmune hepatitis (e.g. , antinuclear antibody)  
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic 
computed tomography or magnetic resonance imaging scans, may be performed at the discretion 
of the Investigator, in consultation with the Spo nsor Medical Monitor.  Repetition of the above 
evaluations should be considered if a patient’s ALT and/or AST levels reach 5 × ULN. 
8.5.2. Safety Monitoring Rules for Platelet Count Results  
Please refer also to Table 2. 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
45 Platelet count will be monitored at least every 4 weeks during the Treatment and Post -Treatment 
Periods.  The Investigator should review all platelet count results within 48 hours of receipt.  
Any unreportable platelet count result must be rechecked ideally within 7 days and determined 
not to have met a stopping rule before dosing can continue.  If a patient’s platelet count falls to 
100,000/mm3 or less, then the patient’s platelet counts should be m onitored weekly.  In case of 
platelet reduction to below 75,000/mm3, the platelet monitoring rule defined in stopping rules 
(Section 8.6.2) should be followed.  
In the event of a platelet count < 75,000/mm3, additional laboratory investigations may be 
conducted in consultation with the Sponsor Medical Monitor.  
8.5.3. Safety Monitoring Rul es for Renal Function Test Results  
If a patient’s results meet Criteria 1 or 2 below, the Investigator should confirm the results and 
initiate weekly monitoring if confirmed.  If the event of a persistent elevation is observed over 
2 consecutive weeks, the n go to Section  8.6.3. 
1. Serum creatinine increase that fulfills all of the following:  ≥ 0.3 mg/dL (26.5  μmol/L) 
and ≥ 40% above baseline creatinine values and > ULN (refer to definition of Baseline in 
Section 8.6) 
2. Proteinuria, urine protein/creatinine ratio > 750 mg/g for baseline values ≥  200 mg/g, or 
4 × baseline value for baseline values < 200 mg/g that are confirmed by repeated urine 
protein/creatinine ratio or by a quantitative total urine protein measurement of 
> 1.0 g/24 hours 
8.5.4. Safety Monitoring for Minor Bleeding Events  
If a bleeding event occ urs, including minor bleeding events such as excess bruising, petechiae, or 
gingival bleeding on brushing teeth, the Investigator should notify the Sponsor Medical Monitor 
and additional testing of coagulation parameters (aPTT, PT, and INR) and platelet co unt should 
be performed.  
8.6. Stopping Rules  
For the purposes of the stopping rules, Baseline is defined as the average of the pre -dose Study 
Day 1 value and the last value prior to Study Day  1.   
8.6.1. Stopping Rules for Liver Chemistry Elevations  
In the event of la boratory results meeting the following criteria, and the event is without an 
alternative explanation as discussed with the Sponsor Medical Monitor,  dosing of a patient 
with Study Drug (ISIS 721744 or placebo) will be stopped permanently; values that are no t 
confirmed due to failure to retest or missing lab values will be presumed confirmed:  
1. ALT or AST > 8 × ULN, which is confirmed  
2. ALT or AST > 5 × ULN, which is confirmed and persists for ≥ 2 weeks  
3. ALT or AST > 3 × ULN (or the greater of 2 × baseline value or 3 × ULN if the baseline 
value was > ULN), which is confirmed and total bilirubin > 1.5 × ULN or INR > 1.5  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
46 4. ALT or AST > 3 × ULN (or the greater of 2 × baseline value or 3 × ULN if the baseline 
value was > ULN) , which is confirmed, and the new appearance (i.e., onset coincides 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or concomitant eosinophilia (> ULN)  
8.6.2. Stopping Rules for Platelet Count Results  
Please refer a lso to Table 2. 
In the event of any platelet count < 25,000/mm3, dosing of the patient with Study Drug will be 
stopped permanently.  Platelet count should b e monitored daily until 3 successive values 
> 25,000/mm3.  Then, monitor twice weekly until 3 successive values > 75,000/mm3.  Then, 
monitor weekly until 3 successive values > 100,000/mm3.  Consider more frequent monitoring if 
additional risk factors for b leeding are present (see Table 2).  Administration of steroids is 
strongly recommended for patients whose platelet count is < 25,000/mm3.  Treatment guidelines 
for immune thrombocytopenia (Provan et al. 2010 ) recommend dexamethasone 40 mg daily for 
4 days every 2 to 4 weeks for 1  to 4 cycles; prednis(ol)one 0.5 to 2  mg/kg/day fo r 2 to 4 weeks 
then taper; or methylprednisolone 30  mg/kg/day for 7 days.  ( Note:  Patient may require 
continuation with oral steroids after methylprednisolone).   
In the event of a platelet count ≥ 25,000/mm3 to < 50,000 /mm3, dosing of the patient with St udy 
Drug will be stopped permanently.  Platelet count should be monitored twice weekly until 
3 successive values > 75,000/mm3.  Then, monitor weekly until 3 successive values 
> 100,000/mm3.  Consider more frequent monitoring and/or the administration of st eroids if 
additional risk factors for bleeding are present (see Table 2). 
In the event of a platelet count ≥ 50,000/mm3 to ˂ 75,000/mm3, and in the absence  of major 
bleeding or clinically relevant non -major bleeding (defined below), dosing with Study Drug 
should be suspended temporarily until the platelet count has recovered to >  100,000/mm3.  The 
suitability of the patient for continued dosing will be deter mined by the Investigator in 
consultation with the Sponsor Medical Monitor and will be based on factors such as the original 
rate of decline in the patient’s platelet count, whether any bleeding events were experienced, and 
the speed of recovery of platele t count after interruption of dosing.  Platelet count must be 
measured twice weekly until 3 successive values > 75,000/mm3, then weekly until 3  successive 
values > 100,000/mm3.  Consider more frequent monitoring if additional risk factors for bleeding 
are present (see Table 2).  Any unreportable platelet count result must be recheck ed, ideally 
within 7 days, and determined not to have met a stopping rule before dosing can continue.  
Definition of Major Bleeding Events (Schulman and Kearon 2005 ) 
1. Fatal bleeding, and/or  
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or  
3. Clinically overt bleeding leading to transfusion of ≥ 2 units of  packed red blood cells or 
whole blood or a fall in hemoglobin of ≥  2.0 g/dL (1.24 mmol/L) within 24  hours 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
47 Definition of Clinically Relevant Non -Major Bleeding Events  
Clinically relevant non -major bleeding is defined as overt bleeding not meeting the criteria for 
major bleeding but that resulted, for example, in medical examination, intervention, or had 
clinical consequences for a patient.  
Definition of Minor Bleeding Events  
Minor bleeding events are those that do not fulfill the criteria for major ble eding or clinically 
relevant, non -major bleeding events (defined above), for example excess bruising, petechiae, or 
gingival bleeding on brushing teeth.  
If the subsequent test confirms the initial test result, then monitoring frequency and dosing 
should be  adjusted as recommended in Table 2. 
Table 2: Actions in Patients with Low Platelet Count  
Platelet count 
(K/mm3) Dosing Monitoring frequency  
> 100 Dosing every 4 weeks should be 
continued.   At least every 4 weeks.  
≥ 75 to ≤ 100 Dosing every 4 weeks should be 
continued.  Every week.  
≥ 50 to < 75  Pause dosing.  When platelet count 
returns to > 100K/mm3, restart 
dosing only if approved by the 
Sponsor Medical Monitor.   Twice weekly until 3 successive 
values > 75K/mm3, then weekly until 
3 successive values > 100K/mm3. 
Consider more frequent monitoring if 
additional risk factors for bleeding are 
present.‡ 
≥ 25 to < 50  Permanently discontinue Study 
Drug. 
Consider corticosteroids if additional 
risk factors for bleeding are present.‡  Twice weekly until 3 successive 
values > 75K/mm3, then weekly until 
3 successive values > 100K/mm3.   
Consider more frequent monitoring if 
additional risk factors for bleeding are 
present.‡ 
< 25 Permanently discontinue Study 
Drug. 
Corticosteroids strongly 
recommended.*  Daily until 3 successive values 
> 25K/mm3, then twice weekly until 
3 successive values > 75K/mm3, then 
weekly until 3 successive values 
> 100K/mm3.   
Consider more frequent monitoring if 
additional risk factors for bleeding are 
present.‡ 
‡ Additional risk factors for bleeding include age > 60 years, receiving anticoagulant or antiplatelet medicinal 
products, and/or prior history of major bleeding events.  
* It is strongly recommended that,  unless corticosteroids are contraindicated, the patient receives glucocorticoid 
therapy to reverse the platelet decline as recovery in platelet count may be accelerated by administration of 
high-dose steroids.  Treatment guidelines for immune thrombocytop enia (Provan et al. 2010 ) recommend 
dexamethasone 40 mg daily for 4 days every 2 to 4 weeks for 1 to 4 cycles; prednis(ol)one 0.5 to 2 mg/kg/day for 
2 to 4 weeks then taper; or methylprednisolone  30 mg/kg/day for 7 days ( Note:  patient may require continuation 
with oral steroids after methylprednisolone).  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
48 8.6.3. Temporary Stopping Rules for Renal Function Test Results  
In the event of a persistent elevation that is observed over 2 consecutive weeks, for either of the 
2 criteria below, dosing of a patient with Study Drug (ISIS 721744 or placebo) may be stopped 
temporarily:  
1. Serum creatinine increase that fulfills all of the following criteria:  ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine va lues and > ULN (refer to definition 
of Baseline in Section  8.6) 
2. Proteinuria, dipstick 2 + (confirmed by dipstick retest and then further confirmed by a 
quantitative total urine protein measurement of > 1.0 g/24 hours)  
The possible dosing reinitiation or follow -up schedule for any events meeting either of these 
criteria will be determined by the Investigator in consultation with  the Sponsor Medical 
Monitor or designee.  
8.7. Adjustment of Dose and/or Treatment Schedule  
Adjustment of dose and/or schedule is not permitted.  
8.8. Discontinuation of Study Drug  
A patient must permanently discontinue study treatment for any of the following:  
• The patient becomes pregnant.  Report the pregnancy according to instructions in 
Section 9.5.4. 
• The patient withdraws consent.  
• The patient withdraws from treatment (but does not withdraw consent).  
• The patient experiences an AE that necessitates permanent discontinuation of Study 
Drug. 
• The patient develops laboratory test abnormalities that meet any of the stopping rules 
listed in Sections  8.6.1, 8.6.2, or 8.6.3. 
• The patient experiences an AE that necessitates unblinding of the Investigator or 
Sponsor to the patient’s treatment assignment.  
The reason for discontinuation of Study Drug must be recorded in the electronic Case Report  
Form (eCRF) and source documentation.  
Patients who discontinue Study Drug will remain in the study and attend the ET Visit 
(Week 17 visit assessments) , unless consent is withdrawn.  Any patient who discontinues early 
from the Treatment Period or from the Post-Treatment Follow -Up Period should be strongly 
encouraged to complete follow -up study visits, procedures and observations  (see Appendix  A). 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
49 8.9. Withdrawal of Patients from the Study Procedures  
Patients must be withdrawn from study procedures for any of the following:  
• Withdrawal of consent  
• The patient is unwilling or unable to comply with the protocol  
Other reasons for withdrawal of patients from t he study may include the following:  
• At the discretion of the Investigator for medical reasons  
• At the discretion of the Investigator or Sponsor for non -compliance  
• Significant protocol deviation  
All efforts will be made to complete and report the observation s as thoroughly as possible up to 
the date of withdrawal.  All information, including the reason for withdrawal from study, must be 
recorded in the eCRF.  
Any patient who withdraws consent to participate in the study will be removed from further 
treatment a nd study observation immediately upon the date of request.  These patients should be 
encouraged to complete the ET study procedures (Week  17 visit assessments) and observations 
at the time of withdrawal (see Appendix  A). 
For patients withdrawn for reasons other than withdrawal of consent, every effort should be 
made to complete the ET study procedures and observations at the time of withdrawal (see 
Appendix  A). 
8.10. Concomitant Therapy and Procedures  
The use of concomitant therapies or procedures defined below must be recorded on the patient’s 
eCRF.  Adverse events related to administration of these therapies or procedures must also be 
documented on the appropriate eCRF.  
8.10.1. Concomitant Therapy  
A concomitant therapy is any non -protocol-specified drug or substance (including 
over-the-counter medications, herbal medications, and vitamin supplements) administered 
between Screening and the end of the Post -Treatment Period.  
Allowed Concomitant Therapy  
During the course of the study, the use of acute medications (plasma -derived or recombinant 
C1-INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to treat angioedema 
attacks is allowed as medically indicated.  Patients can be treated with on -demand therapy as 
determined by their treating physician.  
All other stable medications (if not excluded below) are allowed, so long as the dose and type is 
not expected to change during the study.  
Disallowed Concomitant Therapy  
1. Chronic prophylaxis for angioedema attacks, except for a stable dose of androgens.  Any 
use of lanadelumab will not be permitted.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
50 NOTE:  The use of acute medications (plasma -derived or recombinant C1 -INH 
concentrate or BK2 -receptor antagonist) to treat angioedema attacks is allowed as 
medically indicated.  
2. ACE inhibitors or any estrogen -containing medications with systemic absorption (such as 
oral contraceptive or hormonal replacement therapy).  
3. Any oligonucleotides (including small interfering RNA) other than ISIS  721744. 
4. Plasmapheresis.  
5. Any other investigational drug or device.  
8.10.2. Concomitant Procedures  
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
Screening and the end of the Post -Treatment Period.  
8.11. Treatment Compliance  
Compliance with treatment dosing is to be monitored and recorded in the eCRF by Study Center 
staff. 
9. SERIOUS AND NON -SERIOUS ADVERSE EVENT RE PORTING  
9.1. Sponsor Review of Safety Information  
Safety information will be collected, reviewed, and evaluated by the Sponsor  or designee  in 
accordance with  the applicable Ionis and/or designee Standard Operating Procedures throughout 
the conduct of the clinical study.  
9.2. Regulatory Requirements  
The Sponsor  or designee  is responsible for regulatory submissions and reporting to the 
Investigators of SAEs including  SUSARs per the International Council for Harmonisation (ICH) 
guidelines E2A and ICH Good Clinical Practice (GCP) .  Country-specific regulatory 
requirements will be followed in accordance with local country regulations and guidelines.  
Institutional Review Boards/IECs will be notified of any SAE according to applicable 
regulations.  The DSMB will be notified of any SAE as specified in the DSMB Charter.  
In addition to the Investigator’s assessment of relatedness, the  Sponsor or designee  will evaluate 
the available information and perform an independent assessment of all reported SAEs and 
determine if there is a reasonable possibility that the Study Drug ( ISIS 721744 or placebo) is 
causally related to a reported SAE.  While the Sponsor may upgrade an Invest igator’s decision, it 
is not permissible to downgrade the Investigator’s opinion for the purposes of determining 
whether the SAE meets the definition of a SUSAR.  
Appropriate personnel at the Sponsor or designee will unblind SUSARs for the purpose of 
regulatory reporting.  The Sponsor or designee will submit SUSARs to regulatory agencies in 
blinded or unblinded fashion according to local law.  The Sponsor or designee will submit 
SUSARs to Investigators in a blinded fashion.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
51 9.3. Definitions  
9.3.1. Adverse Event  
An AE ca n be any unfavorable and unintended sign (including an abnormal laboratory finding, 
for example), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not the AE is considered related to the medicinal 
(investigational) product.  
An AE can therefore be any of the following:  
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered  related to the medicinal product  
• Any new disease or exacerbation of an existing disease (a worsening in the character, 
frequency, or severity of a known condition)  
• Recurrence of an intermittent medical condition (e.g., headache) not present at 
Baseline 
• Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from Study Drug  
• Events that are related to a protocol -mandated intervention, including those that occur 
prior to assignment of study treatment (e.g.,  screening invasive procedures such as 
biopsies) 
9.3.2. Adverse Drug Reaction and Unexpected Suspected Adverse Drug Reaction  
Adverse Drug Reaction  
In the pre-approval clinical experience with a new medicinal product or its new usages, 
particularly as the therapeutic dose(s) may not have been established, adverse drug reactions 
(ADRs) are defined as follows:  
All noxious and unintended responses to a medicinal product related to any dose should 
be considered ADRs.  
The phrase “responses to a medicinal product” means that a causal relationship between the 
medicinal product and the AE has been determined by the Sponsor as at least a reasonable 
possibility, i.e., the relationship c annot be ruled out.  
Suspected Unexpected Adverse Drug Reaction  
A suspected unexpected ADR is any ADR, the nature or severity of which is not consistent with 
the applicable product information, e.g., Investigator's Brochure for an unapproved medicinal 
(investigational) product.  
A suspected adverse reaction implies a lesser degree of certainty about causality than an adverse 
reaction. 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
52 9.3.3. Serious Adverse Event  
An SAE is any AE that, in the view of either the Investigator or Sponsor, meets any of the 
following cr iteria: 
• Results in death  
• Is life-threatening; that is, poses an immediate risk of death at the time of the event  
An AE or suspected adverse reaction is considered “life -threatening” if, in the view 
of either the Investigator or Sponsor, its occurrence places the patient at immediate 
risk of death.  It does not include an AE or suspected adverse reaction that , had it 
occurred in a more severe form, might have caused death  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
Hospitalization is defined as an admission of greater than 24 hours to a medical 
facility and does not always qualify as an AE 
• Results in a persistent or significant incapacity or substantial disruption of the ability 
to conduct normal life functions  
• Results in a congenital anomaly or birth defect in the offspring of the patient 
(whether the patient is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do 
not require hospitalization may also be considered serious when, based upon 
appropriate medical judgment, they may jeopardize the patient and may require 
medical or surgical i ntervention to prevent one of the outcomes listed in this 
definition.  Examples of such medical events include  allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpati ent hospitalization, or the development of drug 
dependency or drug abuse  
The terms “severe” and “serious” are not synonymous.  Severity refers to the intensity of an AE 
(e.g., rated as mild, moderate, or severe according to National Cancer Institute Common  
Terminology Criteria for Adverse Events [CTCAE]); the event itself may be of relatively minor 
medical significance (such as severe headache without any further findings).  
Severity and seriousness need to be independently assessed for each AE recorded on t he eCRF.  
9.3.4. Adverse Events of Special Interest  
For the purpose of this study, severe reductions in platelet count < 50,000/mm3 accompanied by 
a major bleeding (MB) event or clinically relevant non -major bleeding (CRNMB) event, or 
platelet count of < 25,000/mm3 independent of a MB or CRNMB event, or any thrombotic 
episode are considered as AEs of special interest (AESIs) and  are subject to 15 -day expedited 
reporting by the Sponsor to the regulatory agencies.  
9.4. Monitoring and Recording Adverse Events  
Any pre-existing conditions or signs and/or symptoms present in a patient prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
53 AEs unless the pre -existing condition worsened.  The Investi gator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible.  Before a 
diagnosis is confirmed, all symptoms should be reported as separate AEs.  
9.4.1. Serious Adverse Events  
In the interest of patient s afety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to Study Drug) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event.  The collection of SAEs will  
begin after the patient signs the ICF and will stop at the end of the patient’s  Post-Treatment 
Period, which is defined as completion of the Week  26/ET Visit .  Serious adverse events should 
be reported using electronic SAE submission (via eDC) whenever po ssible.  In situations where 
electronic SAE submission is unavailable, a paper Initial Serious Adverse Event Form should be 
completed and a copy should be faxed or emailed to the Sponsor or designee.  The SAE 
reporting instructions, including the fax numbe r and email address, can be found in the 
Investigator Site File for the study.   
Detailed information should be actively sought and included as Follow -Up as soon as additional 
information becomes available.  All SAEs will be followed until resolution.  Ser ious adverse 
events that remain ongoing past the patient’s last protocol -specified follow -up visit will be 
evaluated by the Investigator and Sponsor.  If the Investigator and Sponsor agree that the 
patient’s condition is unlikely to resolve, the Investigat or and Sponsor will determine the 
follow-up requirement.  
9.4.2. Non-Serious Adverse Events  
The recording of non -serious AEs will begin after the patient signs the ICF and will stop at the 
end of the patient’s Post -Treatment Period, which is defined as completion of the Week  26/ET 
Visit.  The Investigator will monitor each patient closely and record all  observed or volunteered 
AEs on the eCRF.  
9.4.3. Evaluation of Adverse Events (Serious and Non -Serious) 
The Investigator’s opinion of the following should be documented on the eCRF : 
9.4.3.1. Relationship to the Study Drug  
The event’s relationship to the Study Drug (ISIS 721744 or placebo)  is characterized by 1 of the 
following:  
• Related:  There is clear evidence that the event is related to the use of Study Drug 
(ISIS 721744 or placebo) , e.g., confirmation by positive re -challenge test  
• Possible:   The event cannot be explained by the patient’s medical condition, 
concomitant therapy, or other causes, and there is a plausible temporal relationship 
between the event and Study Dru g (ISIS 721744 or placebo) administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship 
to Study Drug (ISIS 721744 or placebo) administration and/or exposure suggests that 
a causal relationship  is unlikely (for reporting purposes, Unlikely/Remote will be 
grouped together with Not Related)  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
54 • Not Related:   The event can be readily explained by the  patient’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator 
believes no relationship exists between the event and Study Drug (ISIS 721744 or 
placebo) 
9.4.3.2. Severity 
The severity of AEs and SAEs relating to laboratory tests and AEs at the injection s ite will be 
graded based on criteria from the CTCAE Version 5.0, November 2017 (refer to Appendix  D).  
Any AE not listed in Appendix  D will be graded as follows:  
• Mild:  The event is easily tolerated by the patient and does not affect the patient’s 
usual daily activities  
• Moderate:  The event causes the patient more discomfort and interrupts the patient’s 
usual daily activities  
• Severe:  The event is incapacitating and causes considerable interference with the 
patient’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria  must be indicated (criteria listed in 
Section 9.3.3). 
9.4.3.3. Action Taken with Study Drug  
Down-titration of Study Drug (ISIS 721744 or placebo)  will not be allowed during the study.  
Action taken with Study Drug (ISIS 721744 or placebo)  due to an AE is characterized by 1 of the 
following:  
• None:  No changes made to Study Drug (ISIS 721744 or placebo) administration and 
dose 
• Not Applicable:   AE reported during the Screening Period prior to Study Drug 
(ISIS 721744 or placebo)  administration  
• Permanently Discontinued:   Study Drug (ISIS 721744 or placebo)  discontinued and 
not restarted  
• Temporarily Interrupted, Restarted – Same Dose:   Dosing and/or dosing  
frequency temporarily interrupted/changed or delayed due to the AE and restarted at 
the same dose  
9.4.3.4. Treatment Given for Adverse Event  
Any treatment (e.g., medications or procedures) given for the AE should be recorded on the 
eCRF.  Treatment should also be recorded on the concomitant treatment or ancillary procedures 
eCRF, as appropriate.   
9.4.3.5. Outcome of the Adverse Event  
If the event is a non -serious AE, then the event’s outcome is characterized by 1 of the following:  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
55 • AE Persists:   Patient terminates from the study and the AE continues  
• Recovered:   Patient recovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Ons et Date of the 
corresponding SAE)  
• Change in Severity (if applicable):   AE severity changed  
If the event is an SAE, then the event’s outcome is characterized by 1 of the following:  
• Ongoing:   SAE continuing  
• Persists (as non -serious AE):   Patient has not full y recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non -serious AE eCRF 
(the SAE resolution date should be entered as the date of onset of that AE)  
• Recovered:   Patient recovered completely from the SAE (the dat e of recovery should 
be entered as the SAE resolution date)  
• Recovered with Sequelae:   The signs/symptoms of the reported SAE have improved 
but not completely resolved, and a new baseline for the patient is established since 
full recovery is not expected  
• Fatal:  Patient died (the date of death should be entered as the SAE resolution date)  
• Unknown:   The outcome of the reported SAE is not available, e.g., patient is lost to 
follow-up 
9.4.3.6. Follow-up of Adverse Event  
Investigator Follow -up 
During the Study Period, the Investigator should follow each AE until the event has resolved to 
baseline grade or better, the event is assessed as stable, the patient is lost to follow -up, or the 
patient withdraws consent.  Every effort should be made to follow all SAEs considered  to be 
related to Study Drug or related to study procedures until a final outcome can be reported.  
Resolution of AE (with dates) should be documented on the eCRF and in the patient’s medical 
record to facilitate source data verification.   
Investigators sh ould follow -up, or support the Sponsor’s effort to follow up, with all pregnancies 
reported during the study from either the study patient or the female partner of the male study 
patient until pregnancy outcome is available.   
Sponsor Follow -up 
For SAEs an d pregnancy cases in patients who have completed or terminated the study, the 
Sponsor or a designee should follow -up by telephone, fax, email, and/or a monitoring visit to 
obtain additional case details and outcome information (e.g., from hospital discharg e summaries, 
consultant reports, or autopsy reports) in order to perform an independent medical assessment of 
the reported case.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
56 9.5. Procedures for Handling Special Situations  
9.5.1. Abnormalities of Laboratory Tests  
Clinically significant abnormal laboratory test re sults may, in the opinion of the Investigator, 
constitute or be associated with an AE.  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hyp ocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be listed in preference to abnormal laboratory values as AEs.  
Clinically significant abnormalities will be monitored by the Investigator until the p arameter 
returns to its baseline value or until agreement is reached between the Investigator and Sponsor 
Medical Monitor.  Laboratory abnormalities deemed not clinically significant (NCS) by the 
Investigator should not be reported as AEs.  Similarly, labo ratory abnormalities reported as AEs 
by the Investigator should not be deemed NCS on the laboratory sheet.  
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory reports will serve as source docume nts and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values.  
9.5.2. Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospitalized; the Study Center must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled t reatment was 
scheduled (or was on a waiting list to be scheduled) prior to obtaining the patient’s 
consent to participate in the study  
• The condition that required the prescheduled or elective procedure or routinely 
scheduled treatment was present before an d did not worsen or progress in the opinion 
of the Investigator between the patient’s consent to participate in the study and the 
timing of the procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospital admission  
9.5.3. Dosing Errors  
Study Drug ( ISIS 721744 or placebo) dosing errors (including overdose, underdose, and 
administration error) should be documented as protocol deviations.  A brief description should be 
provided in t he deviation, including whether the patient was symptomatic (list symptoms) or 
asymptomatic, and the event accidental or intentional.  
Dosing details should be captured on the Dosing eCRF.  If the patient takes a dose of Study Drug 
(ISIS 721744 or placebo) that exceeds protocol specifications and the patient is symptomatic, 
then the symptom(s) should be documented as an AE and be reported per Section  9.4. 
An overdose is the accidental or intentional use of a drug in an amount higher than the dose 
being studied.  An overdose or incorrect administration of study treatment is not itself an AE, but 
it may result in an AE.  All AEs associated with an overdose or  incorrect administration of Study 
Drug should be recorded on the Adverse Event eCRF.  If the associated AE fulfills seriousness 
criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24  hours 
after learning of the event).  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
57 Should an overdose occur , the Investigator or designee should refer to the “Guidance for 
Investigator” section of the Investigator’s Brochure and  contact the Sponsor or designee within 
24 hours. 
9.5.4. Contraception and Pregnancy  
Male patients and female patients o f childbearing potential must continue to use  highly effective  
contraception with their partners, or refrain from sexual activity, as described in Section  6.3.1. 
If a patient becomes pregnant or a pregnancy is suspected, or if a male patient makes or believes 
that he has made someone pregnant during the study, then the Study Center staff must be 
informed immediately .  An Initial Pregnancy Form should be s ubmitted to the Sponsor or 
designee within 24 hours  of first learning of the occurrence of pregnancy.  Follow -up 
information including delivery or termination is reported by designating as ‘Follow -up’ on the 
Pregnancy Forms and reported within 24 hours.  
Payment for all aspects of obstetrical care, child or related care will be the patient’s 
responsibility.   
Female patients :  If a suspected pregnancy occurs while on the study (including the 
Post-Treatment Period), a pregnancy test will be performed.  The pa tient with a confirmed 
pregnancy will be immediately withdrawn from treatment with Study Drug.  However, the 
patient will be encouraged to complete the Post -Treatment Period of the study to the extent that 
study procedures do not interfere with the pregnan cy.  Regardless of continued study 
participation, the study physician will assist the patient in getting obstetrical care and the 
progress of the pregnancy will be followed until the outcome of the pregnancy is known (i.e., 
delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a 
child, the Study Center and Sponsor may require access to the mother and infant’s medical 
records to obtain additional information relevant to the pregnancy progress and outcome.  A 
longer follow-up may be required if a newborn child experiences a medical condition.  
Follow-up will be performed to the extent permitted by the applicable regulations and privacy 
considerations; e.g., pregnancy ICF may be required.  
Male patients :  The progres s of the pregnancy of a male patient’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor m ay 
follow-up with the mother and may request access to the mother and infant’s medical records to 
obtain additional information relevant to the pregnancy progress and outcome.  A longer 
follow-up may be required if a newborn child experiences a medical con dition.  Follow -up will 
be performed to the extent permitted by the applicable regulations and privacy considerations; 
e.g., partner ICF may be required.  
10. STATISTICAL CONSIDER ATIONS  
The sections below indicate the overall structure and approach to the analy sis of this study.  A 
detailed SAP incorporating these sections below will be prepared separately.  The SAP will 
outline all data handling conventions, including software, and specify additional statistical 
methods to be used for analysis.  The study objec tives and endpoints are listed in Sections  1.1 
and 1.2, respectively.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
58 10.1. Sample Size Considerations  
The study will enroll a total of approximately 24 patients with HAE.  Approximately 18 patients 
with HAE -1/HAE-2 are planned to be enrolled in Part A o f the study and, in parallel, 
approximately 6  patients with HAE -nC1-INH are planned to be enrolled in Part B of the study.  
Due to the rarity of HAE -nC1-INH, enrollment in Part B may be ended early if Study Centers are 
unable to enroll sufficient patients;  this will not impact completion of Part A.  Patients with 
HAE-1/HAE-2 (Part A) will be randomized to SC injections of ISIS 721744 80 mg or placebo 
administered every 4  weeks in a 2:1  ratio (ISIS 721744:placebo), and patients with 
HAE-nC1-INH (Part B) will  be administered open -label SC injections of ISIS  721744 80  mg 
every 4 weeks.  
The sample size of 18 patients with HAE -1/HAE-2 (12 patients administered SC injections of 
ISIS 721744 80 mg and 6 patients administered placebo) is from clinical considerations for 
sufficient safety and tolerability evaluation.  The primary endpoint is the time -normalized 
number of HAE attacks (per month) from Week  1 to Week  17.  From historical data, the placebo 
group is estimated to have 6.8 HAE attacks per 4 -month period.  If the ISIS 721744 80 mg group 
is assumed to have 2.8 HAE attacks per 4 -month period, then with a 0.05 significance level and 
Poisson model, the sample size of 18  patients will provide at least 90% power for the primary 
endpoint, considering a 10% missing dat a or dropout rate for both active treatment and placebo.  
There is no statistical rationale for the sample size of 6  patients with HAE -nC1-INH. 
10.2. Populations  
The Safety Population will include all enrolled patients who receive at least 1 dose of Study 
Drug (ISIS 721744 or placebo).  
The Intent -to-Treat (ITT) Population will include all enrolled or randomized patients.  
The Per-Protocol (PP) Population will include all patients in the ITT Population who are treated 
according to the protocol without any major deviations.  
The PK Population will include all patients who are enrolled and receive at least 1 dose of Study 
Drug (ISIS 721744 or placebo) and have at least 1 evaluable PK sample.  
10.3. Definition of Baseline  
For platelets, Baseline will be defined as the avera ge of all non -missing pre -dose assessments.  
For other assessments, if there are 2 or more pre -dose values available, Baseline will be defined 
as the average of the pre -dose Study Day 1 value and the last pre -dose value prior to Study 
Day 1.  If there is on ly 1 pre-dose measurement available, then it will be assigned as Baseline.   
10.4. Data and Safety Monitoring Board  
An independent DSMB will be established prior to the initiation of the study.  The DSMB will 
be responsible for monitoring the overall safe conduc t of the study.  Based on its ongoing 
assessment of the safety and tolerability of ISIS 721744, the DSMB will provide 
recommendations to the Sponsor for modifying, stopping, or continuing the study as planned.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
59 Details on the safety assessments, frequency of review, meeting schedules and controlled access 
to unblinded data are outlined in the DSMB Charter and SAP.  
10.5. Interim Analysis  
No interim analysis is planned for this study.  
10.6. Planned Methods of Analysis  
10.6.1. Demographic and Baseline Characteristics  
Demographic and baseline characteristics will be summarized using descriptive statistics by 
treatment group.  Patient disposition will be summarized by treatment group.  All patients 
enrolled will be included in a summary of patient disposition.  
10.6.2. Safety Analysis  
The Safety Population will be used for all safety analyses.   
The safety and tolerability of ISIS 721744 will be assessed by determining the number, type, 
severity, and dose -relationship of AEs; vital signs; ECGs; and clinical laboratory parameters.  
Safety resu lts in patients dosed with ISIS 721744 will be compared to safety results in patients 
dosed with placebo.  
Treatment duration and amount of Study Drug (ISIS 721744 or placebo) received will be 
summarized by treatment group.  Patient incidence rates of all A Es will be tabulated by Medical 
Dictionary for Regulatory Activities (MedDRA™) system organ class and by MedDRA preferred 
term.  Tables and/or narratives of treatment -emergent deaths and serious and significant AEs, 
including early withdrawals due to AEs, will also be provided.  
All TEAEs, all TEAEs potentially related to Study Drug, all treatment -emergent SAEs, and all 
treatment -emergent SAEs potentially related to Study Drug (ISIS 721744 or placebo) will be 
summarized.  
Laboratory tests to ensure patient sa fety, including chemistry panel, complete blood count with 
differential, coagulation panel, and complement, will be summarized by study visit for each 
treatment group.  These safety variables will also be presented as change and percent change 
from Baselin e over time after Study Drug (ISIS 721744 or placebo) administration, as 
appropriate.  
Vital sign and ECG measures will be tabulated by treatment group.  In addition, the number of 
patients who experience abnormalities in clinical laboratory evaluations wil l be summarized by 
treatment group.  
10.6.3. Efficacy Analysis  
The ITT Population will be used for all efficacy analyses.  The PP Population will be used for a 
sensitivity analysis to assess robustness of the efficacy analysis results.  
The definition of an HAE attack, including discrete attacks, is provided in Section  6.2.1. 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
60 10.6.3.1. Primary Efficacy Analysis  
The primary endpoint is the time -normalized number of HAE at tacks (per month) from Week  1 
to Week 17. 
The Part A data will be analyzed using a Poisson regression model with treatment group as a 
fixed effect and the number of baseline HAE attacks as a covariate, and the logarithm of 
exposure in month will be used as  the offset.  
The least-squares means, standard errors, and the 2 -tailed 95% confidence intervals for the 
treatment group and placebo group will be presented.  
The Part B data will be summarized using descriptive statistics.  
10.6.3.2. Secondary Efficacy Analysis  
The secondary endpoints include the time -normalized number of HAE attacks (per month) from 
Week 5 to Week  17; the time -normalized number of moderate or severe HAE attacks (per 
month) from Week  5 to Week  17; the number of patients with a clinical response (defi ned as a 
≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in HAE attack rate) by Week  17; the number 
of HAE attacks requiring acute therapy from Week  5 to Week  17; cHK levels at Weeks  9 and 17; 
PKK activity at Weeks  9 and 17; consumption of on -demand medicat ion at Weeks  9 and 17; and 
AE-QoL questionnaire score at Weeks  9 and 17. 
For Part A, the time -normalized number of HAE attacks (per month) from Week  5 to Week  17 
and the time -normalized number of moderate or severe HAE attacks (per month) from Week  5 to 
Week 17 will be analyzed in a similar way to the primary efficacy endpoint.  
Continuous variables will be summarized by descriptive statistics (n, mean, median, standard 
deviation, minimum, and maximum) by treatment group.  Continuous variables will also be 
analyzed using analysis of covariance or analysis of variance.  The least -squares means, standard 
errors, and the 2 -tailed 95% confidence intervals for the treatment group and placebo group will 
be presented.  
Categorical variables will be summarized by freq uency and percentage for the treatment group 
and placebo group.  Categorical variables will be analyzed using a Pearson’s Chi -square test or 
Cochran-Mantel-Haenszel test.  
The Part B data will be summarized using descriptive statistics.  
10.6.3.3. Exploratory Efficacy  Analysis 
Exploratory efficacy endpoints include the number of HAE attack -free patients by Week  17 and 
potential exposure response analysis using relevant exposure parameters and biomarkers.  All 
exploratory efficacy endpoints will be analyzed using the sa me methods as described for the 
secondary efficacy endpoints.  
10.6.4. Pharmacokinetic Analysis  
The plasma PK of ISIS 721744 will be assessed following SC administration.  For all patients, 
Pre-Dose (trough) and Post-Treatment plasma ISIS 721744 concentrations will  be determined 
and summarized using descriptive statistics.  Plasma terminal elimination half -life will also be 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
61 calculated using the Post-Treatment follow up ISIS 721744 plasma concentrations, if data 
permits.  For patients in the PK sub group, non-compartmental PK analysis of ISIS 721744 will 
be carried out on each individual patient dataset.   
Pharmacokinetic parameters include (but are not limited to) the following:  C max, Tmax, AUC, and  
t½.  Other plasma PK parameters, as appropriate, may be determined or calculated at the 
discretion of the PK scientist.  
Metabolite identification and profiling may be conducted on select plasma samples.  
Plasma PK parameters will be summarized using descriptive statistics.  Additional details 
regarding the PK analysis along with  immunogenicity  (IM) analysis will be described in the 
SAP. 
Analysis of potential exposure -response relationship between biomarkers and PK measures may 
also be explored.  
Population PK and PK/PD analyses may be performed using PK data from this study , and/or 
combined with other ISIS 721744 clinical PK/PD data later in the development timeline.  
11. INVESTIGATOR’S REGUL ATORY OBLIGATIONS  
11.1. Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential 
patient popu lation, based on an English version provided by the Sponsor or designee.  
Before a patient’s participation in the study, the Investigator is responsible for obtaining written 
informed consent from the patient after adequate explanation of the aims, methods,  anticipated 
benefits, and potential hazards of the study and before any protocol -specific screening 
procedures or any Study Drug (ISIS 721744 or placebo ) are administered.  The patient must be 
given sufficient time to consider whether to participate in th e study.   
The acquisition of informed consent and the patient’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the ICF 
should be signed and personally dated by the patient and by the  person who conducted the 
informed consent discussion (not necessarily an Investigator).  The original signed ICF should be 
retained in the Study Master File and in any other locations required by institutional policy, and a 
copy of the signed consent form  should be provided to the patient.  
11.2. Ethical Conduct of the Study  
All applicable regulations and guidelines of current GCP as well as the demands of national drug 
and data protection laws and other applicable regulatory requirements must be followed.   
11.3. Independent Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed ICF, other written patient information, and any proposed 
advertising material must be submitted to the IEC/IRB  for written approval.  A copy of the 
written approval of the  protocol and ICF must be received by the Sponsor or designee before 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
62 recruitment of patients into the study and shipment of Study Drug.  A copy of the written 
approval of any other items/materials that must be approved by the Study Center or IEC/IRB  
must also be received by the Sponsor or designee before recruitment of patients into the study 
and shipment of Study Drug.  The Investigator’s Brochure must be submitted to the IEC/IRB for 
acknowledgement.  
The Investigator must submit to and, where necessary, ob tain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH 
GCP.  The Investigator should also notif y the IEC/IRB  of SAEs occurring at the Study Center 
and other AE reports received from the Sponsor or designee, in accordance with local 
procedures.  
The Investigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study.  Copies of the Investigator’s reports, all IEC/IRB  submissions and the 
IEC/IRB continuance of approval must be sent to the Sponsor or designee.  
11.4. Patient Confidentiality  
The Investigator must ensure that the patient’s confidentiality is maintai ned.  On the case report 
forms or other documents submitted to the Sponsor or designee, patients should be identified by 
initials (if permitted by local law) and a patient identification number only.  Documents that are 
not for submission to the Sponsor or  designee (e.g., signed ICFs) should be kept in strict 
confidence by the Investigator.  
In compliance with federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the compan y, of the regulatory 
agency(s), and the IEC/IRB direct access to review the patient’s original medical records for 
verification of study -related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and r eports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality o f the patient.  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.1. Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor or designee.  
Agreement from the Investigator must be obtained for all protocol amendments and amendments 
to the informed consent document.  The regulatory authority and IEC/IRB m ust be informed of 
all amendments and give approval for any amendments likely to affect the safety of the patients 
or the conduct of the study.  The Investigator must send a copy of the approval letter from the 
IEC/IRB to the Sponsor or designee.  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
63 12.2. Study Ter mination  
The Sponsor or designee  reserves the right to terminate the study.  The Investigator reserves the 
right to terminate their participation in the study , according to the terms of the Study Center 
contract.  The Investigator/Sponsor or designee shoul d notify the IEC/IRB in writing of the 
study’s completion or ET and send a copy of the notification to the Sponsor or designee.  
12.3. Study Documentation and Storage  
An eCRF utilizing an Electronic Data Capture application will be used for this study.  
The Invest igator should ensure that all appropriately qualified persons to whom he/she has 
delegated study duties are recorded on a Sponsor -approved Delegation of Site Responsibilities 
Form. 
Source documents are original documents, data, and records from which the p atient’s case report 
form data are obtained.  These include but are not limited to hospital records, clinical and office 
charts, laboratory and pharmacy records, imaging, and correspondence .  In this study, eCRFs 
may not be used as source documents.  
The Investigator and Study Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation in accordance with ICH 
GCP, suitable for inspection at any time by representatives from the Spons or or designee  and/or 
applicable regulatory authorities.  Elements should include the following:  
• Patient files containing completed case report forms, informed consents, and 
supporting copies of source documentation  
• Study files containing the protocol with  all amendments, Investigator’s Brochure, 
copies of pre -study documentation and all correspondence to and from the IEC/IRB 
and the Sponsor or designee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug 
Product Accountability Record, Return of Study Drug Product for Destruction, final 
Study Drug product reconciliation, and all drug -related correspondence  
In addition, all original source documents supporting entries in the case report forms must be 
maintained and be readily avai lable. 
No study document should be destroyed without prior written agreement between the Sponsor or 
designee and the Investigator.  Should the Investigator wish to assign the study records to 
another party or move them to another location, he/she must noti fy the Sponsor or designee.  
12.4. Study Monitoring  
The Sponsor representative and regulatory authority inspectors are responsible for contacting and 
visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting 
the various records of the study (e.g., case report forms and other pertinent data) provided that 
patient confidentiality is respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular 
intervals throughout the study to ver ify adherence to the protocol; completeness, accuracy, and 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
64 consistency of the data; and adherence to local regulations on the conduct of clinical research.  
The monitor should have access to patient medical records and other study -related records 
needed to  verify the entries on the case report forms.  
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved.  
In accordance  with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinical Quality Assurance Department (or designees).  
Inspection of Study Center facilities (e.g., pharmacy, drug storage areas, labora tories) and review 
of study-related records will occur to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be perform ed on 
patient data received by the Sponsor or designee.  During this review, patient data will be 
checked for consistency, omissions, and any apparent discrepancies.  In addition, the data will be 
reviewed for adherence to the protocol and GCP.  To resolve  any questions arising from the 
clinical data management review process, data queries and/or Study Center notifications will be 
sent to the Study Center for completion and return to Sponsor or designee.  
The Principal Investigator will sign and date the ind icated places on the case report form.  These 
signatures will indicate that the Principal Investigator inspected or reviewed the data on the case 
report form, the data queries, and the Study Center notifications, and agrees with the content.  
12.5. Language  
Case report forms must be completed in English.  Generic names and trade names are acceptable 
for concomitant medications.  Combination medications should be recorded using their trade 
name. 
All written information and other material to be used by patients and investigative staff must use 
vocabulary and language that are clearly understood.  
12.6. Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical studies and will follow 
applicable local compensation laws.  Patients will be treate d and/or compensated for any 
study-related illness/injury in accordance with the information provided in the Compensation for 
Injury section of the ICF.   
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
65 13. REFERENCES  
Altmann K -H, Dean NM, Fabbro D, et al. Second generation of antisense oli gonucleotides: From nuclease 
resistance to biological efficacy in animals. CHIMIA Int J Chem 1996; 50: 168‑176.  
Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am 
Physicians 1997; 109: 164‑173.  
Clinical Trial Facilitation  Group 2014. Recommendations related to contraception and pregnancy testing in clinical 
trials. Heads of Medicines Agencies Website. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA _CTFG_Contraception.pdf. Accessed December 5, 2019.  
Crooke ST, and Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996; 
36: 107-129. 
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor -alpha phosphorothioate 2' -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419 -
1428. 
Girolami A, Scarparo P, Candeo N, et al. Congenital prekallikrein deficiency. Expert Rev Hematol 2010; 3: 68 5-
695. 
Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice. J Pharmacol Exp Ther 2000; 292: 468 -479. 
Inoue H, Hayase Y, Iwai S, et al. Sequence -dependent hydrolysis of RNA using modified ol igonucleotide splints 
and RNase H. FEBS Lett 1987; 215: 327 -330. 
Lara‑Marquez ML, Christiansen SC, Riedl MA, et al. Threshold -stimulated kallikrein activity distinguishes 
bradykinin - from histamine -mediated angioedema. Clin Exp Allergy 2018; 48: 1429‑1438.  
Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of 
hereditary angioedema -The 2017 revision and update. Allergy 2018; 73: 1575‑1596.  
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and  specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem 1999; 274: 1715 -1722. 
Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2' -modified oligonucleotides containing 2' -deoxy gaps as 
antisense inhibi tors of gene expression. J Biol Chem 1993; 268: 14514 -14522. 
Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using 
triantennary  N-acetyl galactosamine improves potency 10 -fold in mice. Nucleic Acids Res 20 14; 42: 8796 -8807. 
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010; 115: 168 -186. 
Schulman S, and Kearon C. Definition of major bleeding in clinical inv estigations of antihemostatic medicinal 
products in non -surgical patients. J Thromb Haemost 2005; 3: 692 -694. 
Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 
1995; 75: 591 -609. 
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people 
with raised lipoprotein(a): two randomised, double -blind, placebo -controlled, dose -ranging trials. Lancet 2016; 388: 
2239-2253. 
Weller K, Groffik A, Mager l M, et al. Development, validation, and initial results of the Angioedema Activity 
Score. Allergy 2013; 68: 1185 -1192. 
Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense 
oligonucleotides: a nove l antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684 -4692. 
Zuraw BL, and Christiansen SC. HAE Pathophysiology and Underlying Mechanisms. Clin Rev Allergy Immunol 
2016; 51: 216 -229. 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
66 14. APPENDICES  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
67 APPENDIX  A. SCHEDULE OF PROCEDUR ES 
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
68 Appendix A . Schedule of Procedures  
 Screening1 Treatment Period (12 Weeks)  Post-Treatment Period16 
(13 Weeks) 
Study Week/Day  Weeks -8 to -1 
Days -56 to -1 Week 1 
Day 1 Week 3 
Day 1517 Week 5 
Day 2917 Week 9 
Day 5717 Week 13 
Day 8517 Week 17 
Day 113 
or ET17 Week 21 
Day 
14117 Week 26 
Day 
17617 
Visit Window (Days)  ± 0 ± 0 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 
Informed Consent  X         
Inclusion/Exclusion  X         
Demographics and Medical 
History (including detailed 
HAE history)  X         
Prior/Concomitant 
Medications (including HAE 
treatment)  X X X X X X X X X 
Body Weight and Height2 X X X X X X X X X 
Physical Examination  X X  X X X X X X 
Vital Signs3 X X X X X X X X X 
HIV, Hepatitis  B, and 
Hepatitis C  X         
FSH4 X         
Pregnancy Test5 X X  X X X X X X 
Clinical Laboratory 
Parameters (chemistry, 
hematology, complement, and 
coagulation)6, 7 X X X X X X X X X 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
69 Appendix A . Schedule of Procedures Continued  
 Screening1 Treatment Period (12 Weeks)  Post-Treatment Period16 
(13 Weeks) 
Study Week/Day  Weeks -8 to -1 
Days -56 to -1 Week 1 
Day 1 Week 3 
Day 1517 Week 5 
Day 2917 Week 9 
Day 5717 Week 13 
Day 8517 Week 17 
Day 113 
or ET17 Week 21 
Day 
14117 Week 26 
Day 
17617 
Visit Window (Days)  ± 0 ± 0 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 
Urinalysis X X X X X X X X X 
Threshold -Stimulated 
Kallikrein Activity 
(if applicable)8 X         
Genetic Diagnostic Testing 
(if applicable)9 X         
AE-QoL X X   X  X  X 
Angioedema Activity 
Score10 X X X X X X X X X 
HAE Attack Assessment 
(including on -demand 
treatment)11, 12 X X X X X X X X X 
12-Lead ECG X X   X  X  X 
Randomization13  X        
Study Drug Administration 
(ISIS 721744 or placebo)  X  X X X    
Adverse Events  X X X X X X X X X 
Immunogenicity Testing   Xa X Xa Xa  X  X 
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
70 Appendix A . Schedule of Procedures Continued  
 Screening1 Treatment Period (12 Weeks)  Post-Treatment Period16 
(13 Weeks) 
Study Week/Day  Weeks -8 to -1 
Days -56 to -1 Week 1 
Day 1 Week 3 
Day 1517 Week 5 
Day 2917 Week 9 
Day 5717 Week 13 
Day 8517 Week 17 
Day 113 
or ET17 Week 21 
Day 
14117 Week 26 
Day 
17617 
Visit Window (Days)  ± 0 ± 0 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 
PK Blood Sampling14  Xb X Xa Xa Xb X X X 
PD Blood Sampling15 X Xa X Xa Xa Xa X X X 
Inflammatory Panel  X Xa X Xa Xa Xa X X X 
Note: When multiple procedures are scheduled at the same visit, clinical assessments and procedures should be performed prior to St udy Drug administration, 
unless otherwise indicated, and should proceed in the following order:  vital signs, physical examinations , patient-reported outcomes (such as the AAS and 
the AE-QoL questionnaire), ECGs, and collection of blood and/or urine for laboratory assessments.   
1 The Screening Period is up to 8 weeks in dur ation.  A patient may be randomized after fewer than 8 weeks of Screening if the patient experiences ≥ 2 HAE 
attacks in less than 8 weeks and has completed all other screening activities and has met all other eligibility requirements.  
2 Height will be measured at Screening only.   
3 Vital signs will include blood pressure, heart rate, respiratory rate, and body temperature and should be t aken after sitting for at least 5 min.   
4 For confirmation of menopause at Screening per inclusion criteria . 
5 Only for women who are not surgically sterile or post -menopausal.  A serum pregnancy test will be performed during Screening and urine pregnancy tests 
will be performed at all other study visits.   
6 If the platelet value, serum creatinine, or liver enzyme  tests are uninterpretable (e.g., due to clumping, hemolysis, or quantity not sufficient) or missing, a 
repeat blood specimen should be re -drawn as soon as possible (ideally within 7 days).  
7 For a complete list of laboratory analytes, refer to Appendix  B. 
8 Will be assessed only in patients who have HAE -nC1-INH without a factor XII mutation or the plasminogen or angiopoietin -1 mutation.   
9 Will be performed only for patients who do not have HAE genetic diagnostic testing results prior to Screening.  
10 The AAS questionnaire will be completed by patients on a daily basis (minimum of 4 daily assessments per week) for the durati on of the study.  Patient s will 
be instructed on the use of the AAS during Screening and will record their HAE attacks using the AAS throughout the Screening  Period (daily during up to 
8 consecutive weeks) to confirm study eligibility; patients are required to experience at least 2 HAE attacks (assessed by the AAS and confirmed by the 
Investigator) during the Screening Period to be eligible for enrollment.  If a patient experiences a third attack, the patien t should be randomized as soon as 
possible, assuming all other screening ac tivities have been completed and the patient meets all other eligibility requirements; in such cases, the Screening 
Period may be shorter than 8  weeks.  Enrolled patients will continue to record HAE attacks using the AAS throughout the Treatment and Post -Treatment 
Periods.  
  
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol  5 May 2020  
 
71 Legend Continued  
 
11 Historical HAE attack information will be collected at Screening.  During the study, patients will be instructed to report de tails of any HAE attack to the study 
site within 72 hours of the onset of the attack.  Th roughout the Screening, Treatment, and Post -Treatment Periods, site personnel will contact the patient once 
a week (at approximately 7 days after the last contact with the patient) in order to inquire about any attack that may have o ccurred.  In addition, during study 
visits, site personnel will inquire about any new HAE attack information that was not provided through patient contact with t he site. 
12 The following details relating to the localization, severity, and course of all HAE attacks that occured s ince the previous visit will be collected:   date/time of 
symptom onset; description of symptoms; location of symptoms (peripheral angioedema, abdominal angioedema, or laryngeal angio edema); impact of HAE 
attack on activity level; HAE attack severity (mild,  moderate, or severe); need for assistance, medical intervention, emergency room visit, or hospitalization; 
medications to treat the attack; HAE attack course, including if the HAE attack(s) in question was a typical attack for the p atient, or if there was  an alternative 
diagnosis; and date/time symptoms resolved.  The number of HAE attacks that required on -demand treatment, and the frequency and dose of on -demand 
treatment, will also be recorded.  
13 After all screening assessments have been completed and t he Investigator has verified that the patient is eligible.  
14 Refer to Appendix  C for the PK Sampling Schedule.  
15 To be collected at each visit to asses s plasma PKK, plasma proenzyme activation, and cHK levels.  
16 Patients who complete Study Visit Week 17 , and meet eligibility requirements , may start the Treatment Period in the ISIS 721744 -CS3 OLE study anytime 
after the Week 17 visit and discontinue participation in the CS2 Post -Treatment Evaluation Period .  
17 Assessments and procedures  may be conducted by either a Home Healthcare professional  (if available), or the Study Center as arranged by the Study Center 
personnel.  Physical Exam will be labele d Body Assessment if conducted by Home Healthcare professional.   Study Drug administration by Home Health care 
professional may be done on ly after study drug for home use is available . 
 
Time (time is in reference to Study Drug administration [ISIS 721744 or  placebo]):  
a Pre-dose. 
b Pre-dose, 1, 2, 4, and 6 hours post -dose (PK Subgroup) or Pre-dose and 2 -hours post -dose. 
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
72 APPENDIX  B. LIST OF LABORATORY A NALYTES  
 
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
73 Appendix B  List of Laboratory Analytes  
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better characterize the profile of ISIS 721744 or other similar 
oligonucleotides.  
Chemistry Panel  
• Sodium 
• Potassium  
• Chloride 
• Bicarbonate  
• Total protein  
• Albumin 
• Calcium 
• Magnesium  
• Phosphorus  
• Glucose 
• BUN 
• Creatinine  
• Cholesterol  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin 
• Indirect (unconjugated) 
bilirubin 
• ALT 
• AST 
• Alkaline phosphatase  
• Creatine kinase  
• GGT Screening Tests  
• Hepatitis B surface 
antigen 
• Hepatitis C antibody  
• HIV antibody  
• FSH (for 
confirmation of 
menopause at 
Screening per 
inclusion criteria ) 
• Serum βhCG (only 
women who are not 
surgically sterile or 
post-menopausal)  
 
Coagulation  
• aPTT (sec)  
• PT (sec) 
• INR 
• Plasmin-antiplasmin 
complexes  
• D-dimer 
 
Complement  
• C5a 
• Bb 
• C4 split products  
• C4 
 
Pharmacodynamics 
Panel 
• Plasma PKK  
• Plasma proenzyme 
activation  
• cHK Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets 
• White blood cells 
(WBC) 
• WBC Differential 
(% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 721744 
concentration in plasma 
 
Immunogenicity  
• Anti-ISIS 721744 
antibodies  Inflammatory  
• hs-CRP  
 
Urinalysis  
• Color 
• Appearance  
• Specific gravity  
• pH 
• Protein/creatinine ratio  
• Protein 
• Blood 
• Ketones 
• Urobilinogen  
• Glucose 
• Bilirubin 
• Leukocyte esterase  
• Nitrate 
• eGFR 
• Microscopic 
examination2 
 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments, or to assess other actions of ISIS 721744 with plasma 
constituents.  
2 Will be performed on abnormal findings unless otherwise specified.  
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
74 APPENDIX  C. PHARMACOKINETIC SAMP LING SCHEDULE   
 
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
75 Appendix C  Pharmacokinetic Sampling Schedule  
PK samples on Day 1 and Day 85 will be collected pre-dose, and 1, 2, 4, and 6 hours post -dose 
in PK subgroup only (approximately 6 patients) while pre-dose and 2 hours post -dose samples on 
Day 1 and Day 85 will be collected for all other patients.  The rest of the sampling schedule will 
be the same for both set s of pateints (see table below):  
 
Pharmacokinetic Sampling Schedule  
 Day 1 Day 15 Day 29 Day 57 Day 85 Day 113 Day 141 Day 176 
PK 
Subgroup  Blood:  
Pre-dose, 
1, 2, 4, 
and 
6 hours 
post-dose Blood: 
Anytime Blood: 
Pre-dose Blood: 
Pre-dose Blood:  
Pre-dose, 
1, 2, 4, 
and 
6 hours 
post-dose Blood:  
Anytime Blood: 
Anytime Blood: 
Anytime 
All 
Patients Blood: 
Pre-dose, 
2 hours 
post-dose Blood 
Anytime  Blood: 
Pre-dose  Blood: 
Pre-dose  Blood: 
Pre-dose, 
2 hours 
post-dose Blood 
Anytime  Blood 
Anytime  Blood 
Anytime  
 
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
76 APPENDIX  D. GRADING SCALE FOR AD VERSE EVENTS RELATIN G 
TO LABORATORY ABNORM ALITIES  
 
 
ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
77 Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities  
The following grading recommendations for adverse events relating to lab test abnormalities and 
adverse events at the injection site are based on the CTCAE Version 5.0, Novemb er 2017 with 
modifications outlined in the footnotes below.  
 
  

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
78  
 

ISIS 721744 -CS2 CONFIDENTIAL  Amendment 3  
Protocol   5 May 2020  
 
79  
 

Version: 1
Version Date: 05 May 2020
Title:A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the
Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense
Inhibitor of Prekallikrein, in Patients with Hereditary Angioedema
Protocol

721744-CS02 Protocol Amendment  05 May 2020 | 1.0  
  
 
 
 
 
 
 
 
IONIS PHARMACEUTICALS,  INC. 
 
 
ISIS 721744-CS2 
 
A Randomized, Double-Blind, Placebo -Controlled, Phase 2a Study 
to Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated  Antisense  Inhibitor  of Prekallikrein,  in Patients 
with Hereditary Angioedema  
 
Protocol Amendment  3 – 5 May 2020 
 
EudraCT  No: 2019-001044-22 
 
 
Trial Sponsor: Ionis Pharmaceuticals,  Inc. 
2855 Gazelle Court 
Carlsbad,  CA 92010 
Telephone  Number: 760-603-4665 
Fax Number: 760-603-2625 
 
Key Sponsor Contact: PPD  
Executive  Director, Clinical Development 
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad,  CA 92010 
Telephone  Number: PPD  

721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
2  
  
ISIS 721744-CS2 CONFIDENTIAL  Amendment  3 
Protocol 5 May 2020 
 
ISIS 721744-CS2 
Protocol Amendment  3 
EudraCT  No: 2019-001044-22 
 
Clinical Phase: 2a 
 
A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study 
to Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated  Antisense Inhibitor  of Prekallikrein,  in Patients 
with Hereditary Angioedema  
 
Protocol History: 
Original Protocol: 3 May 2019 
Amendment  1: 21 October 2019 
Amendment  2: 29 January 2020 
 
 
 
Sponsor:  
Ionis Pharmaceuticals,  Inc. 
Carlsbad, CA  92010 
 
 See electronic  signature and date attached at end of document   
 
PPD  
Vice President and Head of Clinical Development  
 
 
 
Confidentiality  Statement  
This document  contains confidential  information  of Ionis Pharmaceuticals, Inc.  that must not be 
disclosed to anyone other than the recipient study staff and members of the Independent Ethics 
Committee, Institutional Review Board, or authorized regulatory agencies.  This information 
cannot be used for any  purpose other than the evaluation or conduct of the clinical  investigation 
without the prior written consent of Ionis Pharmaceuticals, Inc.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
3  
  
ISIS 721744-CS2 CONFIDENTIAL  Amendment  3 
Protocol 5 May 2020 
 
Protocol Signature  Page 
 
 
Protocol Number:  ISIS 721744-CS2 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to 
Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated  Antisense  Inhibitor of Prekallikrein,  in Patients with 
Hereditary Angioedema  
Amendment:  Amendment  3 
Date: 5 May 2020 
 
 
I hereby acknowledge that I  have read and understand the attached clinical protocol, entitled “A 
Randomized, Double -Blind, Placebo-Controlled, Phase 2a Study  to Assess the Clinical Efficacy 
of ISIS 721744, a Second-Generation  Ligand-Conjugated  Antisense  Inhibitor of Prekallikrein,  in 
Patients with Hereditary Angioedema,” dated 5 May 2020, and agree to conduct the study as 
described herein.  
I agree to comply with the International  Conference  on Harmonisation  Tripartite  Guideline  on 
Good Clinical Practice.  
I agree to ensure that the confidential  information  contained  in this document  will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.  
 
 
 
 
 
Investigator’s  Signature  
 
 
Investigator’s  Name (please print) Date (DD Month YYYY) 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
4  
  
ISIS 721744-CS2 CONFIDENTIAL  Amendment  3 
Protocol 5 May 2020 
 
TABLE OF CONTENTS  
PROTOCOL  AMENDMENT  ................................ ................................ ................................ ........... 8 
PROTOCOL  SYNOPSIS  ................................ ................................ ................................ ............... 12 
STUDY DESIGN AND TREATMENT  SCHEMA  ................................ ................................ ........ 21 
STUDY GLOSSARY  ................................ ................................ ................................ ......................  22 
1. OBJECTIVES  AND ENDPOINTS  ................................ ................................ ............. 24 
1.1. Objectives  ................................ ................................ ................................ ....................  24 
1.1.1.  Primary Objective  ................................ ................................ ................................ ....... 24 
1.1.2.  Secondary  Objectives  ................................ ................................ ................................ .. 24 
1.1.3.  Exploratory  Objectives ................................ ................................ ................................  24 
1.2. Study Endpoints  ................................ ................................ ................................ .......... 24 
1.2.1.  Primary Endpoints  ................................ ................................ ................................ ....... 24 
1.2.2.  Secondary  Endpoints  ................................ ................................ ................................ ... 24 
1.2.3.  Safety Endpoints  ................................ ................................ ................................ .......... 25 
1.2.4.  Exploratory  Endpoints  ................................ ................................ ................................  25 
2. BACKGROUND  AND RATIONALE  ................................ ................................ ....... 25 
2.1. Overview  of Disease ................................ ................................ ................................ ... 25 
2.2. Therapeutic  Rationale  ................................ ................................ ................................ . 26 
2.3. ISIS 721744 ................................ ................................ ................................ .................  26 
2.3.1.  Mechanism  of Action ................................ ................................ ................................ .. 26 
2.3.2.  Chemistry  ................................ ................................ ................................ ....................  26 
2.3.3.  Preclinical  Experience  ................................ ................................ ................................ .. 28 
2.3.4.  Clinical Experience  ................................ ................................ ................................ ..... 28 
2.4. Rationale  for Dose and Schedule of Administration  ................................ ...................  29 
2.5. Benefit-Risk Assessment  ................................ ................................ ............................  29 
2.5.1.  Benefit Assessment  ................................ ................................ ................................ ..... 29 
2.5.2.  Risk Assessment  ................................ ................................ ................................ ......... 29 
2.5.3.  Overall Assessment  of Benefit:Risk  ................................ ................................ ............ 30 
3. EXPERIMENTAL  PLAN ................................ ................................ ...........................  30 
3.1. Study Design ................................ ................................ ................................ ............... 30 
3.2. Number of Study Centers ................................ ................................ ............................  31 
3.3. Number of Patients ................................ ................................ ................................ ...... 31 
3.4. Overall Study Duration and Follow-up ................................ ................................ ....... 31 
3.4.1.  Screening  ................................ ................................ ................................ .....................  31 
3.4.2.  Treatment  Period ................................ ................................ ................................ ......... 31 
3.4.3.  Post-Treatment  Period ................................ ................................ ................................ . 32 
3.5. End-of-Study ................................ ................................ ................................ ............... 32 
3.6. Data and Safety Monitoring  Board ................................ ................................ ............. 32 
4. PATIENT  ENROLLMENT ................................ ................................ ..........................  32 
4.1. Screening  ................................ ................................ ................................ .....................  32 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
5  
 ISIS 721744-CS2 CONFIDENTIAL  Amendment  3 
Protocol 5 May 2020 
4.2. Randomization  ................................ ................................ ................................ ............ 33 
4.3. Replacement  of Patients ................................ ................................ ..............................  33 
4.4. Unblinding  of Treatment  Assignment  ................................ ................................ ......... 33 
5. PATIENT  ELIGIBILITY  ................................ ................................ ............................  34 
5.1. Inclusion Criteria ................................ ................................ ................................ ......... 34 
5.2. Exclusion  Criteria ................................ ................................ ................................ ....... 35 
6. STUDY PROCEDURES  ................................ ................................ ..............................  36 
6.1. Study Schedule ................................ ................................ ................................ ............ 36 
6.1.1.  Screening  ................................ ................................ ................................ .....................  37 
6.1.2.  Treatment  Period ................................ ................................ ................................ ......... 37 
6.1.3.  Post-Treatment  Period ................................ ................................ ................................ . 38 
6.2. Study Assessments  ................................ ................................ ................................ ...... 39 
6.2.1.  Collection  of Hereditary  Angioedema  Attack Details ................................ .................  39 
6.2.2.  Patient-Reported Outcomes  ................................ ................................ ........................  40 
6.2.2.1.  Angioedema  Quality of Life Questionnaire  ................................ ................................  40 
6.2.2.2.  Angioedema  Activity Score ................................ ................................ ........................  40 
6.2.3.  Laboratory  Assessments  ................................ ................................ ..............................  41 
6.3. Restriction  on the Lifestyle of Patients ................................ ................................ ....... 41 
6.3.1.  Contraception  Requirements  ................................ ................................ .......................  41 
7. STUDY DRUG ................................ ................................ ................................ ............ 42 
7.1. Study Drug Description  ................................ ................................ ................................  42 
7.2. Packaging  and Labeling ................................ ................................ ..............................  42 
7.3. Study Drug Accountability  ................................ ................................ ..........................  42 
8. TREATMENT  OF PATIENTS ................................ ................................ ...................  43 
8.1. Study Drug Administration  ................................ ................................ .........................  43 
8.2. Other Protocol-Required Drugs ................................ ................................ ..................  43 
8.3. Other Protocol-Required Treatment  Procedures  ................................ .........................  43 
8.4. Treatment  Precautions  ................................ ................................ ................................ . 43 
8.5. Safety Monitoring  Rules ................................ ................................ .............................  43 
8.5.1.  Safety Monitoring  Rules for Liver Chemistry  Tests ................................ ...................  44 
8.5.2.  Safety Monitoring  Rules for Platelet Count Results ................................ ....................  44 
8.5.3.  Safety Monitoring  Rules for Renal Function  Test Results ................................ ......... 45 
8.5.4.  Safety Monitoring  for Minor  Bleeding Events ................................ ...........................  45 
8.6. Stopping Rules ................................ ................................ ................................ ............ 45 
8.6.1.  Stopping Rules for Liver Chemistry  Elevations  ................................ .........................  45 
8.6.2.  Stopping Rules for Platelet Count Results ................................ ................................ .. 46 
8.6.3.  Temporary  Stopping Rules for Renal Function  Test Results ................................ ...... 48 
8.7. Adjustment  of Dose and/or Treatment  Schedule ................................ ........................  48 
8.8. Discontinuation  of Study Drug ................................ ................................ ...................  48 
8.9. Withdrawal  of Patients from the Study Procedures  ................................ ....................  49 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
6  
 ISIS 721744-CS2 CONFIDENTIAL  Amendment  3 
Protocol 5 May 2020 
8.10. Concomitant Therapy  and Procedures  ................................ ................................ ........ 49 
8.10.1.  Concomitant  Therapy ................................ ................................ ................................ .. 49 
8.10.2.  Concomitant  Procedures  ................................ ................................ .............................  50 
8.11. Treatment  Compliance  ................................ ................................ ................................  50 
9. SERIOUS  AND NON-SERIOUS  ADVERSE  EVENT REPORTING  ......................  50 
9.1. Sponsor Review of Safety Information  ................................ ................................ ....... 50 
9.2. Regulatory  Requirements  ................................ ................................ .............................  50 
9.3. Definitions  ................................ ................................ ................................ ...................  51 
9.3.1.  Adverse Event ................................ ................................ ................................ ............. 51 
9.3.2.  Adverse Drug Reaction and Unexpected  Suspected  Adverse Drug Reaction ............. 51 
9.3.3.  Serious Adverse Event ................................ ................................ ................................  52 
9.3.4.  Adverse Events of Special Interest ................................ ................................ ............. 52 
9.4. Monitoring  and Recording  Adverse Events ................................ ................................  52 
9.4.1.  Serious Adverse Events ................................ ................................ ..............................  53 
9.4.2.  Non-Serious Adverse Events ................................ ................................ .......................  53 
9.4.3.  Evaluation  of Adverse Events (Serious and Non-Serious) ................................ ......... 53 
9.4.3.1.  Relationship  to the Study  Drug ................................ ................................ ...................  53 
9.4.3.2.  Severity ................................ ................................ ................................ .......................  54 
9.4.3.3.  Action Taken with Study Drug ................................ ................................ ...................  54 
9.4.3.4.  Treatment  Given for Adverse Event ................................ ................................ ........... 54 
9.4.3.5.  Outcome of the Adverse Event ................................ ................................ ...................  54 
9.4.3.6.  Follow-up of Adverse Event ................................ ................................ ........................  55 
9.5. Procedures  for Handling Special Situations  ................................ ................................  56 
9.5.1.  Abnormalities  of Laboratory  Tests ................................ ................................ ............. 56 
9.5.2.  Prescheduled  or Elective Procedures  or Routinely  Scheduled  Treatments  .................  56 
9.5.3.  Dosing Errors ................................ ................................ ................................ .............. 56 
9.5.4.  Contraception  and Pregnancy  ................................ ................................ .....................  57 
10. STATISTICAL  CONSIDERATIONS  ................................ ................................ ........ 57 
10.1. Sample Size Considerations  ................................ ................................ ........................  58 
10.2. Populations  ................................ ................................ ................................ ..................  58 
10.3. Definition  of Baseline ................................ ................................ ................................ . 58 
10.4. Data and Safety Monitoring  Board ................................ ................................ ............. 58 
10.5. Interim Analysis ................................ ................................ ................................ .......... 59 
10.6. Planned Methods of Analysis ................................ ................................ ......................  59 
10.6.1.  Demographic  and Baseline Characteristics  ................................ ................................ . 59 
10.6.2.  Safety Analysis ................................ ................................ ................................ ........... 59 
10.6.3.  Efficacy Analysis ................................ ................................ ................................ ........ 59 
10.6.3.1.  Primary Efficacy Analysis ................................ ................................ ..........................  60 
10.6.3.2.  Secondary  Efficacy Analysis ................................ ................................ ......................  60 
10.6.3.3.  Exploratory  Efficacy Analysis ................................ ................................ ....................  60 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
7  
 ISIS 721744-CS2 CONFIDENTIAL  Amendment  3 
Protocol 5 May 2020 
10.6.4.  Pharmacokinetic  Analysis ................................ ................................ ...........................  60 
11. INVESTIGATOR’S  REGULATORY  OBLIGATIONS  ................................ ............ 61 
11.1. Informed Consent ................................ ................................ ................................ ........ 61 
11.2. Ethical Conduct of the Study ................................ ................................ ......................  61 
11.3. Independent  Ethics Committee/Institutional  Review Board ................................ ....... 61 
11.4. Patient Confidentiality  ................................ ................................ ................................ . 62 
12. ADMINISTRATIVE  AND LEGAL OBLIGATIONS  ................................ ............... 62 
12.1. Protocol Amendments  ................................ ................................ ................................ . 62 
12.2. Study Termination  ................................ ................................ ................................ ....... 63 
12.3. Study Documentation  and Storage ................................ ................................ .............. 63 
12.4. Study Monitoring  ................................ ................................ ................................ ........ 63 
12.5. Language  ................................ ................................ ................................ .....................  64 
12.6. Compensation  for Injury ................................ ................................ .............................  64 
13. REFERENCES  ................................ ................................ ................................ ............ 65 
14. APPENDICES  ................................ ................................ ................................ ............ 66 
APPENDIX  A. SCHEDULE  OF PROCEDURES  ................................ ................................ ...... 67 
APPENDIX  B. LIST OF LABORATORY  ANALYTES  ................................ ...........................  72 
APPENDIX  C. PHARMACOKINETIC  SAMPLING  SCHEDULE  ................................ .......... 74 
APPENDIX D.  GRADING SCALE FOR ADVERSE EVENTS RELATING TO 
LABORATORY ABNORMALITIES  ................................ ..............................  76 
 
 
 
LIST OF TABLES  
Table 1: Study Drug Characteristics  ................................ ................................ ..........................  42 
Table 2: Actions in Patients with Low Platelet Count ................................ ...............................  47 
 
 
 
LIST OF FIGURES  
Figure 1: Design of GalNAc 3-Conjugated Chimeric 2ʹ -MOE Phosphorothioate 
Oligonucleotides (MOE -Gapmer) ................................ ................................ .............. 27 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
8  
  
 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
  
PROTOCOL  AMENDMENT   
 
 
Protocol Number:  ISIS 721744-CS2 
Protocol Title:  A Randomized,  Double-Blind, Placebo-Controlled,  Phase 2a Study to 
Assess the Clinical Efficacy of ISIS 721744, a Second -Generation 
Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients 
with Hereditary Angioedema  
Amendment  Number: 3 
Amendment Date: 5 May 2020 
 
 
The following  modifications  to Protocol ISIS 721744-CS2 Amendment  2, dated 29 January 
2020, have been made.  
1) To adjust the length of time patients must not have received lanadelumab, prior to 
screening  for ISIS 721744-CS2, from 6 months to 10 weeks (i.e., 5 times the ~14-day 
half life for lanadelumab).  
2) To decrease the burden of site visits where feasible for patients, Study Drug 
administration, assessements and procedures may be conducted by either a Home 
Healthcare  professional  (if available)  or the Study Center, as arranged by the Study 
Center personnel, for visits as noted in Appendix A . 
3) To decrease the burden of PK sampling for patients, only a subgroup of approximately  
6 patients (rather than all patients)  will have blood draws of pre-dose, 1, 2, 4, and 6 hours 
post-dose on Day 1 and Day 85.  This, along with a pre -dose and a 2 hour post -dose 
blood collection on Day  1 and Day  85 in all patients, will provide enough information to 
determine PK parameters.  
Minor changes (not included i n the list of changes below) have been made throughout the 
protocol to correct errors and/or to improve the overall clarity of the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
9  
  
The following  table provides a  summary list of major  changes to the  protocol: 
 
Protocol Section Description  of Change Rationale  
PROTOCOL 
SYNOPSIS  
Study Population 
Exclusion  Criteria 
 
Section 5.2.11.b 
Exclusion  Criteria Deletions  in strikeout and additions in bold: 
11.b Chronic prophylaxis  with Llanadelumab  within 
10 weeks 6 months prior to Screening  To adjust the length of time 
patients must not have received 
lanadelumab,  prior to screening 
for ISIS 721744 -CS2, to 
5 times the ~14 day half life for 
lanadelumab.  
PROTOCOL 
SYNOPSIS  
Study Visit Schedule 
and Procedures  
 
Section 6.1.2 
Treatment  Period Deletions  in strikeout and additions in bold: 
The first dose of Study Drug will be administered at the  
Study Center on Day 1.  ISIS 721744  Study Drug will be 
administered as a SC injection in the abdomen, thigh, or 
outer area of the upper arm by qualified personnel at the 
Study Center or Home Healthcare professional (if 
available and after dosing instructions and training are 
provided by qual ified site personnel) . The first dose of 
Study Drug will be administered  at the Study Center on 
Day 1. Study visits Center personnel (or Home 
Healthcare if available), will complete procedures  per 
the Schedule of Procedures in Appendix A. will be 
performed  during the Treatment Period at Week 1  
(Administration 1), Week 3 (safety monitoring), Week 5  
(Administration 2), Week 9 (Administration 3), and Week  
13 (Administration 4);  Home healthcare  provided to 
decrease the burden of site 
visits, where feasible, for  
patients. 
Section 6.1.3 
Post-Treatment 
Period Additions  in bold: 
Each patient will be followed for safety assessments  for up 
to 13 weeks after the last dose of Study Drug.  During the 
Post-Treatment Period, patients will return to the Study 
Center (or have Home Healthcare (if available), as 
arranged by the Study Center personnel, per the 
Schedule of Procedures in Appendix A) for visits at 
Weeks 17, 21, and 26/ET for safety and clinical laboratory 
evaluations and for blood sampling for PK/PD analyses.  Home healthcare  provided to 
decrease the burden of site 
visits, where feasible, for 
patients. 
Section 8.1 
Study Drug 
Administration  Additions  in bold: 
Study Drug (ISIS 721744 or placebo) will be administered 
as a single -SC injection once every 4 weeks by blinded 
study staff during  on-site visits at the Study  Centers or by 
Home Healthcare professional (if available and after 
dosing instructions and training are provided by 
qualified site personnel) . Home healthcare  provided to 
decrease the burden of site 
visits, where feasible, for 
patients. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
10  
  
Protocol Section Description  of Change Rationale  
Section 10.6.4 
Pharmacokinetics 
Analysis Deletions  in strikeout and additions in bold: 
The plasma PK of ISIS 721744 will be assessed following 
SC administration.  For all patients, pre-dose (trough) and 
post-treatment plasma ISIS 721744 concentrations will 
be determined and summarized using descriptive 
statistics.  Plasma terminal elimination half -life will also 
be calculated using the Post -Treatment follow up  
ISIS 721744 plasma concentrations,  if data permits. For 
patients in the PK sub group, n Non-compartmental PK 
analysis of ISIS 721744 will be carried out on each 
individual patient dataset.  Added paragraph  to define how 
PK data will be analyzed and  
described  
STUDY 
GLOSSARY  
 
Section 10.6.4 
Pharmacokinetics 
Analysis Additions  in bold: 
Additional  details regarding  the PK analysis along with 
immunogenicity  (IM) analysis will be described  in the 
SAP. Added “along with IM 
analysis” to clarify that 
immunogenicity  analysis will 
be performed  
Appendix  A 
Footnote Added: 
17 Assessments and procedures may be conducted by  either 
a Home Healthcare professional (if available), or the 
Study Center as arranged by the Study Center personnel. 
Physical Exam will be labeled Body Assessment if 
conducted  by Home Healthcare  professional.  Study drug 
administration by Home Healthcare professional may be 
done only after study drug for home use is available  Home healthcare  provided to 
decrease the burden of site 
visits, where feasible, for 
patients 
Appendix  A 
Footnote Additions  in bold: 
b Pre-dose, 1, 2, 4, and 6 hours post-dose (PK Subgroup) 
or Pre-dose and 2 -hours post -dose Added to note changes in PK 
schedule 
Appendix  A Removed:  
Week 3 pregnancy  test Pregnancy  test only needed 
every 4 weeks  
Appendix  B Removed 
Thyroid Panel 
TSH 
Free T4 
Free T3 Thyroid panel is not a per 
protocol assessment  
Appendix  C Added: 
PK samples on Day 1 and Day 85 will be collected pre-dose, 
and 1, 2, 4, and 6 hours post-dose in PK subgroup only 
(approximately 6 patients) while pre -dose and 2 hours post - 
dose samples on Day 1 and Day 85  will be collected for all 
other patients. The rest of the sampling schedule will be the 
same for both sets of pateints ( see table bel ow): Added to describe PK sampling 
 
  721744-CS02 Protocol Amendment  05 May 2020 | 1.0  
ISIS 721744 -CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
 
Protocol 
Section Description  of Change Rationale  
Appendix  C Addions in bold: To decrease the 
 burden of PK 
  Day 1 Day 15 Day 29 Day 57 Day 85 Day 113 Day 141 Day 176   sampling for 
 patients, only a 
subgroup of 
approximately  
6 patients (rather 
than all patients) All 
Patients Blood: 
Pre-dose, 
2 hours 
post-dose Blood 
Anytime Blood: 
Pre-dose Blood: 
Pre-dose Blood: 
Pre-dose, 
2 hours 
post-dose Blood 
Anytime Blood 
Anytime Blood 
Anytime 
         
 PK Blood: Blood: Blood: Blood: Blood: Blood: Blood: Blood: will have blood 
 Subgroup  Pre-dose, Anytime Pre-dose Pre-dose Pre-dose, Anytime Anytime Anytime draws of pre- 
  1, 2, 4,    1, 2, 4,    dose, 1, 2, 4, and 
  and    and    6 hours post- 
  6 hours    6 hours    dose on Day 1 
  post-dose    post-dose    and Day 85. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
12  
  
 
PROTOCOL  SYNOPSIS  
 
Protocol Title A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to Assess the 
Clinical Efficacy of ISIS 721744, a Second-Generation  Ligand-Conjugated  Antisense 
Inhibitor of Prekallikrein, in Patients with Hereditary Angioedema  
Study Phase 2a 
Indication  Hereditary  angioedema  (HAE) 
Primary 
Objective  The primary objective of the study is to evaluate the clinical efficacy of antisense 
inhibitor of prekallikrein  (ISIS 721744) in patients with HAE type 1 (HAE-1), HAE 
type 2 (HAE -2), or HAE with normal C1 -inhibitor (C1 -INH). 
Secondary 
Objectives  The secondary  objectives  of the study are to evaluate safety and tolerability  of 
ISIS 721744 in patients with HAE-1/HAE-2 or HAE with normal C1-INH (HAE-nC1- 
INH) and to evaluate the effect of ISIS 721744 on plasma prekallikrein (PKK) and 
other relevant biomarkers.  
Exploratory 
Objectives  The exploratory objectives of the study are to evaluate pharmacokinetics (PK) of 
ISIS 721744 (as a total full -length antisense oligonucleotide (ASO), including fully 
conjugated, partially conjugated, and unconjugated ISIS 721744) over time and to 
assess potential PK/pharm acodynamic  (PD) correlations  on relevant biomarkers  and 
clinical outcomes, as appropriate.  
Study Design The study will be randomized,  double-blind, and placebo-controlled  in Part A and will 
be open-label in Part B.  
Number of 
Patients Approximately 24 patients with HAE are planned to be enrolled in the study: 
approximately 18 patients with HAE -1/HAE-2 are planned to be enrolled in Part A of 
the study, and, in parallel, approximately  6 patients  with HAE-nC1-INH are planned to 
be enrolled  in Part B of the study.  Due to the rarity of HAE -nC1-INH, enrollment in 
Part B may be ended early if Study Centers are unable to enroll  sufficient  patients with 
HAE-nC1-INH; this will not impact completion of Part A.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
13  
  
PROTOCOL  SYNOPSIS  CONTINUED  
 
Study 
Population  Inclusion  Criteria 
1. Patients must provide written informed consent (signed and dated) and any 
authorizations required by local law and be able to comply with all study 
requirements for the duration of the study.  
2. Patients must be aged ≥ 18 years at the time of informed consent. 
3. Patients must have a documented  diagnosis  of HAE-1/HAE-2 (for inclusion in 
Part A) or HAE -nC1-INH (for inclusion in Part B) as defined below:  
a. Documented  diagnosis  of HAE-1/HAE-2 based upon ALL of the following:  
i. Documented  clinical history  consistent with  HAE (subcutaneous  [SC] or 
mucosal, non-pruritic swelling episodes without accompanying  urticaria) 
(Maurer et al. 2018 ). 
ii. Diagnostic  testing results that confirm HAE-1/HAE-2: C1-INH functional 
level < 40% normal level.  Patients with a functional level of 40% to 50% 
of normal can be enrolled if their complement factor C4 (C4) level is 
below the lower limit of normal (LLN) or if a known pathogenic mutation 
in the SERPING1 gene has been demonstrated.  
iii. At least 1 of the follo wing: age at reported HAE onset ≤ 30 years; a 
family history consistent  with HAE-1/HAE-2; or complement  component 
1q within the normal range.  
b. Documented diagnosis of HAE -nC1-INH based upon documented clinical 
history consistent  with HAE (SC or mucosal, non-pruritic swelling episodes 
without accompanying urticaria) ( Maurer et al. 2018 ) AND any 1 of the 
following:  
i. A clinical diagnosis  of bradykinin  (BK)-mediated angioedema  as 
confirmed with threshold -stimulated kallikrein activity and  
Investigator -confirmed  response to acute use of a BK targeted treatment 
(icatibant or ecallantide -). 
ii. One (1) of the established mutations (c.1032C>A, Thr309Lys; 
c.1032C>G,  Thr309Arg;  c.971_1018+24del72*;  or c.892_909dup)  in the 
factor XII gene.  
iii. The established mutation in the plasminogen  gene (c.988A>G, 
p.Lys330Glu).  
iv. The established  mutation in the angiopoietin -1 gene (c.355G>T, 
p.A119S).  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
14  
  
PROTOCOL  SYNOPSIS  CONTINUED  
 
Study 
Population 
Continued  Inclusion  Criteria Continued  
4. Patients must: 
a. Experience  a minimum  of 2 HAE attacks (assessed by the Angioedema 
Activity Score [AAS] and confirmed by the Investigator) during the 
Screening Period.  
b. Complete  the AAS questionnaire  on a daily basis (minimum  of 4 daily 
assessments per week) for the duration of the Screening Period.  
5. Patients must have access to, and the ability to use, ≥ 1 acute medication(s) (e.g., 
plasma-derived or recombinant  C1-INH concentrate  or a BK2-receptor antagonist) 
to treat angioedema attacks.  
6. Female patients must be non-pregnant (and not planning a pregnancy  during the 
study) and non -lactating, and be either:  
a. Surgically  sterile (e.g., tubal occlusion,  hysterectomy,  bilateral salpingectomy, 
or bilateral oophorectomy).  
b. Post-menopausal  (defined as 12 months of spontaneous  amenorrhea  in females 
> 55 years of age or, in females ≤ 55 years of age, 12 months of spontaneous 
amenorrhea without an alternative medical cause and follicle-stimulating 
hormone [FSH] levels in the post -menopausal range for the laboratory 
involved).  
c. Abstinent (only acceptable as true abstinence, i.e., when in line with the 
preferred and usual lifestyle of the patient; periodic abstinence  [e.g., calendar, 
ovulation, symptothermal, or post -ovulation methods], declaration of 
abstinence for the duration of the study, or withdrawal are not acceptable 
methods of contraception).  
d. If engaged in sexual relations of childbearing potential, agree to use highly 
effective contraceptive methods (refer to Section 6.3.1) from the time of 
signing the informed consent form (ICF) until at least 24 weeks  after the last 
dose of Study Drug (ISIS 721744 or placebo).  
7. Male patients must be surgically sterile or, if engaged in sexual relations with a 
female of childbearing potential, the patient must agree to use a highly effective 
contraceptive  method (refer to Section 6.3.1) from the time of signing the ICF until 
at least 24 weeks after the last dose of Study Drug ( ISIS 721744 or placebo).  
Exclusion  Criteria 
1. Anticipated  use of short-term prophylaxis  for angioedema  attacks for a pre-planned 
procedure during the Screening or Study Periods.  
2. Concurrent  diagnosis  of any other type of recurrent angioedema,  including  acquired 
or idiopathic angioedema.  
3. Anticipated  change in the use of concurrent  androgen prophylaxis  used to treat 
angioedema attacks.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
PROTOCOL  SYNOPSIS  CONTINUED  
15  
  
 
 
Study 
Population 
Continued  Exclusion  Criteria Continued  
4. Any clinically significant  abnormalities  in screening  laboratory  values that would 
render a patient unsuitable for inclusion in the study.  The following values are 
exclusionary:  
a. Alanine aminotransferase  (ALT) or aspartate aminotransferase  (AST) 
> 2.5 × upper limit of normal (ULN). 
b. Bilirubin > 1.5 × ULN unless due to Gilbert’s syndrome.  
c. Platelet count < LLN 
d. Estimated  glomerular  filtration rate (eGFR) < 60 mL/min (as determined  by 
the Cockcroft Gault - Equation for creatinine clearance)  
e. aPTT > 1.5 × ULN 
5. Patients with a history of acquired coagulopathies or bleeding diathesis (e.g., 
thrombocytopenia, disseminated intravascular coagulation, coagulopathy of liver 
disease, drug -induced platelet dysfunction, hyperfibrinolysis, acquired clotting 
factor inhibitors)  and inherited bleeding disorders (e.g., hemophilia  A, hemophilia 
B, other clotting factor deficiencies, qualitative platelet disorders, inherited 
thrombocytopenia, vascular abnormalities).  
6. Any clinically significant  renal or hepatic diseases. 
7. Active infection requiring systemic antiviral or antimicrobial  therapy that will not 
be completed prior to dosing.  
8. Active infection with HIV, hepatitis C or hepatitis B diagnosed by initial 
serological  testing and confirmed  with RNA testing, or prior treatment  for hepatitis 
C. Patients at Screening  who test positive by serology, but negative by RNA may 
be allowed in consultation with the Sponsor Medical Monitor.  
9. Malignancy  within 5 years, except for basal or squamous  cell carcinoma  of the skin 
or carcinoma in situ of the cervix that has been successfully treated.  
10. Treatment  with another investigational  drug or biological  agent within 1 month or 
5 half-lives, whichever is longer, of Screening.  
11. Exposure  to any of the following  medications:  
a. Angiotensin -converting enzyme (ACE) inhibitors or any estrogen -containing 
medications  with systemic absorption  (such as oral contraceptive  or hormonal 
replacement therapy) within 4 weeks prior to Screening.  
b. Chronic prophylaxis  with lanadelumab  within 10 weeks prior to Screening.  
c. Oligonucleotides  (including  small interfering  RNA) within 4 months of 
Screening if single dose received, or within 12 months of Screening if 
multiple doses received.  
12. Any condition  that, in the opinion of the Investigator,  may compromise  the 
patient’s safety or compliance,  preclude successful  conduct of the study, or 
interfere with the interpretation of results  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
PROTOCOL  SYNOPSIS  CONTINUED  
16  
  
 
 
Prohibited 
Concomitant 
Medications  The following  medications/procedures  will not be permitted  during the study: 
• Chronic prophylaxis  for angioedema  attacks, except for a stable dose of 
androgens.  Any use of lanadelumab will not be permitted.  
NOTE: The use of acute medications (plasma -derived or recombinant C1 -INH 
concentrate  or BK2-receptor antagonist)  to treat angioedema  attacks is allowed as 
medically indica ted. 
• ACE inhibitors  or any estrogen-containing  medications  with systemic absorption 
(such as oral contraceptive or hormonal replacement therapy).  
• Any oligonucleotides  (including  small interfering  RNA) other than ISIS 721744.  
• Plasmapheresis.  
• Any other investigational  drug or device.  
Treatment 
Groups A total of approximately 24 patients in Parts A and B combined will be administered 
SC injections of ISIS 721744 80 mg or placebo every 4 weeks.  Patients will be 
allocated into Part A or Part B according  to type of HAE, (i.e., either HAE-1/HAE-2 in 
Part A or HAE -nC1-INH in Part B) as follows:  
• In Part A, approximately  18 patients with HAE-1/HAE-2 will be randomized  to 
SC injections of ISIS 721744 80 mg or placebo in a 2:1 ratio  
(ISIS 721744:placeb o). 
• In Part B, approximately  6 patients with HAE-nC1-INH will be administered 
open-label SC injections of ISIS 721744 80 mg.  Due to the rarity of  
HAE-nC1-INH, enrollment in Part B may be ended early if Study Centers are 
unable to enroll sufficient  patients; this will not impact the completion  of Part A. 
Study Drug 
Dosage and 
Administration  The Study Drug (ISIS 721744 or placebo) is contained  in 2-mL stoppered  glass vials. 
The Study Drug (ISIS 721744 or placebo) and its storage and preparation instructions 
will be provided by the Sponsor or designee.  The Study Drug (ISIS 721744 or 
placebo) must be stored securely at 2 °C to 8 °C and be protected from light.  
During the Treatment  Period, Study Drug (ISIS 721744  or placebo) will be 
administered as a single SC injection every 4 weeks.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
PROTOCOL  SYNOPSIS  CONTINUED  
17  
  
 
 
Rationale  for The dose level of 80 mg every 28 days was selected based on the safety, tolerability,  
Dose and PK, and PD data from the ISIS 721744-CS1 study in healthy volunteers.  The Phase 1 
Schedule  study evaluated  doses of 20, 40, 60, and 80 mg ISIS 721744 administered  once every 
Selection  4 weeks for a total of 12 weeks. All dose levels were generally well-tolerated and 
 induced a dose and exposure-dependent  reduction  in plasma PKK, a biomarker  for BK 
 and vascular permeability.  The highest dose level of 80 mg produced near-complete 
 reduction  of plasma PKK levels (a mean reduction  of 93.6% from Baseline on Day 99 
 [2 weeks after the last dose]). The estimated  half-life (t½) from the Phase 1 PK data 
 was approximately  4 to 5 weeks, supporting  the once-every-28-day dosing regimen. 
 Pharmacokinetic/PD  analysis of the Phase 1 data suggested  very minor differences  in 
 plasma PKK reductions  at doses higher than 80 mg. 
Adjustment  of 
Dose and/or 
Treatment 
Schedule  Down-titration of Study Drug (ISIS 721744 or placebo) will not be allowed during the 
study. 
Action taken with Study Drug (ISIS 721744 or placebo) due to an adverse event (AE) 
is characterized by 1 of the following:  
 • None: No changes made to Study Drug (ISIS 721744 or placebo) administration 
and dose.  
 • Not Applicable:  AE reported during the Screening  Period prior to Study Drug 
(ISIS 721744 or placebo) administration.  
 • Permanently  Discontinued:  Study Drug (ISIS 721744 or placebo) discontinued 
and not restarted.  
 • Temporarily Interrupted, Restarted – Same Dose:  Dosing and/or dosing 
frequency  temporarily  interrupted/changed  or delayed due to the AE and restarted 
at the same dose.  
Study Visit 
Schedule  and 
Procedures  The study will be conducted concurrently in 2 parts (Part A and Part B); patients will 
be allocated into Part A or Part B according  to type of HAE (i.e., either HAE-1/HAE-2 
in Part A or HAE-nC1-INH in Part B).  Part A is randomized, double -blind, and 
placebo-controlled; and Part B is open -label. The study visit schedule and procedures 
are nearly identical in Part A and Part B, and thus are presented together; any 
differences are indicated where applicable.  
Patients will be screened for eligibility  criteria following  written informed consent. 
During the Screening Period, the following assessments will be performed: 
demographics; medical history, including a detailed HAE history; prior and 
concomitant medications, including type of prophylaxis (if used) and type of acute 
treatment;  HIV, hepatitis B, and hepatitis C screening;  pregnancy  testing for women of 
childbearing potential and FSH testing for confirmation of menopause per inclusion 
criteria; quality of life as assessed by the angioedema quality of life (AE QoL) 
questionnaire; attack frequency, as assessed by the AAS daily during up to  
8 consecutive weeks, and confirmed by the Investigator; HAE attack assessment; 
physical examinations, i ncluding vital signs, body height, and weight; 
electrocardiograms  (ECGs); AEs; PD blood sampling;  inflammatory  panel; and clinical 
laboratory assessments (chemistry, hematology, coagulation, and urinalysis).  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
PROTOCOL  SYNOPSIS  CONTINUED  
18  
  
 
 
Study Visit 
Schedule  and 
Procedures 
Continued  Threshold stimulated kallikrein activity will be assessed only in patients who have 
HAE-nC1-INH without a factor XII mutation or the plasminogen or angiopoietin -1 
mutation.  Genetic testing will be performed  only for patients who do not have HAE 
genetic diagnostic testing results prior to Screening.  
 During the Screening Period, patients must experience a minimum of 2 HAE attacks 
(assessed by the AAS and confirmed by the Investigator) to be eligible for the study; 
patients will be instructed to report details of any HAE attack to the study site within 
72 hours of the onset of the attack.  Throughout the Screening Period, site personnel 
will contact the patient once a week (at approximately  7 days after the last contact with 
the patient) in order to inquire about any attack that may have occurred.  If a patient 
experiences a third attack, the patient should be randomized as soon as possible, 
assuming all other screening activities have been completed and the patient meets all 
other eligibility requirements; in such cases, the Screening Period may be shorter  than 
8 weeks. 
 During the course of the study, the use of acute medications (plasma derived or 
recombinant  C1 INH concentrate,  BK2-receptor antagonist,  or kallikrein  inhibitor)  to 
treat angioedema attacks is allowed as medically indicated.  Patients can be treated 
with on demand therapy as determined by their treating physician.  
 After a Screening  Period of up to 8 weeks, those patients who had at least 
2 documented  attacks (assessed by  the AAS and confirmed by  the Investigator)  during 
the Screening  Period will be enrolled and/or randomized  to receive ISIS 721744 80 mg 
or placebo (Part A) or open label ISIS  721744 80 mg (Part B) every 4 weeks for a total 
Treatment Period of 12 weeks.  
 Study Drug will be administered as a SC injection in the abdomen, thigh, or outer area 
of the upper arm by qualified personnel at the Study Center or Home Healthcare 
professional (if available and after dosing instructions and training are provided by 
qualified site personnel).  The first dose of  Study Drug will be administered at the 
Study Center on Day 1.  Study Center personnel (or Home Healthcare if available), 
will complete procedures per the Schedule of Procedures in Appendix A.  After 
completion  of the Week 13 visit, eligible patients may elect to enroll in the Open-Label 
Extension (OLE) Study (ISIS 721744 -CS3), pending study approval by the IRB/IEC 
and the appropriate regulatory authority, and will need to sign the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) approved inf ormed consent.  Patients 
who complete Study Visit Week 17, and meet eligibility requirements, may start the 
treatment period in the CS3 study anytime after the Week 17 visit and discontinue 
participation in the CS2 Post -Treatment Evaluation Period.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
PROTOCOL  SYNOPSIS  CONTINUED  
19  
  
 
 
Study Visit 
Schedule  and 
Procedures 
Continued  During the study, patients will be instructed  to report details of any HAE attack to the 
study site within 72 hours of the onset of the attack.  During the Treatment and  
Post-Treatment Periods, the following data will be collected:  daily AAS and number 
of HAE attacks (assessed by the AAS and confirmed by the Investigator); number of 
HAE attacks that required on -demand treatment; HAE attack details, including 
localization,  severity, course, and details of any required treatment  (i.e., frequency  and 
dose); and vital signs.  Throughout the Treatment and Post -Treatment Periods, site 
personnel will contact the patient once a week (at approximately 7 days after the last 
contact wi th the patient) in order to inquire about any attack that may have occurred. 
In addition, at study visit time points, site personnel will inquire about any new HAE 
attack information that was not provided through patient contact with the site.  See 
Section 6.2.1 for further information on the collection of data surrounding HAE 
attacks. 
 Additionally,  blood will be collected at every visit during the Treatment  and 
Post-Treatment Periods to assess PD and coagulation parameters, including, but not 
limited to: plasma PKK, plasma proenzyme  activation,  cleaved high molecular  weight 
kininogen (cHK)  levels, D-dimer levels, activated partial thromboplastin time (aPTT), 
plasmin-antiplasmin  complexes,  C4 split products, and platelet counts. Blood samples 
will also be collected regularly throughout the study for safety and PK/PD analyses.  
Additional  assessments  will be performed  throughout  the study as indicated in the 
Schedule of Procedures table in Appendix A . 
 Patients who discontinue  treatment  will remain in the study and attend the Early 
Termination (ET) Visit unless consent is withdrawn.  
 Detailed information regarding the CS2 procedures is presented in Section 6 and 
Appendix  A. Appendix  B includes a list of laboratory  analytes required for the study. 
Primary 
Endpoint  The primary endpoint is the time-normalized  number of HAE attacks (per month) from 
Week 1 to Week 17.  
Secondary 
Endpoints  Secondary  endpoints  include the following:  
• The time-normalized  number of HAE attacks (per month) from Week 5 to 
Week 17 
• The time-normalized  number of moderate or severe HAE attacks (per month) 
from Week 5 to Week 17  
• The number of patients with a clinical response (defined as a ≥ 50%, ≥ 70%, or 
≥ 90% reduction  from Baseline in HAE attack rate) by Week 17 
• The number of HAE attacks requiring acute therapy from Week 5 to Week 17 
• cHK levels at Weeks 9 and 17 
• PKK activity at Weeks 9 and 17 
• Consumption  of on-demand medication  at Weeks 9 and 17 
• AE-QoL questionnaire  score at Weeks 9 and 17 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
PROTOCOL  SYNOPSIS  CONTINUED  
20  
  
 
 
Exploratory 
Endpoints  Exploratory  endpoints  include the following:  
• The number of HAE attack-free patients by Week 17 
• PK parameters, including, but not limited to:  maximum observed plasma 
concentration  (Cmax), time to Cmax, area under the plasma concentration -time 
curve, and t ½ 
• Potential exposure-response analysis using relevant exposure parameters  and 
biomarkers  
Safety 
Endpoints  The safety and tolerability of ISIS 721744 will be assessed by determining the 
number, type, severity, and dose-relationship  of AEs; vital signs; ECGs; and clinical 
laboratory parameters.  Safety results in patients dosed with ISIS 721744 will be 
compared to safety results in patients dosed with placebo.  
Statistical 
Considerations  The sample size of 18 patients with HAE-1/HAE-2 (12 patients administered  
SC injections of ISIS 721744 80 mg and 6 patients administered placebo) is from 
clinical considerations for sufficient safety and tolerability evaluation.  The primary 
endpoint is the time-normalized  number of HAE attacks (per month) from Week 1 to 
Week 17.  From historical data, the placebo group is estimated to have 6.8 HAE 
attacks per 4 -month period.  If the ISIS 721744 80 mg group is assumed to have  
2.8 HAE attacks per 4 -month period, then with a 0.05  significance level and Poisson 
model, the sample size of 18 patients will provide at least 90% power for the primary 
endpoint, considering a 10% missing data or dropout rate for both active treatment 
and placebo.  There is no statistical rationale for the s ample size of 6 patients with 
HAE-nC1-INH. 
An independent  Data and Safety Monitoring  Board (DSMB) will be established  prior 
to the initiation of the study.  The DSMB will be responsible for monitoring the 
overall safe conduct of the study.  Based on its ongoing assessment of the safety and 
tolerability  of ISIS 721744, the DSMB will provide recommendations  to the Sponsor 
for modifying, stopping, or continuing the study as planned.  Details on the safety 
assessments, frequency of review, meeting schedules an d controlled access to 
unblinded data are outlined in the DSMB Charter and Statistical Analysis Plan.  
Sponsor Ionis Pharmaceuticals,  Inc. 
21  
 POST-TREAT MENT 
 
 
 
 
 721744-CS02 Protocol Amendment  05 May 2020 I 1.0 
 
ISIS 721744-CS2 
Protocol CONFIDENTIAL Amendme nt3 
5 May2020 
 
 
STUDY DESIGN AND TREATME NT SCHEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+ 
 
 
 
 
 
 
 
 
 
 
.,_ ◄ 
 
 
 
 
 
 
 
 
* The Screening Period is up to 8 weeks in duration. A patient may be randomized after fewer than 8 weeks of 
Screening if the patient experiences 2 HAE attacks in less than 8 weeks and has completed all other screening 
activities and has m et all other eligibility requirements.  
 
 
 
 
 
 
  
 
 
 
 
Patients who complete 
Study Visit Week 17, 
and meet eligibility 
requirements, may start 
the Treatment Period  in 
the ISIS 721744-CS3 
OLE study anytime  
after the Week 17 visit 
and discontinue 
participa tion in the CS2 
Post-Treatment 
Evaluation Period   
EARLY TERMINATION 
(ET) 
 
Follow Week 17 Schedule of 
Procedures at ET; Patient 
strongly encouraged to have 
post-treatment assess ments 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
22  
  
STUDY GLOSSARY  
Abbreviation  Definition  
2′-MOE 2′-O-(2-methoxyethyl)  
AAS Angioedema  Activity Score 
ACE angiotensin -converting  enzyme 
ADR adverse drug reaction 
AE(s) adverse event(s) 
AE-QoL angioedema  quality of life 
AESI adverse event of special interest 
ALT alanine aminotransferase  
aPTT activated partial thromboplastin  time 
ASO antisense oligonucleotide  
AST aspartate aminotransferase  
AUC area under the plasma concentration -time curve 
Bb complement  factor Bb (activated  complement  split product) 
βhCG beta-subunit of human chorionic  gonadotropin  (pregnancy  test) 
BK bradykinin  
BUN blood urea nitrogen 
C centigrade  
C1-INH C1-inhibitor 
C4 complement  factor C4 
C5a complement  factor C5a (activated  complement  split product) 
cHK cleaved high molecular weight kininogen  
Cmax maximum  observed plasma concentration  
CTCAE Common Terminology  Criteria for Adverse Events 
dL deciliter 
DNA deoxyribonucleic  acid 
DSMB Data and Safety Monitoring  Board 
ECG electrocardiogram  
eCRF electronic  Case Report Form 
eGFR estimated  glomerular  filtration rate 
ET Early Termination  
FSH follicle-stimulating  hormone 
GalNAc 3 N-acetyl galactosamine  
GCP Good Clinical Practice 
GGT gamma-glutamyl transferase  
HAE hereditary  angioedema  
HAE-1 hereditary  angioedema  type 1 
HAE-2 hereditary angioedema  type 2 
HAE-nC1-INH hereditary  angioedema  with normal C1-inhibitor 
HIV human immunodeficiency virus  
HK high molecular  weight kininogen  
hs-CRP C-reactive protein measured  by high sensitivity  assay 
ICF informed consent form  
ICH International  Council for Harmonisation  
IEC Independent  Ethics Committee  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
23  
  
IgM immunoglobulin  M 
IM imunogenicity  
INR international  normalized  ratio 
IRB Institutional  Review Board 
IRT Interactive Response Technology 
ISIS 721744  antisense inhibitor of prekallikrein 
ITT Intent-to-Treat 
LCRIS local cutaneous  reaction at injection site 
LLN lower limit of normal 
MCH mean corpuscular  hemoglobin  
MCHC mean corpuscular  hemoglobin  concentration 
MCV mean corpuscular volume  
MedDRA™ Medical Dictionary  for Regulatory  Activities 
mRNA messenger ribonucleic acid  
NCS not clinically significant  
OLE open-label extension  
PD pharmacodynamic(s)  
pH measure of the acidity or basicity of a solution 
PK pharmacokinetic(s)  
PKa plasma kallikrein 
PKK prekallikrein  
PP Per-Protocol 
PT prothrombin  time 
RNA ribonucleic  acid 
RNase H1  an ubiquitous  endonuclease  that specifically  hydrolyzes  the RNA strand in 
RNA/DNA hybrids  
SAE serious adverse event 
SAP Statistical  Analysis Plan 
SC subcutaneous(ly)  
Study Day 1  defined as the first day Study Drug is administered  to the patient 
Study Drug  ISIS 721744 or placebo  
SUSAR suspected  unexpected  serious adverse reaction 
t½ half-life 
T3 triiodothyronine  
T4 thyroxine  
TEAE treatment -emergent adverse event 
Tmax time to maximum  observed plasma concentration  
TSH thyroid-stimulating  hormone 
ULN upper limit of normal 
WBC white blood cell 
WOCBP woman/women  of childbearing  potential 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
24  
  
1. OBJECTIVES  AND ENDPOINTS  
1.1. Objectives  
1.1.1. Primary Objective  
The primary objective of the study is to evaluate the clinical efficacy of antisense inhibitor of 
prekallikrein  (ISIS 721744) in patients with hereditary  angioedema  (HAE) type 1 (HAE-1), HAE 
type 2 (HAE -2), or HAE with normal C1 -inhibitor (C1 -INH). 
1.1.2. Secondary  Objectives  
The secondary objectives of the study are to evaluate safety and tolerability of ISIS 721744 in 
patients with HAE-1/HAE-2 or HAE with normal C1-INH (HAE-nC1-INH) and to evaluate the 
effect of ISIS 721744 on plasma prekallikrein (PKK) and other relevant biomarkers.  
1.1.3. Exploratory  Objectives  
The exploratory  objectives  of the study are to evaluate pharmacokinetics  (PK) of ISIS 721744 
(as a total full -length antisense oligonucleotide [ASO], including fully conjugated, partially 
conjugated, and unconjugated ISIS 721744) over time and to assess potential 
PK/pharmacodynamic (PD) c orrelations on relevant biomarkers and clinical outcomes, as 
appropriate.  
1.2. Study Endpoints  
The definition  of an HAE attack, including  discrete attacks, is provided in Section 6.2.1. 
 
1.2.1. Primary Endpoints  
The primary endpoint is the time-normalized  number of HAE attacks (per month) from Week 1 
to Week 17.  
1.2.2. Secondary  Endpoints  
Secondary  endpoints include  the following:  
• The time-normalized  number of HAE attacks (per month) from Week 5 to Week 17 
• The time-normalized  number of moderate or severe HAE attacks (per month) from 
Week 5 to Week 17  
• The number of patients with a clinical response (defined  as a ≥ 50%, ≥ 70%, or 
≥ 90% reduction  from Baseline  in HAE attack rate)  by Week 17 
• The number of HAE attacks requiring  acute therapy from Week 5 to Week 17 
• Cleaved high molecular  weight kininogen  (cHK) levels at Weeks 9 and 17 
• PKK activity at Weeks 9 and 17 
• Consumption  of on-demand medication  at Weeks 9 and 17 
• Angioedema  quality of life (AE-QoL) questionnaire  score at Weeks 9 and 17 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
25  
  
1.2.3. Safety Endpoints  
The safety and tolerability of ISIS 721744 will be assessed by determining the number, type, 
severity, and dose-relationship  of adverse events (AEs); vital signs; electrocardiograms  (ECGs); 
and clinical laboratory parameters.  Safety results in patients dosed with ISIS 721744 will be 
compared to safety results in patients dosed with placebo.  
 
1.2.4. Exploratory  Endpoints  
Exploratory  endpoints include  the following:  
• The number of HAE attack-free patients by Week 17 
• PK parameters, including, but not limited to:  maximum observed plasma 
concentration  (Cmax), time to Cmax (Tmax), area under the plasma concentration -time 
curve (AUC), and half -life (t½) 
• Potential exposure response analysis using relevant exposure parameters  and 
biomarkers  
 
2. BACKGROUND  AND RATIONALE  
2.1. Overview  of Disease 
Hereditary angioedema is a rare genetic disorder that is characterized by disabling recurrent 
episodes of local skin swellings,  painful abdominal  attacks, and, occasionally,  laryngeal attacks 
that can be life -threatening.  The disorder is classified in 3 subtypes.  Hereditary angioedema 
Type I (HAE -1) and Type II (HAE -2) are caused by an autosomal dominant mutation in the 
SERPING1  gene, resulting in either decreased levels of C1-INH (HAE-1) or loss-of-function of 
this protein (HAE -2) (Bissler et al. 1997 ). The third form of HAE is associated with normal 
levels and function of C1 -INH (HAE -nC1-INH). This form is currently categorized as  
4 subtypes, with either specific genetic mutations in the factor XII gene, the plasminogen gene,  
or the angiopoietin -1 gene, or due to an unknown cause ( Maurer et al. 2018 ). Extensive  
evidence from in vitro and in vivo studies supports the key role of bradykinin (BK) in HAE 
attacks, although the data linking HAE -nC1-INH with BK are less strong ( Zuraw and 
Christiansen  2016). Diagnosing  HAE-nC1-INH can be challenging  given the large heterogeneity 
of this patient population, the lack of diagnostic tests, and the fact that specific ge netic mutations 
account only partially for the occurrence of this type of HAE.  Recently, a threshold -stimulated 
kallikrein activity assay was shown to discriminate BK -mediated angioedema from histamine - 
mediated angioedema ( Lara‑Marquez et al. 2018 ). This technique may, therefore, enhance the 
identification of HAE -nC1-INH patients that are likely to benefit from inhibition of the contact 
activation pathway.  
Treatment  options for HAE include on-demand treatment  of attacks and prophylaxis.  
On-demand options include supplementation  of C1-INH (either plasma-derived or recombinant 
C1-INH concentrate) and inhibition of BK2 receptor activation (BK2 -receptor antagonist).  In 
addition, tranexamic acid may relieve symptoms in non -severe angioedema attacks.  
Prophylactic regimens for HAE include plasma-derived C1-INH concentrate  (administered  either 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
26  
  
intravenously or subcutaneously [SC]), attenuated androgens, antifibrinolytics and a recently 
Food and Drug Administration -approved monoclonal  antibody directed against plasma kallikrein 
(PKa). Kallikrein circulates in plasma as a zymogen (i.e., PKK) which is bound to one of its 
main substrates, high molecular weight kininogen (HK).  Prekallikrein is cleaved upon contact 
activation, forming the active pro tease PKa.  Plasma kallikrein cleaves HK in turn, thereby 
releasing BK and the split product cHK.  The binding of BK to the BK2 receptor leads to 
activation of various intracellular signaling pathways resulting in vasodilation, chemotaxis of 
neutrophils,  and increased  vascular permeability  and fluid efflux, which typically characterize  an 
angioedema attack ( Zuraw and Christiansen 2016 ). 
 
2.2. Therapeutic  Rationale  
ISIS 721744 is a second -generation, ligand -conjugated antisense oligonucleotide (ASO) drug 
designed to reduce the production  of PKK mRNA. Antisense  technology  is characterized  by its 
high specificity in inhibiting a single -gene product, thereby diminishing the potential for  
off-target drug effects.  Furthermore, since ligand -conjugated ASOs requi re infrequent 
administration,  ~once every month or even less often, the availability  of a plasma PKK inhibitor 
could be of additional value to the arsenal of prophylactic drugs for the prevention of HAE 
attacks. The long t ½ of second -generation antisense drugs and the lower frequency of 
administration afforded by ligand conjugation might provide additional benefit to patients.  
The Phase 1 clinical data show that ISIS 721744 inhibits plasma PKK effectively  in a 
dose-dependent manner without safety concerns.  
 
2.3. ISIS 721744 
2.3.1. Mechanism  of Action 
ISIS 721744 is an N-acetyl galactosamine  (GalNAc 3)-conjugated,  second-generation  ASO drug 
targeted to human PKK.  It is complementary to the translated regions (Exon 9) of the PKK 
protein messenger ribonucleic acid (mRNA) and, following cleavage of the GalNAc 3 moiety, 
binds to the mRNA by Watson and Crick base pairing.  The hybridization (binding) of  
ISIS 721744 to the  cognate mRNA results in the ubiquitous endonuclease that specifically 
hydrolyzes  the RNA strand in RNA/DNA  hybrids (RNase H1)-mediated degradation  of the PKK 
mRNA, thus preventing production of the PKK protein.  Maximal antisense -mediated reduction 
of target mRNA levels is typically greater than 90% of control levels in sensitive tissues (Crooke 
and Bennett 1996 ; Zhang et al. 2010 ). Furthermore, reduction in target mRNA levels using this 
approach correlates directly with a subsequent reduct ion in target protein levels.  
2.3.2. Chemistry  
Chemically, ISIS 721744 is a synthetic oligomer  of 20 nucleotides (i.e., a 20 -mer) that are 
connected  sequentially  by phosphorothioate  and phosphodiester  linkages (mixed backbone 
design). The nucleotide sequence of ISIS 721744 ( Figure 1) is complementary to a  
20-nucleotide stretch within Exon 9 of the PKK protein mRNA.  Structurally, the 
oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 
5 nucleotides  at the 3′ end, are composed  of 2′-O-(2-methoxyethyl)  (2′-MOE)-modified 
ribonucleotides.  These 2′-MOE-modified nucleotides  confer (1) increased  affinity to the target 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
27  
  
mRNA (Altmann et al. 1996 ; McKay et al. 1999 ), (2) increased resistance to exonucleases and 
endonucleases  (thereby increasing  stability in tissue) (Geary et al. 2003), and (3) amelioration  of 
some of the high -dose toxicities thereby resulting in an improved safety profile compared to 
first-generation antisense drugs containing phosphorothioate modified oligodeoxynucleotides 
(Henry et al. 2000 ). The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and ISIS 721744 
employs this chimeric structure to enable use of the RNase H1-mechanism  for antisense activity. 
This is because while the 2′ -MOE modification confers increased stability and affinity, it does 
not support RNase H1 -catalyzed cleavage of ribonucleic acid (RNA) hybridized to  
2′-MOE-modified nucleotides  (McKay et al. 1999). This is caused by conformational  changes 
induced in the heteroduplex by 2′ -alkoxy:RNA hybrids that are not recognized by RNase H1 
enzyme (Inoue et al. 1987 ; Monia et al. 1993 ). By limiting the 2′ -MOE modification to 
nucleotides flanking the phosphorothioate oligodeoxynucleotide core, the beneficial attributes 
of the 2′-MOE chemistry are preserved while also retaining RNase H1 recognition.  A 
fourth region, comprised of a triantennary cluster of GalNAc 3 sugars, is linked to the 5ʹ end of 
ISIS 721744 via a phosphodiester linkage.  The GalNAc 3 cluster is a high -affinity ligand for the 
asialoglycoprotein receptor, a receptor expressed primarily on the surface of liver hepatocytes 
(Stockert 1995 ). The GalNAc 3 cluster enhances delivery of ISIS 721744 to liver hepatocytes 
over other cell types and enhances potency.  After internalization into cells,  the GalNAc 3 cluster 
is metabolized to release “free ASO” inside the cell ( Prakash et al. 2014 ). The internucleosidic 
linkages are a mixture of phosphorothioate and phosphodiester.  The phosphorothioate linkages 
are introduced into the deoxyribonucleic acid (DNA) gap region and at both ends of the 
oligonucleotide to protect it from nuclease mediated metabo lism. The mixed backbone design 
reduces the total number of phosphorothioate linkages, which reduces non -specific interactions 
with proteins and further enhances potency and therapeutic  index of GalNAc 3-conjugated  ASOs. 
 
2′-MOE 2′-Deoxy 
(RNase H1 sensitive)  
GsTsCsTsCsTsTsGsGsCs  2′-MOE 
 
 
GalNAc3  = THA-GalNAc cluster 
2′-MOE = 2′-methoxylethyl  RNA 
2′-Deoxy = DNA  
s = phosphorothioate  linkage 
o = phosphodiester  linkage 
 
 
Figure 1:  Design of GalNAc 3-Conjugated  Chimeric  2ʹ-MOE Phosphorothioate 
Oligonucleotides (MOE -Gapmer)  
The sequence of ISIS 721744 is shown. AoAoAsCsA  oTsGsCoAoAs  
GalNAc 3 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
28  
  
2.3.3. Preclinical  Experience  
Detailed information  concerning  the preclinical  studies conducted  with PKK ASO ISIS 546254, 
its 5ʹ-GalNAc 3-conjugated mixed backbone variant ISIS 721744, and mouse surrogate PKK 
ASOs can be found in the Investigator’s Brochure.  
The results support the concept that inhibition of PKK through antisense mechanism may  serve 
as a new and effective strategy for the prophylaxis of HAE.  Results also strongly support that 
GalNAc 3-conjugation  of PKK ASO significantly  increases the potency of ASO for inhibition  of 
PKK hepatic mRNA and circulatory  protein expression  and thus these ASOs should be a useful 
therapeutic strategy for the prophylactic treatment of HAE.  
 
2.3.4. Clinical Experience  
ISIS 721744 has been evaluated  in the clinical setting in a Phase 1 safety study 
(ISIS 721744 -CS1). All subjects have  completed study  procedures and final safety  and PD data 
are available.  A summary is included below.  Please refer to the Investigator’s Brochure for a 
detailed description  of the preclinical  pharmacology,  nonclinical  toxicology  and PK, as well as a 
description of previous clinical experi ence with other related 2′ -MOE phosphorothioate 
oligonucleotides.  
ISIS 721744 has been studied in 32 healthy volunteers in a double -blind, multiple -dose, 
dose-escalation  study. Of these, 24 subjects received multiple doses of ISIS 721744.  The 
32 subjects w ere randomized into 4 cohorts (6 subjects each) to receive once -every-4-week SC 
doses of ISIS 721744 20, 40, 60, or 80 mg, or placebo (8 subjects) for a total of 12 weeks (4 total 
doses). All subjects received all planned doses of Study Drug (ISIS 721744 or placebo).  The 
duration of Study Drug exposure was 84 days for each subject.  
No serious adverse events (SAEs) were reported in the ISIS 721744-CS1 study. There were no 
early discontinuations from Study Drug or the study, and all subjects in the IS IS 721744 and 
placebo arms completed all study procedures.  Adverse events at the injection site (defined as 
any preferred term containing “injection site”) were the most commonly reported  
treatment -emergent adverse events (TEAEs) in the ISIS 721744 treatme nt arms; no injection 
site-related TEAEs were reported in the placebo arm. There were no flu-like reactions or events 
of local cutaneous reaction at injection site (LCRIS) reported; LCRIS events were defined as  
(A) moderate or severe injection site erythema,  swelling, pruritus, pain, or tenderness  that started 
on the day of injection and persisted for at least 2 days; or (B) any AE at the injection site, 
regardless of severity, that led to discontinuation of Study Drug, where AE at the injection site  
was the principal reason for discontinuation.  No relationship between incidence of TEAEs and 
the dose administered was observed.  
Thirteen (13) AEs related to study treatment  were reported for 4 (16.7%) subjects in the 
ISIS 721744 arm, and for 1 subject (2  events; 12.5%) in the placebo arm.  One (1) subject each 
in the ISIS 721744 and placebo arm reported AEs of ECG T wave inversion (preferred  term) that 
were assessed as related.  Nine (9) of the total 13 related events with ISIS 721744 concerned 
injection site -related events and were reported by  1 subject in the 80 mg  arm. Additional related 
events were tinnitus (1 subject, 1 event in the 60 mg arm), headache (1 subject, 1 event in the  
60 mg arm), and epistaxis (1 subject, 1 event in the 20 mg arm). All TEAEs related to study 
treatment were mild in severity, and none were serious.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
29  
  
ISIS 721744 resulted in a dose -dependent reduction of PKK concentration and plasma 
proenzyme activation.  The difference in absolute and percent change from Baseline for 
ISIS 721744 vs. placebo was statistically  significant  for PKK concentration  for 40, 60, and 
80 mg (p ≤ 0.043) starting at Day 15, the first evaluation,  and for 20 mg starting at Day 29, and 
for plasma proenzyme activation for all doses (p ≤ 0.002) starting at Day 15.  The nadir was 
generally reached around Day  71, when the percent reduction  with the 80 mg dose was -93.2% 
for PKK concentration and -99.6% for plasma proenzyme activation.  
The difference  in absolute and percent change from Baseline in cHK for ISIS 721744 vs. placebo 
was not statistically significant at any visit.  
Clinical data from other GalNAc 3-conjugated 2ʹ -MOE-gapmer oligonucleotides suggest that 
enhanced  delivery of ISIS 721744 to hepatocytes  vs. non-parenchymal  cells will result in similar 
PD results as ISIS 546254 at 1/10th to 1/30th of the dose ( Viney et al. 2016 ). 
2.4. Rationale  for Dose and Schedule  of Administration  
The dose level of 80 mg every 28 days was selected based on the safety, tolerability,  PK, and PD 
data from the ISIS 721744 -CS1 study  in healthy volunteers.  The Phase 1 study evaluated doses 
of 20, 40, 60, and 80 mg ISIS 721744 administered once every 4 weeks for a total of 12 weeks. 
All dose levels were generally well -tolerated and induced a dose - and exposure -dependent 
reduction  in plasma PKK, a biomarker  for BK and vascular permeability.  The highest dose level 
of 80 mg produced near -complete reduction of plasma PKK levels (a mean reduction of 93.6% 
from Baseline on Day 99 [2 weeks after the last dose]).  The estimated t ½ from the Phase 1 PK 
data was approximately 4 to 5 weeks, supporting the once -every-28-day dosing regimen.  
Pharmacokinetic/PD  analysis of the Phase 1 data suggested  very minor differences  in plasma 
PKK reductions at doses higher than 80 mg.  
 
2.5. Benefit-Risk Assessment  
2.5.1. Benefit Assessment  
The benefits of treatment of ISIS 721744 are currently unknown.  Due to its mechanism of 
action, ISIS 721744 has the potential to be efficacious  for the treatment  of patients with HAE. 
2.5.2. Risk Assessment  
The known potential risks to study participants  associated  with ISIS 721744 are elaborated  on in 
the “Guidance to Investigator” section of the Investigator’s Brochure.  
There are no anticipated risks associated with reducing plasma PKK levels; however, a potential 
theoretical risk associated with PKK inhibition would be prolongation of activated partia l 
thromboplastin  time (aPTT). This risk is informed by 80 cases of PKK deficiency  that have been 
described in the literature ( Girolami et al. 2010 ). In these individuals, there is a discrepancy 
between an observed in vitro defect and an absence of bleeding . Thus, it is believed that most 
cases go undetected or, if detected, go unreported.  Occasional bleeding or thrombosis has been 
reported in a few PKK deficient patients but these instances were due to the presence of 
associated risk factors.  Diagnosis is b ased on the prolongation of partial thromboplastin time  
and normal prothrombin time  (PT) and thrombin time. In these individuals,  platelet and vascular 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
30  
  
tests are normal and  the long partial thromboplastin  time has shown to be fully corrected by the 
addition of normal plasma or normal serum.  
In monkeys,  doses of ISIS 721744 of up to 30 mg/kg/wk  for 13 weeks were well-tolerated with 
the exception of thrombocytopenia observed in 1 female at 12 mg/kg/wk and 1 male at  
30 mg/kg/wk.  The monkey dose of 6 mg/kg/wk  provides an approximate  20-fold margin relative 
to a human dose of 80 mg every 4 weeks and therefore there is sufficient therapeutic margin to 
assure the safe clinical use of ISIS 721744 at the proposed clinical dose and regimen.  
One (1) subject in the ISIS 721744-CS1 study had a confirmed  platelet nadir count between 
100 × 103/µL and the lower limit of normal (LLN) (140 × 103/µL). The subject received 
ISIS 721744 at 20 mg and had a platelet count of 139 × 103/µL on Study Day 99; a ll other 
reported values for this subject were within the reference range.  
Platelet counts will be monitored  closely throughout  the clinical study. 
More complete details can be found in the Investigator’s Brochure.  
2.5.3. Overall Assessment  of Benefit:Risk  
No specific risks have been identified  with ISIS 721744. The AEs that occurred with the related 
drug ISIS 546254 were unrelated to reduction of PKK.  In addition, the conjugated nature of 
ISIS 721744 is anticipated to reduce  systemic exposure  even further.  Consequently, the  platelet 
count reductions observed with the higher doses of the unconjugated molecule are not 
anticipated to occur at the dose tested in this study.  
Taking into account the measures taken to minimize  risk to patients participating  in this study, 
the potential risks identified in association with ISIS 721744 are justified by the anticipated 
benefits that may be afforded to patients with HAE.  
 
3. EXPERIMENTAL  PLAN 
3.1. Study Design 
This Phase 2a study will be conducted  at multiple Study Centers worldwide  to assess the efficacy 
of ISIS 721744 in approximately  24 patients with HAE.  Part A of the study  will be randomized, 
double-blind, and placebo -controlled; Part B of the study will be open -label. 
The study will be conducted concurrently in 2 parts (Part A and Part B); patients will be 
allocated into Part A or Part B according  to type of HAE (i.e., either  HAE-1/HAE-2 in Part A or 
HAE-nC1-INH in Part B).  Part A is randomized, double -blind, and placebo -controlled; and 
Part B is open -label. The study  visit schedule and procedures are nearly  identical in Part A and 
Part B, and thus are presented together; any differences are indicated where applicable.  
In Part A, approximately  18 patients with HAE-1/HAE-2 will be randomiz ed to SC injections  of 
ISIS 721744 80 mg or placebo in a 2:1 ratio (ISIS 721744:placebo).  In Part B, approximately  
6 patients with HAE -nC1-INH will be administered open -label SC injections of ISIS 721744 
80 mg. Due to the rarity of HAE-nC1-INH, enrollment  in Part B may be ended early if Study 
Centers are unable to enroll sufficient patients; this will not impact the completion of Part A.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
31  
  
Patients who discontinue  treatment  will remain in the study and attend the Early Termination 
(ET) Visit unless consent is withdrawn.  
Detailed information  regarding  the study procedures  is presented  in Section 6 and Appendix  A. 
Appendix B includes a list of laboratory analytes required for the study.  
 
3.2. Number of Study Centers 
This study will be conducted  at multiple Study Centers worldwide.  
 
3.3. Number of Patients 
A total of approximately 24 patients in Parts A and B combined will be administered SC 
injections  of ISIS 721744 80 mg or placebo every 4 weeks. Patients will be allocated into Part A 
or Part B according to type of HAE, (i.e., either HAE -1/HAE-2 or HAE -nC1-INH): 
approximately  18 patients with HAE -1/HAE-2 are planned to be enrolled in Part A of the study, 
and, in parallel, approximately 6 patients with HAE -nC1-INH are planned to be enrolled in  
Part B of the study.  Due to the rarity of HAE -nC1-INH, enrollment in Part B may be ended 
early if Study Centers are unable to enroll sufficient  patients with HAE-nC1-INH; this will not 
impact completion of Part A.  
 
3.4. Overall Study Duration  and Follow-up 
The study will consist of Screening,  Treatment,  and Post-Treatment  Periods. Please refer to the 
Schedule of Procedures in Appendix A . 
Patients may be required to attend additional visits for monitoring of AEs or abnormal 
investigation results. The frequency  of additional  monitoring  will be determined  by the Sponsor 
Medical Monitor in consultation with the Investigator.  
The length of each patient’s participation  in the study is approximately  8 months, which includes 
an up to 8-week Screening Period, a 12 -week Treatment Period (patients will receive fixed SC 
doses of Study Drug every 4 weeks during 4 on -site study visits), and a 4 - to 13-week 
Post-Treatment  Period as determined  by whether a patient enrolls in the ISIS 721744-CS3 OLE 
study. 
3.4.1. Screening  
Patient eligibility  for the study will be determined  within 8 weeks (56 days) prior to study entry. 
 
3.4.2. Treatment  Period 
Eligible patients will report to the Study Center for the first administration of Study Drug on 
Study Day 1 (Week 1 Visit) and will continue to receive Study Drug once every  4 weeks during 
the 12-week Treatment Period.  Patients will also return to the Study Center on Week 3 (or 
Home Healthcare (if available), as arranged by  the Study  Center personnel, per the Schedule of 
Procedures in Appendix A ) for a safety monitoring visit.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
32  
  
3.4.3. Post-Treatment  Period 
Patients are to return to the Study Center for post-treatment  follow-up visits (or Home Healthcare 
(if available), as arrang ed by the Study Center personnel, per the Schedule of Procedures in 
Appendix A at Study Weeks 17, 21, and 26/ET.  Alternatively, patients who complete Study 
Visit Week 17, and meet eligibility requirements, may start the treatment period in the  
ISIS 721744-CS3 OLE study anytime after the Week 17 visit and discontinue  participation  in the 
CS2 Post-Treatment Evaluation Period.  Patients may be required to attend additional visits for 
monitoring of AEs or abnormal investigation results.  The frequency of additional monitoring 
will be determined by the Sponsor Medical Monitor in consultation with the Investigator.  
The final study visit, for patients  not enrolling in the OLE, will be the Week 26/ET Visit. 
 
3.5. End-of-Study 
The End-of-Study is defined as the date of the last visit of the last patient in the study. 
 
3.6. Data and Safety Monitoring  Board 
A Data and Safety Monitoring Board (DSMB) will be assembled to review safety, tolerability, 
and efficacy (as needed) data collected on ISIS 721744 during this study. Based on its ongoing 
assessment of the safety and tolerability of ISIS 721744, the DSMB will provide 
recommendations to the Sponsor for modifying, stopping, or continuing the study as planned. 
Details on the safety assessments,  frequency  of review, meeting schedules,  and controlled  access 
to unblinded data are outlined in the DSMB Charter and Statistical Analysis Plan (SAP).  
 
4. PATIENT  ENROLLMENT  
4.1. Screening  
Before patients may be enrolled into the study, the Sponsor or designee requires a copy of the 
Study Center’s written Independent  Ethics Committee  (IEC)/Institutional  Review Board (IRB) 
approval of the protocol, informed consent form (ICF), and all other patient information  and/or 
recruitment material.  
Patients must sign the consent form before any  screening tests or assessments, prior to screening 
blood draws, are performed.  At the time of consent, the patient will be considered enrolled into 
the study and will be assigned a  unique screening  number before any study procedures,  including 
screening procedures, are performed.  At the time of randomization, patients will be assigned a 
unique patient identification  number. This number will be used to identify the patient throughout 
the study and must be used on all study documentation related t o that patient.  The screening 
number and patient identification number must remain constant throughout the entire study.  
In the event the patient is re-consented  and re-screened,  the patient must be given a new 
screening number.  Screening numbers, once ass igned, will not be re -used. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
33  
  
4.2. Randomization  
Patients will be allocated into Part A or Part B according  to type of HAE (i.e., either 
HAE-1/HAE-2 in Part A or HAE-nC1-INH in Part B). Only Part A will be randomized  and 
placebo-controlled.  
Patients will be enrolled and/or randomized  (Part A only) at the Week 1 Visit, after all screening 
assessments  have been completed  and after the Investigator  has verified that they are eligible per 
the criteria in Sections 5.1 and 5.2. No patient may begin treatment prior to randomization  
(Part A only) and assignment  of a unique patient identification  number. 
In Part A, approximately  18 patients with HAE-1/HAE-2 will be randomized  via the Interactive 
Response Technology (IRT) system to SC injections of ISIS 721744 80 mg or placebo in a  
2:1 ratio (ISIS 721744:placebo).  In Part B, approximately  6 patients with HAE -nC1-INH will be 
enrolled via the IRT system to receive open -label SC injections  of ISIS 721744 80 mg.  Due to 
the rarity of HAE-nC1-INH, enrollment  in Part B may be ended early  if Study Centers are unable 
to enroll sufficient patients; this will not impact the completion of Part A.  
Randomization  information  will be concealed  from the Investigators  and patients until the end of 
the study, with the exception of an emergency situation involving a patient that requires 
unblinding of the treatment assignment.  
Both ISIS 721744 and placebo will be provided as injections  for SC administrat ion and will be 
identical in appearance.  
4.3. Replacement  of Patients 
Patients who withdraw  from the study will not be replaced. 
Patients whose randomization  code has been broken will not be replaced. 
 
4.4. Unblinding  of Treatment  Assignment  
For Part A, the Sponsor and all patients, monitors, and Study Center personnel related to the 
study will be blinded throughout the study.  However, if a patient has suffered an SAE (as 
defined in Section 9.3.3), and/or when knowledge of the treatment assignment will impact  the 
clinical management  of the patient, the Investigator  will have the ability to unblind the treatment 
assignment for that patient via the IRT system.  
In the case of unblinding, the IRT system will send a blinded notification to the Sponsor or 
designee within 24 hours to let them know that a patient was unblinded.  In addition, all 
suspected  unexpected  serious adverse reactions (SUSARs)  will be unblinded  by the Sponsor or 
designee for the purpose of regulatory reporting (see Section 9.2). 
Every reasonable  attempt should be made to complete the ET study procedures  and observations 
(see Appendix A ) prior to unblinding,  as knowledge  of the treatment  arm could influence patient 
assessment.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
34  
  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study  candidates must meet the following eligibility  criteria 
within 8 weeks (56 days) of the Week 1 Visit (Study Day 1) or at the time point specified in the 
eligibility criteria listed.  
5.1. Inclusion  Criteria 
1. Patients must provide written informed consent (signed and dated) and any authorizations 
required by local law and be able to comply with all study requirements for the duration 
of the study.  
2. Patients must be aged ≥ 18 years at the time of informed consent. 
3. Patients must have a documented  diagnosis  of HAE-1/HAE-2 (for inclusion in Part A) or 
HAE-nC1-INH (for inclusion in Part B) as defined below:  
a. Documented  diagnosis  of HAE-1/HAE-2 based upon ALL of the following:  
i. Documented  clinical history consistent  with HAE (SC or mucosal, non-pruritic 
swelling episodes without accompanying urticaria) ( Maurer et al. 2018 ). 
ii. Diagnostic  testing results that confirm HAE-1/HAE-2: C1-INH functional  level 
< 40% normal level.  Patients with a functional level of 40% to 50% of normal 
can be enrolled if their complement  factor C4 (C4) level is below the  LLN or if a 
known pathogenic mutation in the SERPING1 gene has been demonstrated.  
iii. At least 1 of the following:  age at reported HAE onset ≤ 30 years; a family 
history consistent  with HAE-1/HAE-2; or complement  component  1q within the 
normal range.  
b. Documented  diagnosis  of HAE-nC1-INH based upon documented  clinical history 
consistent with HAE (SC or mucosal, non -pruritic swelling episodes without 
accompanying urticaria) ( Maurer et al. 20 18) AND any 1 of the following:  
i. A clinical diagnosis  of BK-mediated angioedema  as confirmed  with 
threshold-stimulated  kallikrein  activity and Investigator -confirmed  response to 
acute use of a BK targeted treatment (icatibant or ecallantide).  
ii. One (1) of the established mutations (c.1032C>A, Thr309Lys; c.1032C>G, 
Thr309Arg;  c.971_1018+24del72*;  or c.892_909dup)  in the factor XII gene. 
iii. The established  mutation in the plasminogen gene  (c.988A>G,  p.Lys330Glu).  
iv. The established  mutation in the angiopoietin -1 gene (c.355G>T,  p.A119S).  
4. Patients must: 
a. Experience  a minimum  of 2 HAE attacks (assessed by the Angioedema  Activity 
Score [AAS] and confirmed by the Investigator) during the Screening Period.  
b. Complete  the AAS questionnaire  on a daily basis (minimum  of 4 daily assessments 
per week) for the duration of the Screening Period.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
35  
  
5. Patients must have  access to, and the ability  to use, ≥ 1 acute medication(s)  
(e.g., plasma-derived or recombinant  C1-INH concentrate  or a BK2-receptor antagonist) 
to treat angioedema attacks.  
6. Female patients must be non-pregnant (and not planning a pregnancy  during the study) 
and non-lactating, and be either:  
a. Surgically  sterile (e.g., tubal occlusion,  hysterectomy,  bilateral salpingectomy,  or 
bilateral o ophorectomy).  
b. Post-menopausal  (defined as 12 months of spontaneous  amenorrhea  in females 
> 55 years of age or, in females ≤ 55 years of age, 12 months of spontaneous 
amenorrhea  without an alternative  medical cause and follicle-stimulating  hormone 
[FSH] levels in the post -menopausal range for the laboratory involved).  
c. Abstinent  (only acceptable  as true abstinence,  i.e., when in line with the preferred and 
usual lifestyle of the patient; periodic abstinence [e.g., calendar, ovulation, 
symptothermal,  or post-ovulation  methods],  declaration  of abstinence  for the duration 
of the study, or withdrawal are not acceptable methods of contraception).  
d. If engaged in sexual relations of childbearing  potential, agree to use highly effective 
contraceptive  methods (refer to Section 6.3.1) from the time of signing the ICF until 
at least 24 weeks after the last dose of Study Drug (ISIS 721744 or placebo).  
7. Male patients must be surgically  sterile or, if engaged in sexual relations with a female of 
childbearing potential, the patient must agree to use a highly effective contraceptive 
method (refer to Section 6.3.1) from the time of signing the ICF until at least 24 weeks 
after the last dose of Study Drug (ISIS 721744 or placebo).  
5.2. Exclusion  Criteria 
1. Anticipated  use of short-term prophylaxis  for angioedema  attacks for a pre-planned 
procedure during the Screening or Study Periods.  
2. Concurrent  diagnosis  of any other type of recurrent angioedema,  including  acquired or 
idiopathic angioedema.  
3. Anticipated  change in the use of concurrent  androgen prophylaxis  used to treat 
angioedema attacks.  
4. Any clinically significant  abnormalities  in screening  laboratory  values that would render 
a patient unsuitable for inclusion in the study.  The following valu es are exclusionary:  
a. Alanine aminotransferase  (ALT) or aspartate aminotransferase  (AST) > 2.5 × upper 
limit of normal (ULN).  
b. Bilirubin > 1.5 × ULN unless  due to Gilbert’s syndrome.  
c. Platelet count < LLN. 
d. Estimated  glomerular  filtration rate (eGFR) < 60 mL/min (as determined  by the 
Cockcroft -Gault Equation for creatinine clearance).  
e. aPTT > 1.5 × ULN 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
36  
  
5. Patients with a history of acquired coagulopathies or bleeding diathesis (e.g., 
thrombocytopenia,  disseminated  intravascular  coagulation,  coagulopathy  of liver disease, 
drug-induced platelet dysfunction, hyperfibrinolysis, acquired clotting factor inhibito rs) 
and inherited bleeding disorders (e.g., hemophilia A, hemophilia B, other clotting factor 
deficiencies, qualitative platelet disorders, inherited thrombocytopenia, vascular 
abnormalities).  
6. Any clinically significant  renal or hepatic diseases. 
7. Active infection requiring systemic antiviral or antimicrobial  therapy that will not be 
completed prior to dosing.  
8. Active infection with HIV, hepatitis C or hepatitis B diagnosed by initial serological 
testing and confirmed  with RNA testing, or prior treatment  for hepatitis C. Patients at 
Screening who test positive by serology, but negative by RNA may be allowed in 
consultation with the Sponsor Medical Monitor.  
9. Malignancy  within 5 years, except for basal or squamous  cell carcinoma  of the skin or 
carcinoma in situ of the cervix that has been successfully treated.  
10. Treatment  with another investigational  drug or biological  agent within 1 month or 
5 half-lives, whichever is longer, of Screening.  
11. Exposure  to any of the following  medications:  
a. Angiotensin -convertin g enzyme (ACE) inhibitors or any estrogen -containing 
medications  with systemic absorption  (such as oral contraceptive  or hormonal 
replacement therapy) within 4 weeks prior to Screening.  
b. Chronic prophylaxis  with lanadelumab  within 10 weeks prior to Screening.  
c. Oligonucleotides  (including  small interfering  RNA) within 4 months of Screening  if 
single dose received, or within 12 months of Screening if multiple doses received.  
12. Any condition  that, in the opinion of the Investigator,  may compromise  the patient’s 
safety or compliance, preclude successful conduct of the  study, or interfere with the 
interpretation of results.  
 
6. STUDY PROCEDURES  
6.1. Study Schedule  
The study will be conducted concurrently in 2 parts (Part A and Part B); patients wil l be 
allocated into Part A or Part B according  to type of HAE (i.e., either  HAE-1/HAE-2 in Part A or 
HAE-nC1-INH in Part B).  Part A is randomized, double -blind, and placebo -controlled; and 
Part B is open label.  The study  visit schedule and procedures are nearly  identical in Part A and 
Part B, and thus are presented together; any differences are indicated where applicable.  
All required study procedures  are outlined in Appendix  A. 
The safety of ISIS 721744 will be continually  monitored  throughout the study by the Investigator 
and the Sponsor Medical Monitor.  
The length of each patient’s participation  from Screening  to the last study visit is up to 
approximately 8 months (231 days).  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
37  
  
6.1.1. Screening  
Written informed consent for the study will be obtained prior to the performance of any 
study-related procedures,  including  screening  procedures.  A 56-day period is provided for 
completing screening assessments and determining patient eligibility for the study.  
Safety labs may be retested for determination  of patient eligibility  at the Investigator’s  discretion. 
The Sponsor Medical Monitor will be available for consultation, if needed.  
After providing written informed consent, patients will be screened for eligibility criteria. 
During the Screening Period, the following assessments will be performed:  demographics; 
medical history, including  a detailed HAE history; prior  and concomitant  medications,  including 
type of prophylaxis (if used) and type of acute treatment; HIV, hepatitis B, and hepatitis C 
screening;  pregnancy  testing for women of childbearing  potential (WOCBP)  and FSH testing for 
confirmation of menopause per inclusion criteria ; quality of life as assessed by the AE -QoL 
questionnaire;  attack frequency,  as assessed by the AAS daily during up to 8 consecutive  weeks, 
and confirmed by the Investigator; HAE attack assessment; physical examinations, including 
vital signs, body height,  and weight; ECGs; AEs; PD blood sampling; inflammatory panel; and 
clinical laboratory assessments (chemistry, hematology, coagulation, and urinalysis).  
Threshold -stimulated  kallikrein  activity will be assessed only in patients who have 
HAE-nC1-INH without a factor XII mutation or the plasminogen or angiopoietin -1 mutation. 
Genetic testing will be performed only for patients who do not have HAE genetic diagnostic 
testing results prior to Screening.  During the Screening Period, patients mu st experience a 
minimum of 2 HAE attacks (assessed by the AAS and confirmed by the Investigator) to be 
eligible for the study; patients will be instructed  to report details of any HAE attack to the study 
site within 72 hours of the onset of the attack.  Throughout the Screening  Period, site personnel 
will contact the patient once a week (at approximately 7 days after the last contact with the 
patient) in order to inquire about any attack that may have occurred.  If a patient experiences a 
third attack, the pa tient should be randomized as soon as possible, assuming all other screening 
activities have been completed and the patient meets all other eligibility requirements; in such 
cases, the Screening Period may be shorter than 8 weeks.  
During the course of the study, the use of acute medications  (plasma-derived or recombinant 
C1-INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to treat angioedema 
attacks is allowed as medically  indicated.  Patients can be treated with on-demand therapy as 
determined by their treating physician.  
 
6.1.2. Treatment  Period 
After a Screening Period of up to 8 weeks, those patients who had at least 2 documented attacks 
(assessed by the AAS and confirmed  by the Investigator)  during the Screening  Period and met all 
other eligibility criteria will be administered Study Drug (ISIS 721744 or placebo).  Patients in 
Part A will be randomized to receive ISIS 721744 80 mg or placebo every 4 weeks for a total 
Treatment Period of 12 weeks.  Patients in Part B will all receive o pen-label ISIS 721744 80 mg 
every 4 weeks for a total Treatment Period of 12 weeks.  
Study Drug will be administered as SC injections in the abdomen, thigh, or outer area of the 
upper arm by qualified personnel  at the Study Center or by Home Healthcare  professional (if available 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
38  
  
and after dosing instructions and training are provided by qualified site personnel).  The first dose of 
Study Drug will be administered at the Study Center on Study Day 1 (Week 1 Visit).  Study 
Center personnel (or Home Healthcare if available), will complete procedures per the Schedule 
of Procedures  in Appendix A.  A ± 2-day excursion  from the scheduled  visit date is permitted  for 
all visits (excluding the Week 1 Visit on Study Day 1) during the Treatment Period. 
During the study, patients will be instructed to report details of any HAE attack to the study site 
within 72 hours of the onset of the attack.  During the Treatment Period, the following data will 
be collected:  daily AAS and number of HAE attacks (assessed by the AAS and confirmed  by the 
Investigator); number of HAE attacks that required on -demand treatment; HAE attack details, 
including localization, severity, course, and details of any  required treatment (i.e., frequency  and 
dose); and vital signs . Throughout the Treatment Period, site personnel will contact the patient 
once a week (at approximately 7 days after the last contact with the patient) in order to inquire 
about any attack that may have occurred.  In addition, at study visit time points, s ite personnel 
will inquire about any new HAE attack information  that was not provided through patient contact 
with the site.  See Section 6.2.1 for further information on the collection of data surrounding 
HAE attacks.  Additional assessments will be performed throughout the Treatment Period as 
indicated in the Schedule of Procedures table in Appendix A . 
Additionally,  blood will be collected to assess PD and coagulation  parameters,  including,  but not 
limited to:  plasma PK K, plasma proenzyme activation, cHK levels, D -dimer levels, aPTT, 
plasmin-antiplasmin complexes, C4 split products, and platelet counts.  Blood samples will also 
be collected regularly throughout the study for safety and PK/PD analyses.  
Patients who discontinue treatment  will remain in the study and attend the ET Visit unless 
consent is withdrawn.  
Detailed information  regarding  the study procedures  is presented  in Section 6 and Appendix  A. 
Appendix B includes a list of laboratory analytes required for the study. Detailed information 
regarding PK subgroups and collection times is provided in Appendix C . 
6.1.3. Post-Treatment  Period 
Each patient will be followed for safety assessments for up to 13 weeks after the last dose of 
Study Drug. During the Post -Treatment Pe riod, patients will return to the Study  Center (or have 
Home Healthcare (if available), as arranged by the Study Center personnel, per the Schedule of 
Procedures in Appendix A ) for visits at Weeks 17, 21, and 26/ET for safety and clinical 
laboratory evaluations and for blood sampling for PK/PD analyses.  A ± 2-day excursion from 
the scheduled visit date is permitted for the visits at Weeks 17 and 21, and a ± 3 -day excursion 
from the scheduled visit date is permitted for the visit at Week 26/ ET. Alternatively, after 
completion of the Week 13 visit, eligible patients may elect to enroll in the ISIS 721744 -CS3 
OLE study, pending study approval by the IRB/IEC and the appropriate  regulatory  authority,  and 
will need to sign the Institutional Review  Board/Independent Ethics Committee (IRB/IEC) 
approved informed consent.  Patients who complete Study Visit Week 17, and meet eligibility 
requirements, may start the treatment period in the CS3 study anytime after the Week 17 visit 
and discontinue participa tion in the CS2 Post -Treatment Evaluation Period.  
During the Post-Treatment  Period, the following  data will be collected:  daily AAS and number 
of HAE attacks (assessed by the AAS and confirmed by the Investigator); number of HAE  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
39  
  
attacks that required on-demand treatment;  HAE attack details, including  localization,  severity, 
course, and details of any required treatment (i.e., frequency and dose); and vital signs.  
Throughout the Post -Treatment Period, site personnel will contact the patient once a week (at 
approximately  7 days after the last contact with the patient) in order to inquire about any attack 
that may have occurred.  In addition, during study visits, site personnel will inquire about any 
new HAE attack information that was n ot provided through patient contact with the site.  See 
Section 6.2.1 for further information on the collection of data surrounding HAE attacks.  
Additionally,  blood will be collected to assess PD and coagulation  parameters,  including,  but not 
limited to:  plasma PKK, plasma proenzyme activation, cHK levels, D -dimer levels, aPTT, 
plasmin-antiplasmin complexes, C4 split products, and platelet counts.  Blood samples will also 
be collected regularly throughout the study for safety and PK/PD analyses.  Additional 
assessments will be performed throughout the Post -Treatment Period as indicated in the 
Schedule of Procedures table in Appendix A . 
Patients who withdraw early from the study during the Treatment Period will be required to 
complete their End-of-Study evaluations following  procedures  listed for the Week 26/ET Visit; 
see Appendix A . 
 
6.2. Study Assessments  
6.2.1. Collection  of Hereditary  Angioedema  Attack Details 
Historical  HAE attack information  will be collected at Screening.  During the study, patients will 
be instructed to report details of any  HAE attack to the study  site within 72 hours of the onset of 
the attack.  Throughout the Screening, Treatment, and Post -Treatment Periods, site personnel 
will contact the patient once a week (at approximately 7 days after  the last contact with the 
patient) in order to inquire about any attack that may have occurred.  In addition, during study 
visits, site personnel will inquire about any new HAE attack information that was not provided 
through patient contact with the site.  
During the Screening,  Treatment,  and Post-Treatment  Periods, detailed information  on each 
HAE attack will be collected, and the number of HAE attacks that required on -demand 
treatment, and the details of any  on-demand treatment used (frequency  and dosing) , will be 
assessed. For each HAE attack, the following data will be collected:  
• Date/time  of symptom onset 
• Description  of symptoms  
• Location and description  of symptoms:  
− Peripheral  angioedema:  cutaneous  swelling involving  an extremity,  face, neck, 
torso, and/or genitourinary region  
− Abdominal  angioedema:  abdominal  pain, with or without abdominal  distension, 
nausea, vomiting, or diarrhea  
− Laryngeal angioedema:  stridor, dyspnea, difficulty speaking, difficulty 
swallowing,  throat tightening,  or swelling of the tongue, palate, uvula, or larynx 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
40  
  
• HAE attack severity: 
− Mild: transient or mild discomfort  
− Moderate:  mild to moderate limitation  in activity, some assistance  needed 
− Severe: marked limitation  in activity, assistance  required 
• Need for assistance,  medical intervention,  emergency  room visit, or hospitalization  
• Medications  to treat the attack 
• HAE attack course, including  if the HAE attack(s) in question was a typical attack for 
the patient, or if there was an alternative diagnosis  
• Date/time symptoms  resolved 
An HAE attack will be defined as an event with signs or symptoms  consistent  with an attack in at 
least 1 of the locations noted above.  A discrete attack will be counted if there is an at least  
24-hour symptom-free period between attacks. 
 
6.2.2. Patient-Reported  Outcomes  
 
6.2.2.1. Angioedema  Quality of Life Questionnaire  
Quality of life will be assessed by the AE-QoL questionnaire  during Screening  and at Weeks 1, 
9, 17, and 26/ET.  
The AE-QoL questionnaire  is a validated tool to assess symptom-specific health-related quality 
of life impairment in patients suffering from recurrent angioedema ( Weller et al. 2013 ). The 
AE-QoL is a self -administered questionnaire that can be completed in less than 5 minutes; it 
comprises 17 questions across 4 domains:  functioning, fatigue/mood, fears/shame, and food.  
The AE-QoL can be used to calculate scores for the 4 individual  domains, and can also be used 
to determine a total score.  The AE-QoL will be completed by the patient.  
6.2.2.2. Angioedema  Activity Score 
Patients will be instructed  on the use of the AAS questionnaire  during Screening  and will record 
their HAE attacks using the AAS questionnaire during the Screening Period to confirm study 
eligibility.  The AAS questionnaire will be completed by  patients on a daily basis (minimum of 
4 daily assessments per week) for the duration of the study.  
During the Screening  Period, patients must experience  a minimum  of 2 HAE attacks (assessed 
by the AAS and confirmed by the Investigator) to be eligible for t he study. 
Enrolled patients will continue to record HAE attacks using the AAS questionnaire  throughout 
the Treatment and Post -Treatment Periods.  
The AAS is a validated patient -reported outcome instrument to assess disease activity  in patients 
with recurren t angioedema.  The AAS was designed as a diary -type tool, and is easy to 
administer and fast to complete.  Using the AAS questionnaire, patients score each of 5 key 
symptom-related factors from  0 to 3, resulting in a total daily score of 0 to 15. Daily AAS can be 
summed to provide scores every  7 days, every  4 weeks, and every  12 weeks ( Weller et al. 2013 ). 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
41  
  
6.2.3. Laboratory  Assessments  
Laboratory  analyte samples will be collected throughout  the study. A list of these analytes is 
contained in Appendix B . 
If the platelet value, serum creatinine, or liver enzyme tests are uninterpretable (e.g., due to 
clumping,  hemolysis,  or quantity not sufficient)  or missing, a repeat blood specimen  should be 
re-drawn as soon as possible (ideall y within 7 days) either in clinic or by  Home Healthcare or 
local laboratory.  
 
6.3. Restriction  on the Lifestyle of Patients 
6.3.1. Contraception  Requirements  
All male patients and WOCBP must refrain from sperm/egg  donation and either be abstinent† or 
use highly effective contraception from the time of signing the ICF until at least 24 weeks after 
their last dose of Study Drug.  
For male patients engaged in sexual relations with a WOCBP,  if their female partner is using 
highly effective contraception  from the time of the patient signing the informed consent until 
24 weeks after the patient’s last dose of study treatment, then it is not required for the male 
patient to also use a highly effective contraceptive method.  
For the purposes of this study, a WOCBP is defined as any female who has experienced 
menarche, and who does not meet 1 of the following conditions:  
• Post-menopausal:  12 months of spontaneous  amenorrhea  in females > 55 years of 
age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an 
alternative medical cause and FSH levels in the post -menopausal range for the 
laboratory involved  
• 6 weeks after surgical bilateral oophorectomy  with or without hysterectomy  
• Post-hysterectomy  
For the purposes of the study, highly effective contraception  is defined as follows: 
For male patients:  
• Highly effective male contraception includes a vasectomy with negative semen 
analysis at follow-up, or the non-pregnant female partner of childbearing  potential 
uses a highly effective contraceptive method (defined below).  
• Male patients with partners that are pregnant must use condoms as contraception  to 
ensure that the fetus is not exposed to the Study Drug.  
Note: A female condom and a male condom should not be used together as friction 
between the two can result in either or both products failing.  
For female patients and female partners of male patients, highly effective contraception  methods 
comprise 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
42  
  
• Surgical sterilization  (i.e., bilateral tubal occlusion);  progestogen -only hormonal 
contraception associated with inhibition of ovulation; intrauterine contraception 
device or intrauterine hormone -releasing system.  
†Note: Abstinence (i.e., refraining from heterosexual intercourse throughout the duration of 
study participation) is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, 
ovulation , symptothermal,  or post-ovulation  methods),  declaration  of abstinence  for the 
duration of the study, or withdrawal are not acceptable methods of contraception.  
 
7. STUDY DRUG 
7.1. Study Drug Description  
Study Drug (ISIS 721744 or placebo) characteristics  are listed in Table 1. 
The Study Drug (ISIS 721744 or placebo) is contained  in 2-mL stoppered glass  vials. The Study 
Drug (ISIS 721744 or placebo) and its storage and preparation instructions will be provided by 
the Sponsor or designee. The Study Drug (ISIS 721744 or placebo) must be stored securely at  
2 °C to 8 °C and be protected from light. 
During the Treatment  Period, Study Drug (ISIS 721744 or  placebo) will be administered  as a 
single-SC injection every 4 weeks.  
Table 1: Study Drug Characteristics  
 
Study Drug ISIS 721744 Placebo 
Strength 100 mg/mL Not Applicable  
Volume/Formulation  0.8 mL solution per vial 0.8 mL solution per vial 
Route of Administration  SC SC 
 
 
7.2. Packaging  and Labeling 
The Sponsor will provide the Investigator  with packaged  Study Drug (ISIS 721744 or placebo) 
labeled in accordance with specific country regulatory requirements.  
7.3. Study Drug Accountability  
The study staff is required to document  the receipt, dispensing,  and return/destruction  of Study 
Drug (ISIS 721744 or placebo) supplies provided by the Sponsor according to Sponsor 
instruction and in accordance with institutional policy.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
43  
  
8. TREATMENT  OF PATIENTS  
8.1. Study Drug Administration  
Study Drug (ISIS 721744 or placebo) will be administered as a single -SC injection once every 
4 weeks by blinded study staff during on-site visits at the Study Centers or  by Home Healthcare  
professional  (if available and  after dosing instructions  and training are provided by qualified site 
personnel).  Vials of Study Drug (ISIS 721744 or placebo) are for single use only.  
Please refer to the Study Drug Manual provided by the Sponsor or designee for more detailed 
instructions for Study Drug (ISIS 721744 or placebo) preparation and administratio n. 
8.2. Other Protocol-Required  Drugs 
Patients must have access to, and the ability to use, ≥ 1 acute medication(s)  (e.g., plasma-derived 
or recombinant C1 -INH concentrate or a BK2 -receptor antagonist) to treat angioedema attacks. 
During the course of the study, the use of acute medications (plasma -derived or recombinant  
C1-INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to treat angioedema 
attacks is allowed as medically  indicated.  Patients can be treated with on-demand therapy as 
determined by their treating physician.  
8.3. Other Protocol-Required  Treatment  Procedures  
There are no other protocol-required treatment  procedures.  
 
8.4. Treatment  Precautions  
There are no specific treatment  precautions  required. 
 
8.5. Safety Monitoring  Rules 
Please refer also to the “Guidance  for Investigator”  section of the Investigator’s  Brochure.  
For the purposes of safety monitoring,  Baseline is defined  as the average of the pre-dose Study 
Day 1 value and the last value prior to Study Day 1.  
In addition to the standard monitoring  of clinical safety parameters,  the following  guidelines  are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations.  
Confirmation Guidance : At any time during the study (Treatment or Post -Treatment Periods), 
the initial clinical laboratory  results meeting the safety monitoring  criteria presented  below must 
be confirmed by performing measurements (ideally in the same laboratory that performed the 
initial measurement)  on new specimens.  All new specimen  collections  should take place as soon 
as possible (ideally within 3 days of the initial collection).  For stopping rules, if the initial 
laboratory result is observed during the Treatment Period, the results from the retest must be 
available prior to administering the next dose of Study Drug (ISIS 721744 or placebo).  
Re-dosing Guidance : Patients with initial laboratory  test values that reach a stopping rule must 
not be re-dosed until the retest results are available.  In general, p atients who do not meet the 
stopping rules based upon retest may continue dosing.  However, the Investigator and the  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
44  
  
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether 
additional  close monitoring  of the patient is appropriate.  If any of the stopping criteria described 
below (refer to Section 8.6) are met, the patient will be permanently discontinued from further 
treatment with Study Drug (ISIS 721744 or placebo), evaluated fully as outli ned below and in 
consultation with the Sponsor Medical Monitor or appropriately qualified designee, and will be 
followed up in accordance with Section 8.8 of the protocol.  
 
8.5.1. Safety Monitoring  Rules for Liver Chemistry  Tests 
The following rules are adapted from the draft guidance for industry, “Drug -Induced Liver 
Injury: Premarketing  Clinical Evaluation,”  issued by the U.S. Department  of Health and Human 
Services, Food and Drug Administration,  July 2009. For a definition of Ba seline, please refer to 
guidance in Section 8.5 above. 
In the event of an ALT or AST measurement that is > 3 × ULN (or the greater of 2 × baseline 
value or 3 × ULN if the baseline value was > ULN) at any time during the study (Treatment  or 
Post-Treatment P eriod), the initial measurement(s) should be confirmed as described above.  
Additional,  confirmatory  measurements  should also be performed  if ALT or AST levels increase 
to 5 × ULN.  
Frequency  of Repeat Measurements : Patients with confirmed  ALT or AST levels > 3 × ULN (or 
the greater of 2 × baseline value or 3 × ULN if the baseline value was > ULN) should have their 
liver chemistry  tests (ALT, AST, alkaline phosphatase,  international  normalized  ratio [INR], and 
total bilirubin) retested at least once -weekly until ALT and AST levels become ≤ 1.2 × ULN or  
1.2 × baseline value if the baseline value was > ULN. 
Further Investigation  into Liver Chemistry  Elevations : For patients with confirmed  ALT or AST 
levels > 3  × ULN (or the greater of 2 × baseline value or 3 × ULN if the baseline value was  
> ULN), the following  evaluations  should be performed:  
• Obtain a more detailed history of symptoms  and prior and concurrent  diseases 
• Obtain further history for concomitant drug use (including non -prescription 
medications,  herbal and dietary supplement  preparations),  alcohol use, recreational 
drug use, and special diets  
• Obtain a history for exposure to environmental  chemical agents and travel 
• Perform serology for viral hepatitis (hepatitis A virus immunoglobulin  M ([IgM], 
hepatitis B surface antigen, hepatitis C virus antibody, cytomegalovirus  IgM, and 
Epstein-Barr Virus antibody panel)  
• Perform serology for autoimmune  hepatitis (e.g., antinuclear  antibody)  
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic 
computed  tomography  or magnetic resonance  imaging scans, may be performed  at the discretion 
of the Investigator, in consultation with the Sponsor Medical Monitor.  Repetition of the above 
evaluations should be considered if a patient’s ALT and/or AST levels reach 5 × ULN.  
 
8.5.2. Safety Monitoring  Rules for Platelet Count Results 
Please refer also to Table 2. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
45  
  
Platelet count will be monitored  at least every 4 weeks during the Treatment  and Post-Treatment 
Periods. The Investigator should review all platelet count results within 48 hours of receipt.  
Any unreportable  platelet count  result must be rechecked  ideally within 7 days and determined 
not to have met a stopping rule before dosing can continue.  If a patient’s platelet count falls to 
100,000/mm3 or less, then the patient’s platelet counts should be monitored  weekly. In case of 
platelet reduction to below 75,000/mm3, the platelet monitoring rule defined in stopping rules 
(Section 8.6.2) should be followed.  
In the event of a platelet count < 75,000/mm3, additional  laboratory  investigations  may be 
conducted in consultation with the Sponsor Medical Monitor.  
 
8.5.3. Safety Monitoring  Rules for Renal Function  Test Results 
If a patient’s results meet Criteria 1 or 2 below, the Investigator  should confirm the results and 
initiate weekly monitoring  if confirmed.  If the event of a persistent  elevation is observed over 
2 consecutive weeks, then go to Section 8.6.3. 
1. Serum creatinine increase that fulfills all of the following:  ≥ 0.3 mg/dL (26.5 μmol/L) 
and ≥ 40% above baseline creatinine  values and > ULN (refer to definition  of Baseline in 
Section 8.6) 
2. Proteinuria,  urine protein/creatinine  ratio > 750 mg/g for baseline values ≥ 200 mg/g, or 
4 × baseline value for baseline values < 200 mg/g that are confirmed by repeated urine 
protein/creatinine ratio or by a quantitative total urine protein measurement of  
> 1.0 g/24 hours 
 
8.5.4. Safety Monitoring  for Minor Bleeding Events 
If a bleeding event occurs, including  minor bleeding events such as excess bruising, petechiae,  or 
gingival bleeding on brushing teeth, the Investigator should notify  the Sponsor Medical Monitor 
and additional testing of coagulation parameters (aPTT, PT, and INR) and platelet count should 
be performed.  
8.6. Stopping  Rules 
For the purposes of the stopping rules, Baseline  is defined as the average of the pre-dose Study 
Day 1 value and the last value prior to  Study Day 1.  
 
8.6.1. Stopping  Rules for Liver Chemistry  Elevations  
In the event of laboratory results meeting the following criteria, and the event is without an 
alternative  explanation  as discussed  with the Sponsor Medical Monitor, dosing of a patient 
with Study Drug (ISIS 721744 or placebo) will be stopped permanently; values that are not 
confirmed due to failure to retest or missing lab values will be presumed confirmed:  
1. ALT or AST > 8 × ULN, which is confirmed  
2. ALT or AST > 5 × ULN, which is confirmed  and persists  for ≥ 2 weeks 
3. ALT or AST > 3 × ULN (or the greater of 2 × baseline value or 3 × ULN if the baseline 
value was > ULN), which is confirmed and total bilirubin > 1.5 × ULN or INR > 1.5  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
46  
  
4. ALT or AST > 3 × ULN (or the greater of 2 × baseline value or 3 × ULN if the baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coincides 
with the changes in hepatic enzymes)  of fatigue, nausea, vomiting, right  upper quadrant 
pain or tenderness, fever, rash, and/or concomitant eosinophilia (> ULN)  
 
8.6.2. Stopping  Rules for Platelet Count Results 
Please refer also to Table 2. 
In the event of any platelet count < 25,000/mm3, dosing of the patient with Study Drug will be 
stopped permanently.  Platelet count should be monitored daily until 3 successive values  
> 25,000/mm3. Then, monitor twice weekly until 3 successive values > 75,000/mm3. Then, 
monitor weekly until 3 successive  values > 100,000/mm3. Consider more frequent monitoring  if 
additional risk factors for bleeding are present (see Table 2). Administration of steroids is 
strongly recommended for  patients whose platelet count  is < 25,000/mm3. Treatment guidelines 
for immune thrombocytopenia ( Provan et al. 2010 ) recommend dexamethasone 40 mg daily for 
4 days every 2 to 4 weeks for 1 to 4 cycles; prednis(ol)one 0.5 to 2 mg/kg/day for 2 to 4 weeks 
then taper; or methylprednisolone 30 mg/kg/day for 7 days.  (Note: Patient may require 
continuation with oral steroids af ter methylprednisolone).  
In the event of a platelet count ≥ 25,000/mm3 to < 50,000/mm3, dosing of the patient with Study 
Drug will be stopped permanently.  Platelet count should be monitored twice weekly until  
3 successive  values > 75,000/mm3. Then, monitor weekly until 3 successive  values 
> 100,000/mm3. Consider more frequent monitoring  and/or the administration  of steroids if 
additional risk factors for bleeding are present (see Table 2). 
In the event of a platelet count ≥ 50,000/mm3 to ˂ 75,000/mm3, and in the absence of major 
bleeding or clinically relevant non -major bleeding (defined below), dosing with Study Drug 
should be suspended temporarily until the platelet count has recovered to > 100,000/mm3. The 
suitability of the patient for continued d osing will be determined by the Investigator in 
consultation with the Sponsor Medical Monitor and will be based on factors such as the original 
rate of decline in the patient’s platelet count, whether  any bleeding events were experienced, and 
the speed of recovery of platelet count after interruption of dosing.  Platelet count must be 
measured twice weekly until 3 successive values > 75,000/mm3, then weekly until 3 successive 
values > 100,000/mm3. Consider more frequent monitoring  if additional  risk factors for bleeding 
are present (see Table 2). Any unreportable platelet count result must be rechecked, ideally 
within 7 days, and determined not to have met a stopping rule before dosing can continue.  
Definition  of Major Bleeding Events (Schulman  and Kearon 2005) 
1. Fatal bleeding, and/or 
2. Symptomatic  bleeding in a critical area or organ, such as intracranial,  intraspinal, 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or  
3. Clinically  overt bleeding leading to transfusion  of ≥ 2 units of packed  red blood cells or 
whole blood or a fall in hemoglobin of ≥ 2.0 g/dL (1.24 mmol/L) within 24 hours  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
47  
  
Definition  of Clinically  Relevant  Non-Major Bleeding Events 
Clinically  relevant non-major bleeding is defined as overt bleeding not meeting the criteria  for 
major bleeding but that resulted, for example, in medical examination, intervention, or had 
clinical consequences for a patient.  
Definition  of Minor Bleeding Events 
Minor bleeding events are those that do not fulfill the criteria for major bleeding or clinically 
relevant, non-major bleeding events (defined above), for example excess bruising, petechiae,  or 
gingival bleeding on brushing teeth.  
If the subsequent  test confirms the initial test result, then monitoring  frequency  and dosing 
should be adjusted as recommended in Table 2. 
Table 2: Actions in Patients with Low Platelet Count 
 
Platelet count 
(K/mm3) Dosing Monitoring  frequency  
> 100 Dosing every 4 weeks should be 
continued.  At least every 4 weeks. 
≥ 75 to ≤ 100 Dosing every 4 weeks should be 
continued.  Every week. 
≥ 50 to < 75 Pause dosing. When platelet count 
returns to > 100K/mm3, restart 
dosing only if approved by the 
Sponsor Medical Monitor.  Twice weekly until 3 successive 
values > 75K/mm3, then weekly until 
3 successive values > 100K/mm3. 
Consider more frequent monitoring if 
additional  risk factors for bleeding are 
present.‡ 
≥ 25 to < 50 Permanently  discontinue  Study 
Drug. 
Consider corticosteroids  if additional 
risk factors for bleeding are present.‡ Twice weekly until 3 successive 
values > 75K/mm3, then weekly until 
3 successive values > 100K/mm3. 
Consider more frequent monitoring if 
additional  risk factors for bleeding are 
present.‡ 
< 25 Permanently  discontinue  Study 
Drug. 
Corticosteroids  strongly 
recommended.*  Daily until 3 successive  values 
> 25K/mm3, then twice weekly until 
3 successive  values > 75K/mm3, then 
weekly until 3 successive values  
> 100K/mm3. 
Consider more frequent monitoring if 
additional  risk factors for bleeding are 
present.‡ 
‡ Additional  risk factors for bleeding include age > 60 years, receiving anticoagulant  or antiplatelet  medicinal 
products, and/or prior history of major bleeding events.  
* It is strongly recommended  that, unless  corticosteroids  are contraindicated,  the patient receives glucocorticoid 
therapy to reverse the platelet decline as recovery in platelet count may be accelerated by administration of 
high-dose steroids.  Treatment guideline s for immune thrombocytopenia ( Provan et al. 2010 ) recommend  
dexamethasone  40 mg daily for 4 days every 2 to 4 weeks for 1 to 4 cycles; prednis(ol)one  0.5 to 2 mg/kg/day  for 
2 to 4 weeks then taper; or methylprednisolone 30 mg/kg/day  for 7 days (Note: patient may  require continuation 
with oral steroids after methylprednisolone).  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
48  
  
8.6.3. Temporary  Stopping  Rules for Renal Function  Test Results 
In the event of a persistent  elevation that is observed over 2 consecutive  weeks, for either of the 
2 criteria below, dosing  of a patient with Study  Drug (ISIS 721744 or placebo) may  be stopped 
temporarily:  
1. Serum creatinine  increase that fulfills all of the following  criteria: ≥ 0.3 mg/dL 
(26.5 μmol/L) and ≥ 40% above baseline creatinine  values and > ULN (refer to definition 
of Baseline in Section 8.6) 
2. Proteinuria,  dipstick 2 + (confirmed  by dipstick retest and then further confirmed  by a 
quantitative total urine protein measurement of > 1.0 g/24 hours)  
The possible dosing reinitiation  or follow-up schedule for any events meeting either of these 
criteria will be determined by the Investigator in consultation with the Sponsor Medical 
Monitor or designee.  
8.7. Adjustment  of Dose and/or Treatment  Schedule  
Adjustment  of dose and/or schedule is not permitted.  
 
8.8. Discontinuation  of Study Drug 
A patient must permanently  discontinue  study treatment for  any of the following:  
• The patient becomes pregnant. Report the pregnancy  according  to instructions  in 
Section 9.5.4. 
• The patient withdraws  consent. 
• The patient withdraws  from treatment  (but does not withdraw  consent). 
• The patient experiences  an AE that necessitates  permanent  discontinuation  of Study 
Drug. 
• The patient develops laboratory  test abnormalities  that meet any of the stopping rules 
listed in Sections 8.6.1, 8.6.2, or 8.6.3. 
• The patient experiences  an AE that necessitates  unblinding  of the Investigator  or 
Sponsor to the patient’s treatment assignment.  
The reason for discontinuation  of Study Drug must be recorded in the electronic  Case Report 
Form (eCRF) and source documentation.  
Patients who discontinue  Study Drug will remain in the study and attend the ET Visit 
(Week 17 visit assessments),  unless consent is withdrawn.  Any patient who discontinues  early 
from the Treatment Period or from the Post -Treatment Follow -Up Period should be strongly 
encouraged  to complete follow-up study visits, procedures  and observations  (see Appendix  A). 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
49  
  
8.9. Withdrawal  of Patients from the Study Procedures  
Patients must be withdrawn  from study procedures  for any of the following:  
• Withdrawal  of consent 
• The patient is unwilling  or unable to comply  with the protocol 
Other reasons for withdrawal  of patients from the study may include the following:  
• At the discretion  of the Investigator  for medical reasons 
• At the discretion  of the Investigator  or Sponsor for non-compliance  
• Significant  protocol deviation 
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal.  All information,  including  the reason for withdrawal  from study, must be 
recorded in the eCRF.  
Any patient who withdraws consent to participate in the study will be removed from further 
treatment  and study observation  immediately  upon the date of request. These patients should be 
encouraged to complete the ET study  procedures (Week 17 visit assessments) and observations 
at the time of withdrawal (see Appendix A ). 
For patients withdrawn  for reasons other than withdrawal  of consent, every effort should be 
made to complete the ET study  procedures and observations at the time of withdrawal (see 
Appendix A ). 
 
8.10. Concomitant  Therapy and Procedures  
The use of concomitant  therapies or procedures  defined below must be recorded on the patient’s 
eCRF. Adverse events related to administration of these therapies or procedures must also be 
documented on the appropriate eCRF.  
8.10.1. Concomitant  Therapy 
A concomitant  therapy is any non-protocol-specified drug or substance  (including  
over-the-counter medications,  herbal medications,  and vitamin supplements)  administered 
between Screening and the end of the Post -Treatment Period.  
Allowed Concomitant  Therapy 
During the course of the study, the use of acute medications  (plasma-derived or recombinant 
C1-INH concentrate, BK2 -receptor antagonist, or kallikrein inhibitor) to treat angioedema 
attacks is allowed as medically  indicated.  Patients can be treated with on-demand therapy as 
determined by their treating physician.  
All other stable medications  (if not excluded below) are allowed, so long as the dose and type is 
not expected to change during the study.  
Disallowed  Concomitant  Therapy 
1. Chronic prophylaxis  for angioedema  attacks, except for a stable dose of androgens.  Any 
use of lanadelumab will not be permitted.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
50  
  
NOTE: The use of acute medications (plasma -derived or recombinant C1 -INH 
concentrate  or BK2-receptor antagonist)  to treat angioedema  attacks is allowed as 
medically indicated.  
2. ACE inhibitors  or any estrogen-containing  medications  with systemic absorption  (such as 
oral contraceptive or hormonal replacement therapy).  
3. Any oligonucleotides  (including  small interfering  RNA) other than ISIS 721744. 
4. Plasmapheresis.  
5. Any other investigational  drug or device. 
 
8.10.2. Concomitant  Procedures  
A concomitant  procedure  is any therapeutic  intervention  (e.g., surgery/biopsy,  physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
Screening and the end of the Post-Treatment Period.  
 
8.11. Treatment  Compliance  
Compliance  with treatment  dosing is to be monitored  and recorded in the eCRF by Study Center 
staff. 
 
9. SERIOUS  AND NON-SERIOUS  ADVERSE  EVENT REPORTING  
9.1. Sponsor Review of Safety Information  
Safety information will be collected, reviewed, and evaluated by the Sponsor or designee in 
accordance  with the applicable  Ionis and/or designee Standard Operating  Procedures  throughout 
the conduct of the clinical study.  
 
9.2. Regulatory  Requirements  
The Sponsor or de signee is responsible for regulatory submissions and reporting to the 
Investigators  of SAEs including  SUSARs per the International  Council for Harmonisation  (ICH) 
guidelines E2A and ICH Good Clinical Practice (GCP).  Country-specific regulatory 
requirements will be followed in accordance with local country regulations and guidelines.  
Institutional Review Boards/IECs will be notified of any SAE according to applicable 
regulations.  The DSMB will be notified of any SAE as specified in the DSMB Charter. 
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee will evaluate 
the available information and perform an independent assessment of all reported SAEs and 
determine if there is a reasonable possibility that the Study Drug (I SIS 721744 or placebo) is 
causally related to a reported SAE. While the Sponsor may upgrade an Investigator’s  decision, it 
is not permissible to downgrade the Investigator’s opinion for the purposes of determining 
whether the SAE meets the definition of a SUSAR. 
Appropriate personnel at the Sponsor or designee will unblind SUSARs for the purpose of 
regulatory  reporting.  The Sponsor or designee will submit SUSARs to regulatory  agencies in 
blinded or unblinded fashion according to local law.  The Sponsor or designee will submit 
SUSARs to Investigators in a blinded fashion.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
51  
  
9.3. Definitions  
9.3.1. Adverse Event 
An AE can be any unfavorable  and unintended  sign (including  an abnormal  laboratory  finding, 
for example), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not the AE is considered related to the medicinal 
(investigational) product.  
An AE can therefore be any of the following:  
• Any unfavorable  and unintended  sign (including  an abnormal  laboratory  finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product  
• Any new disease or exacerbation  of an existing disease (a worsening  in the character, 
frequency, or severity of a known condition)  
• Recurrence  of an intermittent  medical condition  (e.g., headache)  not present at 
Baseline 
• Any deterioration  in a laboratory  value or other clinical test (e.g., ECG, X-ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from Study Drug  
• Events that are related to a protocol-mandated  intervention,  including  those that occur 
prior to assignment of study treatment (e.g., screening invasive proced ures such as 
biopsies) 
9.3.2. Adverse Drug Reaction  and Unexpected  Suspected  Adverse Drug Reaction 
Adverse Drug Reaction  
In the pre-approval clinical experience with a new medicinal product or its new usages, 
particularly  as the therapeutic  dose(s) may not have been established,  adverse drug reactions 
(ADRs) are defined as follows:  
All noxious and unintended  responses  to a medicinal  product related to any dose should 
be considered ADRs.  
The phrase “responses  to a medicinal  product” means that a causal relationship  between the 
medicinal product and the AE has been determined by the Sponsor as at least a reasonable 
possibility, i.e., the relationship cannot be ruled out.  
Suspected  Unexpected  Adverse Drug Reaction 
A suspected  unexpected  ADR is any ADR, the nature or severity of which is not consistent  with 
the applicable product information, e.g., Investigator's Brochure for an unapproved medicinal 
(investigational) product.  
A suspected  adverse reaction implies a lesser degree of certainty about causality than an adverse 
reaction. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
52  
  
9.3.3. Serious Adverse Event 
An SAE is any AE that, in the view of either the Investigator  or Sponsor, meets any of the 
following criteria:  
• Results in death 
• Is life-threatening;  that is, poses an immediate  risk of death at the time of the event 
An AE or suspected  adverse reaction is considered  “life-threatening”  if, in the view 
of either the Investigator or Sponsor, its occurrence places the patient at immediate 
risk of death.  It does not include an AE or suspected adverse reaction that, had it 
occurred in a more severe form, might have caused death  
• Requires inpatient hospitalization  or prolongation  of existing hospitalization  
Hospitalization  is defined as an admission  of greater than 24 hours to a medical 
facility and does not always qualify as an AE  
• Results in a persistent  or significant  incapacity  or substantial  disruption  of the ability 
to conduct normal life functions  
• Results in a congenital  anomaly or birth defect in the offspring of the patient 
(whether the patient is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do 
not require hospitalization may also be considered serious when, based upon 
appropriate medical judgment, they may jeopardize the  patient and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasia s or 
convulsions  that do not result in inpatient hospitalization,  or the development  of drug 
dependency or drug abuse  
The terms “severe” and “serious” are not synonymous.  Severity refers to the intensity of an AE 
(e.g., rated as mild, moderate, or severe a ccording to National Cancer Institute Common 
Terminology  Criteria for Adverse Events [CTCAE]);  the event itself may be of relatively  minor 
medical significance (such as severe headache without any further findings).  
Severity and seriousness need  to be independently  assessed for each AE recorded on the eCRF. 
 
9.3.4. Adverse Events of Special Interest 
For the purpose of this study, severe reductions  in platelet count < 50,000/mm3 accompanied  by 
a major bleeding (MB) event or clinically relevant non-major bleeding (CRNMB) event, or 
platelet count of < 25,000/mm3 independent of a MB or CRNMB event, or any thrombotic 
episode are considered as AEs of special interest (AESIs) and  are subject to 15 -day expedited 
reporting by the Sponsor to the regulato ry agencies.  
9.4. Monitoring  and Recording  Adverse Events 
Any pre-existing conditions  or signs and/or symptoms  present in a patient prior  to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
53  
  
AEs unless the pre-existing condition  worsened.  The Investigator  should always group signs and 
symptoms into a single term that constitutes a single unifying diagnosis if possible.  Before a 
diagnosis is confirmed, all symptoms should be repo rted as separate AEs.  
 
9.4.1. Serious Adverse Events 
In the interest of patient safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to Study Drug) should be reported to the Sponsor or designee 
within 24 hours  of the Study Center’s first knowledge  of the event.  The collection of  SAEs will 
begin after the patient signs the ICF and will stop at the end of the patient’s Post -Treatment 
Period, which is defined as completion of  the Week 26/ET Visit.  Serious adverse  events should 
be reported using electronic SAE submission (via eDC) whenever possible.  In situations where 
electronic  SAE submission  is unavailable,  a paper Initial Serious Adverse Event Form should be 
completed and a copy should be faxed or emailed to the  Sponsor or designee.  The SAE 
reporting instructions, including the fax number and email address, can be found in the 
Investigator Site File for the study.  
Detailed information  should be actively sought and included as Follow-Up as soon as additional 
information becomes available.  All SAEs will be followed until resolution.  Serious adverse 
events that remain ongoing past the patient’s last protocol -specified follow -up visit will be 
evaluated by the Investigator and Sponsor.  If the Investigator and Sponsor a gree that the  
patient’s condition  is unlikely to resolve, the Investigator  and Sponsor will determine  the 
follow-up requirement.  
 
9.4.2. Non-Serious Adverse Events 
The recording of non -serious AEs will begin after the patient signs the ICF and will stop at the 
end of the patient’s Post -Treatment Period, which is defined as completion of the Week 26/ET 
Visit. The Investigator  will monitor each patient closely and record all observed  or volunteered 
AEs on the eCRF.  
9.4.3. Evaluation  of Adverse Events (Serious and Non-Serious) 
The Investigator’s  opinion of the following  should be  documented  on the eCRF: 
9.4.3.1. Relationship  to the Study Drug 
The event’s relationship  to the Study Drug (ISIS 721744 or placebo) is characterized  by 1 of the 
following:  
• Related: There is clear evidence that the event is related to the use of Study Drug 
(ISIS 721744 or placebo), e.g., confirmation by positive re -challenge test  
• Possible:  The event cannot be explained by the patient’s medical condition, 
concomitant  therapy, or other causes, and there is a plausible temporal relationship 
between the event and Study Drug (ISIS 721744 or placebo) administration  
• Unlikely/Remote:  An event for which an alternative  explanation  is more likely (e.g., 
concomitant medications or ongoing  medical conditions) or the temporal relationship 
to Study Drug (ISIS 721744 or placebo) administration and/or exposure  suggests that 
a causal relationship is unlikely (for reporting purposes, Unlikely/Remote will be 
grouped together with Not Related)  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
54  
  
• Not Related: The event can  be readily explained by  the patient’s  underlying  medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator 
believes no relationship exists between the event and Study Drug (ISIS 721744 or 
placebo) 
9.4.3.2. Severity 
The severity  of AEs and SAEs relating to laboratory  tests and AEs at the injection site will be 
graded based on criteria from the CTCAE Version 5.0, November  2017 (refer to Appendix  D). 
Any AE not listed in Appendix D will be graded as follows:  
• Mild: The event is easily tolerated by the patient and  does not affect the patient’s 
usual daily activities  
• Moderate:  The event causes the patient more discomfort  and interrupts  the patient’s 
usual daily activities  
• Severe: The event is incapacitating  and causes considerable  interference  with the 
patient’s usual daily activities  
If the event is an SAE, then all applicable  seriousness  criteria must be indicated (criteria listed in 
Section 9.3.3). 
 
9.4.3.3. Action Taken with Study Drug 
Down-titration of Study Drug (ISIS 721744 or placebo) will not be allowed during the study. 
Action taken with Study Drug (ISIS 721744 or placebo) due to an AE is characterized  by 1 of the 
following:  
• None: No changes made to Study Drug (ISIS 721744 or placebo) administration  and 
dose 
• Not Applicable:  AE reported during the Screening  Period prior to Study Drug 
(ISIS 721744 or placebo) administration  
• Permanently  Discontinued:  Study Drug (ISIS 721744 or placebo) discontinued  and 
not restarted  
• Temporarily Interrupted, Restarted – Same Dose:  Dosing and/or dosing 
frequency  temporarily  interrupted/changed  or delayed due to the AE and restarted at 
the same dose  
 
9.4.3.4. Treatment  Given for Adverse Event 
Any treatment (e.g., medications or procedures) given for the AE should be recorded on the 
eCRF. Treatment  should also be recorded on the concomitant  treatment  or ancillary procedures 
eCRF, as appropriate.  
 
9.4.3.5. Outcome  of the Adverse Event 
If the event is a non-serious AE, then the event’s outcome is characterized  by 1 of the following:  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
55  
  
• AE Persists: Patient terminates  from the study and the AE continues  
• Recovered:  Patient recovered  completely  from the AE 
• Became Serious: The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE)  
• Change in Severity (if applicable):  AE severity changed 
If the event is an SAE, then  the event’s outcome  is characterized  by 1 of the following:  
• Ongoing:  SAE continuing  
• Persists (as non-serious AE): Patient has not fully recovered  but the event no longer 
meets serious criteria and should be captured as an AE on the non -serious AE eCRF 
(the SAE resolution date should be entered as the date of onset of that AE)  
• Recovered:  Patient recovered  completely  from the SAE (the date of recovery should 
be entered as th e SAE resolution date)  
• Recovered  with Sequelae:  The signs/symptoms  of the reported SAE have improved 
but not completely resolved, and a new baseline for the patient is established since 
full recovery is not expected  
• Fatal: Patient died (the date of death should be entered as the SAE resolution  date) 
• Unknown:  The outcome of the reported SAE is not available,  e.g., patient is lost to 
follow-up 
 
9.4.3.6. Follow-up of Adverse Event 
Investigator Follow -up 
During the Study Period, the  Investigator  should follow each AE until the event has resolved to 
baseline grade or better, the event is assessed as stable, the patient is lost to follow -up, or the 
patient withdraws consent.  Every effort should be made to follow all SAEs considered to be 
related to Study D rug or related to study procedures until a final outcome can be reported.  
Resolution  of AE (with dates) should be documented  on the eCRF and in the patient’s medical 
record to facilitate source data verification.  
Investigators  should follow-up, or support the Sponsor’s  effort to follow up, with all pregnancies 
reported during the study from either the study patient or the female partner of the male study 
patient until pregnancy outcome is available.  
Sponsor Follow-up 
For SAEs and pregnancy cases in patients who have completed or terminated the study, the 
Sponsor or a designee should follow -up by telephone, fax, email, and/or a monitoring visit to 
obtain additional  case details and outcome information  (e.g., from hospital discharge  summaries, 
consultant reports, or autopsy reports) in order to perform  an independent medical  assessment  of 
the reported case.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
56  
  
9.5. Procedures  for Handling  Special Situations  
9.5.1. Abnormalities  of Laboratory  Tests 
Clinically significant abnormal laboratory test results may, in the opinion of the Investigator, 
constitute or be associated with an AE.  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia,  or cardiac arrhythmias  due to hyperkalemia.  Whenever  possible, the 
underlying diagnosis should be listed in preference to abnormal laboratory values as AEs.  
Clinically significant abnormalities will be monitored by the Investigator until the parameter 
returns to its baseline value or until agreement is reached between the Investigator and Sponsor 
Medical Monitor.  Laboratory abnormalities deemed not clinically significant (NCS) by the 
Investigator  should not be reported as AEs. Similarly,  laboratory abnormalities  reported as AEs 
by the Investigator should not be deemed NCS on the laboratory sheet.  
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical laboratory  reports will serve as source document s and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values.  
9.5.2. Prescheduled  or Elective Procedures  or Routinely  Scheduled  Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospitalized;  the Study Center must document  all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was 
scheduled  (or was on a waiting list to be scheduled)  prior to obtaining  the patient’s 
consent to participate in the study  
• The condition that required the prescheduled or elective procedure or routinely 
scheduled  treatment  was present before and did not worsen or progress in the opinion 
of the Investigator between the patient’s consent to participate in the study and the 
timing of the procedure or treatment  
• The prescheduled  or elective procedure  or routinely scheduled  treatment  is the sole 
reason for the intervention or hospital admission  
9.5.3. Dosing Errors 
Study Drug (ISIS 721744 or placebo) dosing errors (including overdose, underdose, and 
administration  error) should be documented  as protocol deviations.  A brief description  should be 
provided in the deviation, including whether the patient was symptomatic (list symptoms) or 
asymptomatic, and the event accidental or intentional.  
Dosing details should be captured on the Dosing eCRF. If the patient  takes a dose of Study Drug 
(ISIS 7217 44 or placebo) that exceeds protocol specifications and the patient is symptomatic, 
then the symptom(s) should be documented as an AE and be reported per Section 9.4. 
An overdose is the accidental or intentional use of a drug in an amount higher than the d ose 
being studied. An overdose or incorrect administration  of study treatment  is not itself an AE, but 
it may result in an AE. All AEs associated  with an overdose or incorrect administration  of Study 
Drug should be recorded on the Adverse Event eCRF.  If the associated AE fulfills seriousness 
criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours 
after learning of the event).  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
57  
  
Should an overdose occur , the Investigator or designee should refer to the “G uidance for 
Investigator”  section of the Investigator’s  Brochure and contact the Sponsor or designee within 
24 hours. 
 
9.5.4. Contraception  and Pregnancy  
Male patients and female patients of childbearing  potential must continue to use highly effective 
contraception with their partners, or refrain from sexual activity, as described in Section 6.3.1. 
If a patient becomes pregnant or a pregnancy  is suspected,  or if a male patient makes or believes 
that he has made someone pregnant during the study, then the Study Center staff must be 
informed immediately.  An Initial Pregnancy Form should be submitted to the Sponsor or 
designee within 24 hours of first learning of the occurrence of pregnancy.  Follow-up 
information  including  delivery or termination is reported by designating  as ‘Follow-up’ on the 
Pregnancy Forms and reported within 24 hours.  
Payment for all aspects of obstetrical  care, child or related care will be the patient’s 
responsibility.  
Female patients: If a suspected  pregnancy  occurs while on the study (including  the 
Post-Treatment Period), a pregnancy test will be performed.  The patient with a confirmed 
pregnancy will be immediately withdrawn from treatment with Study Drug.  However, the 
patient will be encouraged to complete th e Post-Treatment Period of the study to the extent that 
study procedures do not interfere with the pregnancy.  Regardless of continued study 
participation, the study physician will assist the patient in getting obstetrical care and the 
progress of the pregn ancy will be followed until the outcome of the pregnancy is known (i.e., 
delivery, elective termination,  or spontaneous  abortion).  If the pregnancy  results in the birth of a 
child, the Study Center and Sponsor may require access to the mother and infant’s medical 
records to obtain additional information relevant to the pregnancy progress and outcome.  A 
longer follow -up may be required if a newborn child experiences a medical condition.  
Follow-up will be performed  to the extent permitted  by the applicable  regulations  and privacy 
considerations; e.g., pregnancy ICF may be required.  
Male patients : The progress of the pregnancy of a male patient’s partner should be followed 
until the outcome of the pregnancy  is known (i.e., delivery, elective termination, or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
follow-up with the mother and may request access to the mother and infant’s medical records to 
obtain additional information relevant to the pregnancy progress and outcome.  A longer 
follow-up may be required if a newborn child experiences  a medical condition.  Follow-up will 
be performed to the extent permitted by the applicable regulations and privacy considerations; 
e.g., partn er ICF may be required.  
 
10. STATISTICAL  CONSIDERATIONS  
The sections below indicate the overall structure and approach to the analysis of this study. A 
detailed SAP incorporating these sections below will be prepared separately.  The SAP will 
outline all data handling conventions, including software, and specify additional statistical 
methods to be  used for analysis. The study objectives and endpoints are  listed in Sections 1.1 
and 1.2, respectively.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
58  
  
10.1. Sample Size Considerations  
The study will enroll a total of approximately 24 patients with HAE.  Approximately  18 patients 
with HAE -1/HAE-2 are planned to be enrolled in Part A of the study and, in parallel, 
approximately 6 patients with HAE -nC1-INH are planned to be enrolled in Part B of the study. 
Due to the rarity of HAE-nC1-INH, enrollment  in Part B may be ended early  if Study Centers are 
unable to enroll sufficient patients; this will not impact completion of Part A.  Patients with  
HAE-1/HAE-2 (Part A) will be randomized  to SC injections  of ISIS 721744 80 mg or placebo 
administered every 4 weeks in a 2:1 ratio (ISIS 721744:placebo), and patients with  
HAE-nC1-INH (Part B) will be administered  open-label SC injections  of ISIS 721744 80 mg 
every 4 weeks.  
The sample size of 18 patie nts with HAE -1/HAE-2 (12 patients administered SC injections of 
ISIS 721744 80 mg and 6 patients administered placebo) is from clinical considerations for 
sufficient safety and tolerability evaluation.  The primary endpoint is the time -normalized 
number of HAE attacks (per month) from Week 1 to Week 17. From historical data, the placebo 
group is estimated  to have 6.8 HAE attacks per 4-month period. If the ISIS 721744 80 mg group 
is assumed to have 2.8 HAE attacks per 4 -month period, then with a 0.05 significance level and 
Poisson model, the sample size of 18 patients will provide at least 90% power for the primary 
endpoint, considering a 10% missing data or dropout rate for both active treatment and placebo. 
There is no statistical rationale for the s ample size of 6 patients with HAE -nC1-INH. 
10.2. Populations  
The Safety Population  will include all enrolled patients who receive at least 1 dose of Study 
Drug (ISIS 721744 or placebo).  
The Intent-to-Treat (ITT) Population  will include all enrolled or randomized  patients. 
The Per-Protocol (PP) Population  will include all patients in the ITT Population  who are treated 
according to the protocol without any major deviations.  
The PK Population  will include all patients who are enrolled and receive at least 1 dose of Study 
Drug (ISIS 721744 or placebo) and have at least 1 evaluable PK sample.  
 
10.3. Definition  of Baseline 
For platelets, Baseline  will be defined as the average of all non-missing pre-dose assessments.  
For other assessments,  if there are 2 or more pre-dose values available,  Baseline will be defined 
as the average of the pre -dose Study Day 1 value and the last pre -dose value prior to Study  
Day 1. If there is only 1 pre-dose measurement  available,  then it will be assigned as  Baseline. 
 
10.4. Data and Safety Monitoring  Board 
An independent  DSMB will be established  prior to the initiation of the study. The DSMB will 
be responsible for monitoring the overall safe conduct of the study.  Based on its ongoing 
assessment of the safety and tolerability of ISIS 721744, the DSMB will provide 
recommendations to the Sponsor for modifying, stopping, or continuing the study as planned.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
59  
  
Details on the safety assessments,  frequency  of review, meeting schedules  and controlled  access 
to unblinded data are outlined in the DSMB Charter and SAP.  
10.5. Interim Analysis 
No interim analysis is planned for this study. 
 
10.6. Planned Methods of Analysis 
10.6.1. Demographic  and Baseline Characteristics  
Demographic  and baseline characteristics  will be summarized  using descriptive  statistics by 
treatment group.  Patient disposition will be summarized by treatment group.  All patients 
enrolled will be included in a summary of patient disposition.  
10.6.2. Safety Analysis 
The Safety Population  will be used for all safety analyses. 
The safety and tolerability of ISIS 721744 will be assessed by determining the number, type, 
severity, and dose -relationship of AEs; vital signs; ECGs; and clinical laboratory parameters. 
Safety results in patients dosed with ISIS 721744 will be compared  to safety results in patients 
dosed with placebo.  
Treatment duration and amount of Study Drug (ISIS 721744 or placebo) received will be 
summarized by  treatment group.  Patient incidence rates of all AEs will be tabulated by  Medical 
Dictionary  for Regulatory  Activities  (MedDRA™) system organ class and by MedDRA  preferred 
term. Tables and/or narratives of treatment -emergent deaths and serious and significant AEs, 
including early withdrawals due to AEs, will also be provided.  
All TEAEs, all TEAEs potentially  related to Study Drug, all treatment -emergent SAEs, and all 
treatment -emergent SAEs potentially related to Study Drug (ISIS 721744 or placebo) will be 
summarized.  
Laboratory  tests to ensure patient safety, including  chemistry  panel, complete blood count with 
differential, coagulation panel, and complement, will be summarized by study visit for each 
treatment group.  These safety variables will also be presented as change and percent change 
from Baseline over time after Study Drug (ISIS 721744 or placebo) administration, as 
appropriate.  
Vital sign and ECG measures will be tabulated by  treatment group.  In addition, the number of 
patients who experience  abnormalities  in clinical laboratory  evaluations  will be summarized  by 
treatment g roup. 
10.6.3. Efficacy Analysis 
The ITT Population  will be used for all efficacy analyses. The PP Population  will be used for a 
sensitivity analysis to assess robustness of the efficacy analysis results.  
The definition  of an HAE attack,  including  discrete attacks, is provided in Section  6.2.1. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
60  
  
10.6.3.1. Primary Efficacy Analysis 
The primary endpoint is the time-normalized  number of HAE attacks (per month) from Week 1 
to Week 17.  
The Part A data will be analyzed using a Poisson regression  model with treatment  group as a 
fixed effect and the number of baseline HAE attacks as a covariate, and the logarithm of 
exposure in month will be used as the offset.  
The least-squares means, standard errors, and the 2-tailed 95% confidence  intervals for the 
treatment group and placebo group will be presented.  
The Part B data will be summarized  using descriptive  statistics. 
 
10.6.3.2. Secondary  Efficacy Analysis 
The secondary  endpoints  include the time-normalized  number of HAE attacks (per month) from 
Week 5 to Week 17; the time-normalized number of moderate or severe HAE attacks (per 
month) from Week 5 to Week 17; the number of patients with a clinical response (defined as a  
≥ 50%, ≥ 70%, or ≥ 90% reduction from Baseline in HAE attack rate) by Week 17; the number  
of HAE attacks requiring acute therapy from Week 5 to Week 17; cHK levels at Weeks 9 and 17; 
PKK activity  at Weeks 9 and 17; consumption of on -demand medication at Weeks 9 and 17; and 
AE-QoL questionnaire score at Weeks 9 and 17.  
For Part A, the time-normalized number of HAE attacks (per month) from Week 5 to Week 17 
and the time-normalized  number of moderate or severe HAE attacks (per month) from Week 5 to 
Week 17 will be analyzed in a similar way to the primary efficacy endpoint.  
Continuous vari ables will be summarized by descriptive statistics (n, mean, median, standard 
deviation, minimum, and maximum) by treatment group.  Continuous variables will also be 
analyzed using analysis of covariance  or analysis of variance. The least-squares means, standard 
errors, and the 2 -tailed 95% confidence intervals for the treatment group and placebo group will 
be presented.  
Categorical variables will be summarized by  frequency  and percentage for  the treatment group 
and placebo group. Categorical  variables will be analyzed using a Pearson’s  Chi-square test or 
Cochran-Mantel-Haenszel test.  
The Part B data will be summarized  using descriptive  statistics. 
 
10.6.3.3. Exploratory  Efficacy Analysis 
Exploratory  efficacy endpoints  include the number of HAE attack-free patients by Week 17 and 
potential exposure response analysis using relevant exposure parameters and biomarkers.  All 
exploratory efficacy endpoints will be analyzed using the same methods as described for the 
secondary efficacy endpoints.  
 
10.6.4. Pharmacokinetic  Analysis 
The plasma PK of ISIS 721744 will be assessed following  SC administration.  For all patients, 
Pre-Dose (trough) and Post -Treatment plasma ISIS 721744 concentrations will be determined 
and summarized using  descriptive  statistics. Plasma terminal elimination  half-life will also be 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
61  
  
calculated using the Post -Treatment follow up ISIS 721744 plasma concentrations, if data 
permits. For patients in the PK sub group, non-compartmental  PK analysis of ISIS 721744 will 
be carried out on each individual patient dataset.  
Pharmacokinetic  parameters  include (but are not limited to) the following:  Cmax, Tmax, AUC, and 
t½. Other plasma PK parameters, as appropriate, may be determined or calculated at the 
discretion of the PK scientist.  
Metabolite  identification  and profiling may be conducted  on select plasma samples. 
Plasma PK parameters will be summarized using descriptive statistics. Additional details 
regarding  the PK analysis along with immunogenicity  (IM) analysis will be described  in the 
SAP. 
Analysis of potential exposure-response relationship  between biomarkers  and PK measures may 
also be explored.  
Population  PK and PK/PD analyses may be performed  using PK data from this study, and/or 
combined with other ISIS 721744 clinical PK/PD data later in the development timeline.  
 
11. INVESTIGATOR’S  REGULATORY  OBLIGATIONS  
11.1. Informed  Consent 
The written informed consent document  should be prepared in the language(s)  of the potential 
patient population, based on an English version provided by the Sponsor or designee.  
Before a patient’s participation  in the study, the Investigator  is responsible  for obtaining  written 
informed consent from the patient after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study and before any protocol -specific screening 
procedures or any  Study Drug (ISIS 721744 or placebo) are adminis tered. The patient must be 
given sufficient time to consider whether to participate in the study.  
The acquisition of informed consent and the patient’s agreement or refusal to notify his/her 
primary care physician should be documented in the patient’s medical records and the ICF  
should be signed and personally dated by the patient and by the person who conducted the 
informed consent discussion  (not necessarily  an Investigator).  The original signed ICF should be 
retained in the Study Master File and in any other locations required by institutional  policy, and  a 
copy of the signed consent form should be provided to the patient.  
 
11.2. Ethical Conduct of the Study 
All applicable  regulations  and guidelines  of current GCP as well as the demands of national drug 
and data protection laws and other applicable regulatory requirements must be followed.  
 
11.3. Independent  Ethics Committee/Institutional  Review Board 
A copy of the protocol, proposed ICF, other written patient information, and any proposed 
advertising material must be submitted to the IEC/IRB for written approval.  A copy of the 
written approval of the protocol and ICF must be received by the Sponsor or designee before 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
62  
  
recruitment of patients into the study and shipmen t of Study Drug.  A copy of the written 
approval of any other items/materials that must be approved by the Study Center or IEC/IRB 
must also be received by the Sponsor or designee before recruitment of patients into the study 
and shipment of Study Drug. The Investigator’s  Brochure must be submitted  to the IEC/IRB for 
acknowledgement.  
The Investigator  must submit to and, where necessary,  obtain approval from the IEC/IRB, for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB of deviations from the protocol in accordance with ICH 
GCP. The Investigator should also notify the IEC/IRB of SAEs occurring at the Study Center 
and other AE reports received from the Sponsor or designee, in accor dance with local 
procedures.  
The Investigator  will be responsible  for obtaining  annual IEC/IRB approval/renewal  throughout 
the duration of the study. Copies of the Investigator’s  reports, all IEC/IRB submissions  and the 
IEC/IRB continuance of approval must be sent to the Sponsor or designee.  
11.4. Patient Confidentiality  
The Investigator  must ensure that the patient’s confidentiality  is maintained.  On the case report 
forms or other documents  submitted  to the Sponsor or designee, patients should be identified  by 
initials (if permitted by  local law) and a  patient identification number  only. Documents that are 
not for submission to the Sponsor or designee (e.g., signed ICFs) should be kept in strict 
confidence by the Investigator.  
In compliance with fe deral and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives  of the company,  of the regulatory 
agency(s), and the IEC/IRB direct access to review the patient’s original medical recor ds for 
verification  of study-related procedures  and data. Direct access includes examining,  analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study. The Investigator is obligated to inform and obtain the consent of the patient to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient.  
 
12. ADMINISTRATIVE  AND LEGAL OBLIGATIONS  
12.1. Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor or designee. 
Agreement  from the Investigator  must be obtained for all protocol amendments  and amendments 
to the informed consent document.  The regulatory authority and IEC/IRB must be informed of 
all amendments a nd give approval for any amendments likely to affect the safety of the patients 
or the conduct of the study.  The Investigator must send a copy of the approval letter from the 
IEC/IRB to the Sponsor or designee.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
63  
  
12.2. Study Termination  
The Sponsor or designee reserves the right to terminate  the study. The Investigator  reserves the 
right to terminate their participation in the study, according to the terms of the Study Center 
contract. The Investigator/Sponsor or designee should notify the IEC/IRB in writing of the 
study’s completion or ET and send a copy of the notification to the Sponsor or designee.  
 
12.3. Study Documentation  and Storage 
An eCRF utilizing an Electronic  Data Capture application  will be used for this study. 
The Investigator should ensure that all appropriately qualified persons to whom he/she has 
delegated  study duties are recorded on a Sponsor-approved Delegation  of Site Responsibilities 
Form. 
Source documents  are original documents,  data, and records from which the patient’s case report 
form data are obtained.  These include but are not limited to hospital records, clinical and office 
charts, laboratory and pharmacy records, imaging, and correspondence . In this study, eCRFs 
may not be used as source documents . 
The Investigator and Study Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation in accordance with ICH 
GCP, suitable for inspection  at any time by representatives  from the Sponsor or designee and/or 
applicable regulatory authorities.  Elements should include the following:  
• Patient files containing  completed  case report forms, informed consents, and 
supporting copies of source documentation  
• Study files containing the protocol with all amendments, Investigator’s Brochure, 
copies of pre-study documentation  and all correspondence  to and from the IEC/IRB 
and the Sponsor or designee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug 
Product Accountability  Record, Return of Study Drug Product for Destruction,  final 
Study Drug product reconciliation, and all drug -related correspondence  
In addition, all original source documents  supporting  entries in the case report forms must be 
maintained and be readily available.  
No study document  should be destroyed  without prior written agreement  between the Sponsor or 
designee and the Investigator.  Should the Investigator wish to assign the study records to 
another party or move them to anoth er location, he/she must notify the Sponsor or designee.  
12.4. Study Monitoring  
The Sponsor representative  and regulatory  authority inspectors  are responsible  for contacting  and 
visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting 
the various records of the study (e.g., case report forms and other pertinent data) provided that 
patient confidentiality is respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular 
intervals throughout  the study to verify adherence  to the protocol; completeness,  accuracy,  and 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
64  
  
consistency  of the data; and adherence  to local regulations  on the conduct of clinical research. 
The monitor should have access to patient medical rec ords and other study -related records 
needed to verify the entries on the case report forms.  
The Investigator  agrees to cooperate  with the monitor to ensure that any problems detected in the 
course of these monitoring  visits, including  delays in completing  case report forms, are resolved. 
In accordance  with ICH GCP and the Sponsor’s  audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinical Quality Assurance Department (or designees).  
Inspection  of Study Center facilities (e.g., pharmacy,  drug storage areas, laboratories)  and review 
of study-related records will occur to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of cl inical data a clinical data management review will be performed on 
patient data received by the Sponsor or designee.  During this review, patient data will be 
checked for consistency,  omissions,  and any apparent discrepancies.  In addition, the data will be 
reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the 
clinical data management review process, data queries and/or Study Center notifications will be 
sent to the Study Center for completion and return to Sponsor or desig nee. 
The Principal Investigator  will sign and date the indicated places on the case report form. These 
signatures  will indicate that the Principal Investigator  inspected  or reviewed the data on the case 
report form, the data queries, and the Study Center notifications, and agrees with the content.  
12.5. Language  
Case report forms must be completed  in English. Generic names and trade names are acceptable 
for concomitant medications.  Combination medications should be recorded using their trade 
name. 
All written information  and other material to be used by patients and investigative  staff must use 
vocabulary and language that are clearly understood.  
12.6. Compensation  for Injury 
The Sponsor maintains  appropriate  insurance  coverage for clinical studies and will follow 
applicable local compensation laws.  Patients will be treated and/or compensated for any  
study-related illness/injury  in accordance  with the information  provided in the Compensation  for 
Injury section of the ICF.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
65  
  
13. REFERENCES  
Altmann K-H, Dean NM, Fabbro D, et al. Second generation  of antisense oligonucleotides:  From nuclease 
resistance to biological efficacy in animals. CHIMIA Int J Chem 1996; 50: 168‑176.  
Bissler JJ, Aulak KS, Donaldson  VH, et al. Molecular  defects in hereditary  angioneurotic  edema. Proc Assoc Am 
Physicians 1997; 109: 164‑173.  
Clinical Trial Facilitation  Group 2014. Recommendations  related to contraception  and pregnancy  testing in clinical 
trials. Heads of Medicines Agencies Website. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 - 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf. Acces sed December 5, 2019.  
Crooke ST, and Bennett CF. Progress in antisense oligonucleotide  therapeutics.  Annu Rev Pharmacol  Toxicol 1996; 
36: 107-129. 
Geary RS, Yu RZ, Watanabe T, et al.  Pharmacokinetics  of a tumor necrosis  factor-alpha phosphorothioate 2' -O-(2- 
methoxyethyl) modified  antisense oligonucleotide:  comparison  across species. Drug Metab Dispos  2003; 31: 1419- 
1428. 
Girolami A, Scarparo P, Candeo N, et al. Congenital  prekallikrein  deficiency.  Expert Rev Hematol 2010; 3: 685- 
695. 
Henry S, Stecker K, Brooks D, et al. Chemically  modified oligonucleotides  exhibit decreased  immune stimulation  in 
mice. J Pharmacol Exp Ther 2000; 292: 468 -479. 
Inoue H, Hayase Y, Iwai S, et al. Sequence -dependent  hydrolysis  of RNA using modified oligonucleotide  splints 
and RNase H. FEBS Lett 1987; 215: 327 -330. 
Lara‑Marquez  ML, Christiansen  SC, Riedl MA, et al. Threshold -stimulated  kallikrein  activity distinguishes 
bradykinin - from histamine -mediated angioedema. Clin Exp Allergy 2018; 48: 1429‑1438.  
Maurer M, Magerl M, Ansotegui  I, et al. The international  WAO/EAACI  guideline for the management  of 
hereditary angioedema -The 2017 revision and update. Allergy 2018; 73: 1575‑1596.  
McKay RA, Miraglia LJ, Cummins  LL, et al. Characterization  of a potent and specific  class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem 1999; 274: 1715 -1722. 
Monia BP, Lesnik EA, Gonzalez  C, et al. Evaluation  of 2'-modified oligonucleotides  containing  2'-deoxy gaps as 
antisense inhibitors of gene expression. J Biol Chem 1993; 268: 14514 -14522. 
Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using 
triantennary  N-acetyl galactosamine  improves potency 10-fold in mice. Nucleic Acids Res 2014; 42: 8796-8807. 
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of  
primary immune thrombocytopenia.  Blood 2010; 115: 168-186. 
Schulman  S, and Kearon C. Definition  of major bleeding in clinical investigations  of antihemostatic  medicinal 
products in non -surgical patients. J Thromb Haemost 2005; 3: 692 -694. 
Stockert RJ. The asialoglycoprotein  receptor: relationships  between structure, function, and expression.  Physiol Rev 
1995; 75: 591-609. 
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people 
with raised lipoprotein(a):  two randomised,  double-blind, placebo-controlled,  dose-ranging trials. Lancet 2016; 388: 
2239-2253. 
Weller K, Groffik A, Magerl M, et al. Development,  validation,  and initial results of the Angioedema  Activity 
Score. Allergy 2013; 68: 1185 -1192. 
Zhang H, Lowenberg  EC, Crosby JR, et al. Inhibition  of the intrinsic  coagulation  pathway factor XI by antisense 
oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684 -4692. 
Zuraw BL, and Christiansen  SC. HAE Pathophysiology  and Underlying  Mechanisms.  Clin Rev Allergy Immunol 
2016; 51: 216 -229. 

721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
66  
  
14. APPENDICES  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
67  
  
 
APPENDIX  A. SCHEDULE  OF PROCEDURES  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
68  
  
Appendix  A. Schedule  of Procedures  
 
 
Screening1 Treatment  Period (12 Weeks) Post-Treatment  Period16 
(13 Weeks)  
Study Week/Day  Weeks -8 to -1 
Days -56 to -1 Week 1 
Day 1 Week 3 
Day 1517 Week 5 
Day 2917 Week 9 
Day 5717 Week 13 
Day 8517 Week 17 
Day 113 
or ET17 Week 21 
Day 
14117 Week 26 
Day 
17617 
Visit Window (Days) ± 0 ± 0 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 
Informed Consent X         
Inclusion/Exclusion  X         
Demographics  and Medical 
History (including detailed 
HAE history)   
X         
Prior/Concomitant 
Medications  (including  HAE 
treatment)   
X  
X  
X  
X  
X  
X  
X  
X  
X 
Body Weight and  Height2 X X X X X X X X X 
Physical Examination  X X  X X X X X X 
Vital Signs3 X X X X X X X X X 
HIV, Hepatitis B, and 
Hepatitis C  X         
FSH4 X         
Pregnancy  Test5 X X  X X X X X X 
Clinical Laboratory 
Parameters (chemistry, 
hematology,  complement,  and 
coagulation)6, 7  
X  
X  
X  
X  
X  
X  
X  
X  
X 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
Appendix  A. Schedule  of Procedures  Continued  
69  
  
 
 
 
Screening1 Treatment  Period (12 Weeks) Post-Treatment  Period16 
(13 Weeks) 
Study Week/Day  Weeks -8 to -1 
Days -56 to -1 Week 1 
Day 1 Week 3 
Day 1517 Week 5 
Day 2917 Week 9 
Day 5717 Week 13 
Day 8517 Week 17 
Day 113 
or ET17 Week 21 
Day 
14117 Week 26 
Day 
17617 
Visit Window (Days) ± 0 ± 0 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 
Urinalysis  X X X X X X X X X 
Threshold -Stimulated 
Kallikrein Activity  
(if applicable)8  
X         
Genetic Diagnostic  Testing 
(if applicable)9 X         
AE-QoL X X   X  X  X 
Angioedema  Activity 
Score10 X X X X X X X X X 
HAE Attack Assessment 
(including on -demand 
treatment)11, 12  
X  
X  
X  
X  
X  
X  
X  
X  
X 
12-Lead ECG X X   X  X  X 
Randomization13  X        
Study Drug Administration 
(ISIS 721744 or placebo)   
X  
X X X    
Adverse Events X X X X X X X X X 
Immunogenicity  Testing  Xa X Xa Xa  X  X 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
Appendix  A. Schedule  of Procedures  Continued  
70  
  
 
 
 
Screening1 Treatment  Period (12 Weeks) Post-Treatment  Period16 
(13 Weeks)  
Study Week/Day  Weeks -8 to -1 
Days -56 to -1 Week 1 
Day 1 Week 3 
Day 1517 Week 5 
Day 2917 Week 9 
Day 5717 Week 13 
Day 8517 Week 17 
Day 113 
or ET17 Week 21 
Day 
14117 Week 26 
Day 
17617 
Visit Window (Days) ± 0 ± 0 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 
PK Blood Sampling14  Xb X Xa Xa Xb X X X 
PD Blood Sampling15 X Xa X Xa Xa Xa X X X 
Inflammatory  Panel X Xa X Xa Xa Xa X X X 
Note: When multiple procedures are scheduled at the same visit, clinical assessments and procedures should be performed prior to Study Drug administration, 
unless otherwise  indicated,  and should proceed in the following  order: vital signs, physical examinations,  patient-reported outcomes  (such as the AAS and 
the AE-QoL questionnaire), ECGs, and collection of blood and/or urine for laboratory assessments.  
1 The Screening  Period is up to 8 weeks in duration. A patient may  be randomized  after fewer than 8 weeks of Screening  if the patient experiences ≥  2 HAE 
attacks in less than 8 weeks and has completed all other screening activities and has met all other eligibility requirements.  
2 Height will be measured  at Screening  only. 
3 Vital signs will include blood pressure, heart rate, respiratory  rate, and body temperature  and should be taken after sitting for at least 5 min. 
4 For confirmation  of menopause  at Screening  per inclusion criteria. 
5 Only for women  who are not surgically  sterile or post-menopausal.  A serum pregnancy  test will be performed  during Screening  and urine pregnancy  tests 
will be performed at all other study visits.  
6 If the platelet value, serum creatinine,  or liver enzyme tests are uninterpretable  (e.g., due to clumping,  hemolysis,  or quantity not sufficient)  or missing, a 
repeat blood specimen  should be re-drawn as soon as possible (ideally within 7 days). 
7 For a complete list of laboratory  analytes, refer to Appendix  B. 
8 Will be assessed only in patients who have HAE-nC1-INH without a factor XII mutation or the plasminogen  or angiopoietin -1 mutation. 
9 Will be performed  only for patients who do not have HAE genetic diagnostic  testing results prior to Screening.  
10 The AAS questionnaire will  be completed by  patients on a daily basis (minimum  of 4 daily assessments  per week) for the duration of the study.  Patients will 
be instructed on the use of the AAS during Screening and will record their HAE attacks using the AAS throughout the Screening  Period (daily  during up to  
8 consecutive  weeks) to confirm study eligibility;  patients are required to experience  at least 2 HAE attacks (assessed by the AAS and confirmed  by the 
Investigator)  during the Screening  Period to be eligible for enrollment.  If a patient experiences  a third attack, the patient should  be randomized  as soon as 
possible, assuming all other screening activities have been completed and the patient meets all other eligibility  requirements; in such cases, the Screening 
Period may be shorter than 8 weeks.  Enrolled patients will continue to record HAE attacks using the AAS throughout the Treatment and Post -Treatment 
Periods. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
71  
  
Legend Continued  
 
11 Historical  HAE attack information  will be collected at Screening.  During the study,  patients will be instructed  to report details of any HAE attack to the study 
site within 72 hours of  the onset of  the attack.  Throughout the Screening, Treatment, and Post -Treatment Periods, site personnel will contact the patient once 
a week (at approximately  7 days after the last contact with the patient) in order to inquire about any  attack that may have occurred.  In addition, during study 
visits, site personnel will inquire about any new HAE attack information that was not provided through pati ent contact with the site.  
12 The following details relating to the localization, severity, and course of all HAE attacks that occured since the previous v isit will be collected:  date/time of 
symptom onset; description of symptoms; location of symptoms (pe ripheral angioedema, abdominal angioedema, or laryngeal angioedema); impact of HAE 
attack on activity level; HAE attack severity (mild, moderate, or severe); need for assistance, medical intervention, emergen cy room visit, or hospitalization; 
medications  to treat the attack; HAE  attack course, including  if the HAE attack(s) in question was a typical attack for the patient,  or if there was an  alternative 
diagnosis; and date/time symptoms resolved.  The number of HAE attacks that required on -demand treatment, and the frequency and dose of on -demand 
treatment, will also be recorded.  
13 After all screening  assessments  have been completed  and the Investigator  has verified that the patient is eligible. 
14 Refer to Appendix  C for the PK Sampling  Schedule.  
15 To be collected at each visit to assess plasma PKK, plasma proenzyme  activation,  and cHK levels. 
16 Patients who complete Study Visit Week 17, and meet eligibility  requirements, may  start the Treatment  Period in the ISIS 721744-CS3 OLE study anytime 
after the Week 17 visit and discontinue participation in the CS2 Post -Treatment Evaluation Period.  
17 Assessments and procedures may  be conducted by  either a Home Healthcare professional (if  available), or the Study  Center as arranged by  the Study Center 
personnel.  Physical Exam will be labeled Body Assessment if  conducted  by Home Healthcare  professional.  Study Drug administration  by Home Healthcare 
professional may be done only after study drug for home use is available.  
 
 
Time (time is in reference  to Study Drug administration  [ISIS 721744 or placebo]):  
a Pre-dose. 
b Pre-dose, 1, 2, 4, and 6 hours post-dose (PK Subgroup)  or Pre-dose and 2-hours post-dose. 
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
72  
  
 
APPENDIX  B. LIST OF LABORATORY  ANALYTES  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
73  
 Appendix  B List of Laboratory  Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed  on stored samples to better characterize  the profile of ISIS 721744 or other similar 
oligonucleotides.  
 
Chemistry  Panel 
• Sodium 
• Potassium  
• Chloride 
• Bicarbonate  
• Total protein 
• Albumin 
• Calcium 
• Magnesium  
• Phosphorus  
• Glucose 
• BUN 
• Creatinine  
• Cholesterol  
• Uric Acid 
• Total bilirubin 
• Direct (conjugated) 
bilirubin 
• Indirect (unconjugated) 
bilirubin 
• ALT 
• AST 
• Alkaline phosphatase  
• Creatine kinase 
• GGT Screening  Tests 
• Hepatitis B surface 
antigen 
• Hepatitis C antibody 
• HIV antibody 
• FSH (for 
confirmation of 
menopause at 
Screening per 
inclusion criteria) 
• Serum βhCG (only 
women who are not 
surgically  sterile or 
post-menopausal)  
 
Coagulation  
• aPTT (sec) 
• PT (sec) 
• INR 
• Plasmin-antiplasmin 
complexes  
• D-dimer 
 
Complement  
• C5a 
• Bb 
• C4 split products 
• C4 
 
Pharmacodynamics  
Panel 
• Plasma PKK 
• Plasma proenzyme 
activation  
• cHK Hematology  
• Red blood cells 
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets 
• White blood cells 
(WBC) 
• WBC Differential 
(% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
 
• ISIS 721744 
concentration in plasma 
 
Immunogenicity  
• Anti-ISIS 721744 
antibodies  Inflammatory  
• hs-CRP 
 
Urinalysis  
• Color 
• Appearance  
• Specific gravity 
• pH 
• Protein/creatinine  ratio 
• Protein 
• Blood 
• Ketones 
• Urobilinogen  
• Glucose 
• Bilirubin 
• Leukocyte  esterase 
• Nitrate 
• eGFR 
• Microscopic 
examination2 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes,  stability assessments, metabolite  assessments,  or to assess other actions of ISIS 721744 with plasma 
constituents.  
2 Will be performed  on abnormal findings unless otherwise  specified.  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
74  
  
 
APPENDIX  C. PHARMACOKINETIC  SAMPLING  SCHEDULE  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
75  
 Appendix  C Pharmacokinetic  Sampling  Schedule  
PK samples on Day 1 and Day 85 will be collected pre -dose, and 1, 2, 4, and 6 hours post-dose 
in PK subgroup only (approximately  6 patients) while pre -dose and 2 hours post-dose samples on 
Day 1 and Day  85 will be collected for all other patients.  The rest of the sampling schedule will 
be the same for both sets of pateints (see table belo w): 
 
Pharmacokinetic  Sampling  Schedule  
 
 Day 1 Day 15 Day 29 Day 57 Day 85 Day 113 Day 141 Day 176 
PK Blood: Blood: Blood: Blood: Blood: Blood: Blood: Blood: 
Subgroup  Pre-dose, Anytime Pre-dose Pre-dose Pre-dose, Anytime Anytime Anytime 
 1, 2, 4,    1, 2, 4,    
 and    and    
 6 hours    6 hours    
 post-dose    post-dose    
All Blood: Blood Blood: Blood: Blood: Blood Blood Blood 
Patients Pre-dose, Anytime Pre-dose Pre-dose Pre-dose, Anytime Anytime Anytime 
 2 hours    2 hours    
 post-dose    post-dose    
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
76  
  
 
APPENDIX D.  GRADING  SCALE FOR ADVERSE  EVENTS  RELATING 
TO LABORATORY ABNORMALITIES  
721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
77  
 Appendix  D Grading Scale for Adverse Events Relating to Laboratory  Abnormalities  
The following  grading recommendations  for adverse events relating to lab test abnormalities  and 
adverse events at the injection site are based on the CTCAE Version 5.0, November 2017 with 
modifications outlined in the footnotes below.  
 

721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
78  
  
 

721744-CS02 Protocol Amendment  05 May 2020 | 1.0 
ISIS 721744-CS2 
Protocol CONFIDENTIAL  Amendment  3 
5 May 2020 
79  
  
 

ISIS 721744-CS2 
Ionis Pharmaceuticals  CONFIDENTIAL  Protocol 
Amendment  Changes  
  
 
 
PROTOCOL  AMENDMENTS  
 
 
Protocol Number: ISIS 721744-CS2 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled, Phase 2a Study to 
Assess the Clinical Efficacy of ISIS 721744, a Second-Generation  Ligand- 
Conjugated Antisense Inhibitor of Prekallikrein, in Patients With 
Hereditary Angioedema  
 
 
 
A list of changes to the protocol are below: 
 
Amendment  Description  of Changes Dates 
Amendment  1 The purpose of this protocol amendment  is to implement 
the following modifications to Protocol ISIS 721744 - 
CS2 date 03 May 2019:  
 
1. Specify a minimal compliance  level in the inclusion 
criteria for completion of the Angioedema Activity 
Score, during the screening  period, as a requirement 
prior to randomization to treatment in Part A, or 
initiation of treatment in Part B, of the study  
2. Broaden the exclusion criteria to include: elevated 
PTT, history of coagulopathy  or bleeding diathesis, 
and renal and hepatic diseases  
3. Modify the exclusion  criteria to allow for participants 
that test positive for hepatitis B or C enzyme but are 
non-reactive 
4. Provide the definition  of an HAE attack and delineate 
how discrete attacks will be counted  
5. Designate  adverse events of special  interest (AESIs) 
6. Add anti-drug antibody testing at Day 15 and Day 29 
visits, and remove the requirement for a physical 
examination  from the day 15 visit, in the Schedule of 
Procedures  
 
Minor changes have been made throughout  the protocol 
to correct errors and/or to improve the overall clarity of 
the original 21 October  2019 
Amendment  2 The purpose of this protocol amendment  is to implement 
the following modifications to Protocol ISIS 721744 - 
CS2, Amendment  1, dated 21 October 2019: 29 January 2019 
ISIS 721744-CS2 
Ionis Pharmaceuticals  CONFIDENTIAL  Protocol 
Amendment  Changes  
  1. To update the established mutations in the 
plasminogen and angiopoietin genes from the legacy 
description to the Human Genome Variation Society 
(HGVS) description in the diagnostic report. The 
plasminogen gene was changed from c.9886A>G to 
988A>G and the angiopoietin -1 gene from c.807G>T 
to 355G>T  
2. The duration of male and female contraceptive  advice 
has been changed from at least 13 weeks to at least  
24 weeks. This will al low for near -complete 
elimination  of ISIS 721744  as 24 weeks encompasses 
approximately 5 half -lives of ISIS 721744 and 1 
menstrual cycle (requested by the MHRA, to comply 
with CTFG guidance (Clinical Trial Facilitation 
Group 2014)  
3. To add language that patients who complete Study 
Visit Week 17, and meet eligibility requirements, 
may start the Treatment Period in the ISIS 721744 - 
CS3 OLE study anytime after the Week 17 visit and 
discontinue  participation  in the CS2 Post-Treatment 
Evaluation Period at that  time 
4. To remove as secondary endpoints the time 
normalized  number of HAE attacks (per month) from 
Week 9 to Week 21  and the time normalized  number 
of moderate or severe HAE  attacks (per  month) from 
Week 9 to Week 21, because patients will be allowed 
to rollover to the ISIS 721744 -CS3 OLE study after 
the Week 17 visit in CS2  
5. To remove the requirement that patients must fast 
before visits that require blood sampling because 
none of the laboratories  listed in Appendix  B require 
fasting and, therefore, fasti ng is an unnecessary 
burden for the patient.  
 
Minor changes have been made throughout  the protocol 
to correct errors and/or to  improve the overall  clarity of 
the original protocol but these changes do not impact  
subject safety, exposure,  or the overall study design.  
Amendment  3 The following  modifications  to Protocol ISIS 721744- 
CS2 Amendment  2, dated 29 January 2020, have been 
made: 
 
1. To adjust the length of time patients must not have 
received lanadelumab, prior to screening for ISIS 
721744-CS2, from 6 months to 10 weeks (i.e., 5  
times the ~14-day half life for lanadelumab).  05 May 2020 
ISIS 721744-CS2 
Ionis Pharmaceuticals  CONFIDENTIAL  Protocol 
Amendment  Changes  
  2. To decrease the burden of site visits where feasible 
for patients, Study Drug administration,  assessements 
and procedures may be conducted by either a Home 
Healthcare professional (if available) or the Study 
Center, as arranged by the Study Center personnel, 
for visits as noted in Appendix A.  
3. To decrease the burden of PK sampling for patients, 
only a subgroup of approximately 6 patients (rather 
than all patients) will have blood draws of pre -dose, 
1, 2, 4, and 6  hours post -dose on Day 1 and  Day 85. 
This, along with a pre -dose and a 2 hour post -dose 
blood collection  on Day 1 and Day 85 in all patients, 
will provide enough information to determine PK 
parameters.  
4.  
Minor changes have been made throughout  the protocol 
to correct errors and/or to  improve the overall  clarity of 
the original protocol but these changes do not impact  
subject safety, exposure,  or the overall study design.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL   
  
 
 
 
 
 
 
 
 
 
 
 
Statistical  Analysis Plan 
 
 
 
ISIS 721744-CS2 
 
A Randomized, Double -Blind, Placebo -Controlled, Phase 2a 
Study to Assess the Clinical Efficacy of ISIS 721744, a Second- 
Generation Ligand -Conjugated Antisense Inhibitor of 
Prekallikrein, in Patients with Hereditary Angioedema  
 
 
 
Date: Feb 17, 2021 
 
Version: 1.0 
 
 
 
 
 
CONFIDENTIAL  
 
Confidential/Trade Secret  information  subject  to 18 -USC -1905  and to which all  claims of privilege  and 
confidentiality are asserted in both statutory and common law. Further dissemination may be made 
only with the e xpress written permission of Ionis Pharmaceuticals, Inc.  

Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
ii  
  
Statistical  Analysis Plan Signature  Page 
 
Ionis Pharmaceuticals,  Inc. 
2855 Gazelle Court Carlsbad,  CA 92010 
 
Compound Name:  721744 
Protocol: CS2 
Study Title: Randomized,  Double-Blind, Placebo-Controlled,  Phase 2a Study 
to Assess the Clinical Efficacy of ISIS 721744, a Second-Generation 
Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients 
with Hereditary Angioedema  
 
Issue Date: 5 May 2020 (Protocol Amendment  3) 
Signature:   Date:   
 
 
Assistant Director, Biometrics 
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad,  CA 92010 
 
Signature:   Date:   
 
 
Assistant Director, PK and Clinical Pharmacology 
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad,  CA 92010 
Signature:    Date:   
 
 
 
Executive  Director, Project Team Leader, Clinical Development 
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad,  CA 92010 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
3  
  
Table of Contents  
1 INTRODUCTION  ................................ ................................ ................................ .. 5 
1.1 Study Overview  ................................ ................................ ................................ .. 5 
1.2 Objectives  ................................ ................................ ................................ ........... 5 
1.2.1 Primary Objective  ................................ ................................ ...........................  5 
1.2.2 Secondary  Objectives  ................................ ................................ .....................  6 
1.2.3 Exploratory  Objectives  ................................ ................................ ...................  6 
1.3 Endpoints  ................................ ................................ ................................ ............ 6 
1.3.1 Primary Endpoints  ................................ ................................ ..........................  6 
1.3.2 Secondary  Endpoints  ................................ ................................ ......................  6 
1.3.3 Safety Endpoints ................................ ................................ .............................  6 
1.3.4 Exploratory  Endpoints  ................................ ................................ ....................  7 
2 PROCEDURES  ................................ ................................ ................................ ...... 7 
2.1 General Overview  of Procedures ................................ ................................ ........ 7 
2.2 Randomization  & Treatment  Allocation  ................................ ............................  7 
2.3 Conduct ................................ ................................ ................................ .............. 8 
2.4 Data Monitoring  ................................ ................................ ................................ . 8 
2.4.1 Safety Data Monitoring  ................................ ................................ ..................  8 
2.4.2 Data Monitoring  Board ................................ ................................ ..................  8 
2.5 Data Management  ................................ ................................ ..............................  8 
2.5.1 Case Report Form Data ................................ ................................ ..................  9 
2.5.2 Laboratory  Data ................................ ................................ ..............................  9 
2.5.3 Pharmacokinetics  Data ................................ ................................ ...................  9 
3 ANALYTICAL  PLAN ................................ ................................ ...........................  9 
3.1 General Overview  of Analyses ................................ ................................ ........... 9 
3.1.1 Statistical  Methods ................................ ................................ .........................  9 
3.1.2 Subject Population  Analyzed  ................................ ................................ ....... 12 
3.1.3 Sample Size Consideration  ................................ ................................ ............ 12 
3.1.4 Planned Interim Analysis ................................ ................................ ............. 13 
3.1.5 Incomplete  or Missing Data ................................ ................................ .......... 13 
3.2 Demographic  and Baseline Characteristics  and Patient Disposition  ................  14 
3.3 Efficacy Analyses ................................ ................................ ..............................  15 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
4  
 3.3.1 Analysis of Primary Endpoint ................................ ................................ ..... 15 
3.3.2 Analysis of Secondary  Endpoints  ................................ ................................  17 
3.3.2.1  Time-normalized number of investigator -confirmed HAE attacks (per month) from  
Week 5to Week 17  ................................ ................................ ................................ .......... 17 
3.3.2.2  Time-normalized number of moderate or severe investigator -confirmed HAE attacks 
(permonth) from Week 5 to Week 17  ................................ ................................ ............. 18 
3.3.2.3  The number of patients with a clinical response (defined as a ≥ 50%, ≥ 70%, or ≥ 
90%reduction  from Baseline in HAE attack rate) by Week 17 ................................ ........ 18 
3.3.2.4  The number of investigator -confirmed  HAE attacks requiring acute therapy from 
Week 5 to Week 17 ................................ ................................ ................................ ......... 18 
3.3.2.5  Change and Percent Change in cHK and PKK levels at Week 5 to Week 17 ..................  19 
3.3.2.6  Consumption  of on-demand medication  by Weeks 9 and 17 ................................ ........... 20 
3.3.2.7  AE-QoL score at Weeks 9 and 17 ................................ ................................ ....................  20 
3.3.3 Analysis of Exploratory  Endpoints  ................................ .............................  21 
3.3.3.1  The number of HAE attack-free patient by Week 17 ................................ .......................  21 
3.4 Safety Analyses ................................ ................................ ...............................  21 
3.4.1 Exposure ................................ ................................ ................................ ...... 21 
3.4.2 Adverse Events ................................ ................................ ............................  22 
3.4.3 Laboratory  Measurements  ................................ ................................ ........... 24 
3.4.4 Vital Signs, Weight, and BMI ................................ ................................ ..... 26 
3.4.5 Physical Examinations  ................................ ................................ ................  26 
3.4.6 12-Lead Electrocardiograms  (ECG) ................................ ............................  26 
3.4.7 Prior and Concomitant  Medications  ................................ ............................  26 
3.4.8 Angioedema  Activity Score ................................ ................................ ........ 27 
3.5 Pharmacokinetic  Analysis ................................ ................................ ............... 27 
3.5.1 Plasma Concentration  Data of Total Full Length Oligonucleotides  .................  28 
3.5.2 Plasma Pharmacokinetic  Parameters  ................................ ...........................  28 
3.5.3 Pharmacokinetic/Pharmacodynamic  Exposure -Response  Analysis ............ 29 
3.4.5 Immunogenicity  (IM) Analysis ................................ ................................ ... 30 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
5  
 1 INTRODUCTION  
This document provides a description of the study organization, study procedures, and the 
plan for the statistical  analysis of the study data. Section 1 discusses study design, objectives, 
and endpoints; Section 2 provides the study procedures; Section 3 provides the detailed plan 
for the statistical anal yses. 
As with any statistical analysis plan (SAP), the  proposed methods and approaches to the  data 
analysis should be viewed as flexible. The statistical  analysis to some degree is iterative since 
so much of the planning is based on statistical and other a ssumptions, which require 
verification.  
1.1 Study Overview  
 
This is a Phase 2a study, will be  conducted at multiple  Study Centers worldwide  to assess the 
efficacy of ISIS 721744 in approximately 24 patients with HAE. Part A of the study will be 
randomized, double -blind, and placebo -controlled; Part B of the study will be open -label. 
The study will be conducted concurrently in 2 parts (Part A and Part B); patients will be 
allocated into Part A or Part B according  to type of HAE (i.e., either  HAE-1/HAE-2 in Part A 
or HAE-nC1-INH in Part B).  
 
In Part A, approximately 18  patients with HAE-1/HAE-2 will be randomized  to SC injections 
of ISIS 721744 80 mg or placebo in a 2:1 ratio (ISIS 721744:placebo).  In Part B, approximately 
6 patients with HAE-nC1-INH will be administered open -label SC injections of ISIS 721744 
80 mg. Due to the rarity of HAE -nC1-INH, enrollment in Part B may be ended early if study 
centers are unable to enroll sufficient patients; this will not impact the completion of Part  A. 
 
The study will consist of Screening,  Treatment,  and Post-Treatment  Periods. Please refer to the 
Schedule of Procedures in protocol Appendix A . Patients may be  required to attend additional 
visits for monitoring of AEs or abnormal investigation results. The frequency of additional 
monitoring will be determined by the Sponsor Medical Monitor in consultation with the 
Investigator.  The length of each patient’s participation  in the study is approximately  8 months, 
which includes an up to 8-week Screening Period, a 12 -week Treatment Period (patients  will 
receive fixed SC doses of Study Drug every 4 weeks during 4 on-site study visits),and  a 4 to 13- 
week Post -Treatment Period as determined by whether a patient enrolls in the ISIS 721744 - 
CS3 OLE study.  
 
1.2 Objectives  
 
1.2.1 Primary Objective 
The primary objective of the study is to evaluate the clinical efficacy of antisense inhibitor of 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
6  
  
prekallikrein (ISIS 721744) in patients with hereditary angioedema (HAE) type 1 (HAE -1), 
HAE type 2 (HAE -2), or HAE with normal C1 -inhibitor (HAE -nC1-INH). 
 
1.2.2 Secondary  Objectives  
The secondary  objectives of  the study are to evaluate safety and tolerability  of ISIS 721744  in 
patients with HAE -1/HAE-2 or HAE with normal C1 -INH (HAE -nC1-INH) and to ev aluate 
the effect of ISIS 721744 on plasma prekallikrein (PKK) and other relevant biomarkers.  
 
1.2.3 Exploratory  Objectives  
The exploratory  objectives  of the study are to evaluate pharmacokinetics  (PK) of ISIS 721744 
(as a total full -length antisense oligonucleotide [ASO], including fully conjugated, partially 
conjugated, and unconjugated ISIS 721744) over time and to assess potential 
PK/pharmacodynamic (PD) correlations on relevant biomarkers and clinical outcomes, as 
appropriate.  
 
1.3 Endpoints  
 
1.3.1 Primary Endpoints  
The primary endpoint is the time-normalized  number of investigator -confirmed  HAE attacks 
(per month) from Week 1 to Week 17.  
 
1.3.2 Secondary  Endpoints  
Secondary  endpoints  include the following:  
• The time-normalized  number of investigator -confirmed  HAE attacks (per month) from Week 5 to Week 17  
• The number of patients with a clinical response (defined as a ≥ 50%, ≥ 70%, or 
≥ 90% reduction  from Baseline  in Investigator -confirmed  HAE attack rate) by Week 
17 
• The number of investigator -confirmed  HAE attacks requiring acute therapy from Week 5 to Week 17  
• Cleaved high molecular  weight kininogen  (cHK) levels  at Weeks 9 and 17 
• PKK activity at Weeks 9 and 17 
• Consumption  of on-demand medication  at Weeks 9 and 17 
• Angioedema  quality of life (AE-QoL) questionnaire  score at Weeks 9 and 17 
1.3.3 Safety Endpoints  
The safety and tolerability  of ISIS 721744 will be assessed by determining  the number, type, 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
7  
  
severity, and dose -relationship of adverse events (AEs); vital signs; electrocardiograms 
(ECGs); and clinical laboratory  parameters.  Safety results  in patients dosed with ISIS 721744 
will be compared to safety results in patients dosed with placebo.  
 
1.3.4 Exploratory  Endpoints  
• The number of HAE attack-free patients by Week 17 
• PK parameters, including, but not limited to maximum observed plasma 
concentration  (Cmax), time to Cmax (tmax), area under the plasma concentration -time 
curve (AUC), and half -life (t½) 
• Potential exposure response analysis using relevant exposure parameters  and Biomarkers  
 
1.3.5 Additional  Endpoint  
• The time-normalized  number of moderate or severe investigator -confirmed  HAE 
attacks (per month) from Week 5 to Week 17  
 
 
2 PROCEDURES  
2.1 General Overview  of Procedures  
Ionis Pharmaceuticals,  Inc. will review all study data including  source documents,  CRFs, and 
laboratory reports. The study site will enter subject source data into the case report form.  
Laboratory  data will be transferred  electronically  to Ionis Pharmaceuticals,  Inc. 
 
2.2 Randomization  & Treatment  Allocation  
Patients will be allocated into Part A or Part B according  to type of HAE (i.e., either 
HAE-1/HAE-2 in Part A or HAE-nC1-INH in Part B). Only Part A will be randomized  and 
placebo-controlled.  
 
Patients will be enrolled and/or randomized (Part A only) at the Week 1 Visit, after all 
screening  assessments  have been completed  and after the Investigator  has verified that they 
are eligible per the criteria in protocol Sections 5.1 and 5.2. No patient may begin treatment 
prior to randomization (Part A only) and assignment of a unique patient identification 
number. 
 
In Part A, approximately 18 patients with HAE -1/HAE-2 will be randomized via the 
Interactive Response Technology (IRT) system to SC injections of ISIS 721744 80 mg or 
placebo in a 2:1 ratio (ISIS 721744:placebo).  In Part B, approximately  6 patients with HAE- 
nC1-INH will be enrolled via the IRT system to receive open -label SC injections of ISIS  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
8  
  
721744 80 mg. Due to the rar ity of HAE -nC1-INH, enrollment in Part B may be ended early 
if Study Centers are unable to enroll sufficient  patients; this will not impact the completion  of 
Part A. 
 
Randomization  information  will be concealed  from the Investigators  and patients until the 
end of the study, with the exception of an emergency situation involving a patient that 
requires unblinding of the treatment assignment.  
 
2.3 Conduct 
The study will be conducted in accordance with current Good Clinical Practice (GCP) and 
Internationa l Conference  on Harmonization  (ICH) guidelines,  the World Medical Association 
Declaration of Helsinki guidelines, the Food and Drug Administration (FDA) Code of 
Federal Regulations, and all other local regulatory requirements.  
 
2.4 Data Monitoring  
 
2.4.1 Safety Data Monitoring  
Ionis Pharmaceuticals, Inc. (or designee) is responsible for processing all reported adverse 
events (AEs). All serious adverse events (SAEs), reported to Ionis Pharmaceuticals,  Inc. (or 
designee), are reviewed according to standard operating procedures. The medical monitor 
will review all AEs and SAEs on an ongoing basis throughout the study. Ionis 
Pharmaceuticals, Inc. (or designee) will prepare and submit safety reports to the health 
authorities worldwide in accordance wit h local requirements. If it becomes necessary to 
communicate new safety information, Ionis Pharmaceuticals, Inc. (or designee) will also 
prepare a safety notification letter and transmit it to study site.  
 
2.4.2 Data Monitoring  Board 
An independent  Data and Safety Monitoring  Board (DSMB) will be established  to monitor the 
overall safe conduct of the study. Based on its ongoing assessment  of the safety and tolerability 
of ISIS 721744, the DSMB will provide recommendations to the Sponsor for modifying, 
stopping or continuing the study as planned. Details on the safety assessments, frequency of 
review, meeting schedules,  and controlled  access to unblinded  data are outlined in the DSMB 
Charter. 
 
2.5 Data Management  
An electronic  case report form (eCRF) utilizing an Electronic  Data Capture (EDC) 
application will be used for this Study.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
9  
  
2.5.1 Case Report Form Data 
BioClinica (or designee) is responsible for creating the Electronic Data Capture (EDC) data 
entry screens, database and edit checks using definitions  developed  by Ionis Pharmaceuticals, 
Inc. Ionis Pharmaceuticals, Inc. is responsible  for the review, data  management querying and 
locking of the database.  
Data are single-entered into the EDC system by the investigator  site staff. Programmed  edit 
checks (computer logic that checks the validity of the data entered and also prompts for 
missing data that is expected to be entered) are run and automatic queries are generated.  
Ionis Pharmaceuticals, Inc. reviews all data for accuracy and  validity and generates 
additional queries in the EDC system when necessary. The data is corrected or an 
explanation  concerning  the query is provided in the EDC system. After all data are entered, 
reviewed (by Data Management and Clinical Development) and queried, and all queries 
resolved, the database is locked.  
 
2.5.2 Laboratory  Data 
Ionis Pharmaceuticals, Inc. is responsible for the format of the laboratory electronic data 
transfers, transfer schedule and review of the clinical laboratory  data. This lab data will be 
stored as SAS data sets or Excel files.  
 
2.5.3 Pharmacokinetics  Data 
Ionis Pharmaceuticals,  Inc. is responsible  for the management  and review of  the plasma drug 
concentration  data. Final data, which has been approved by Quality Assurance,  will be stored 
in version -controlled repository  
 
3 ANALYTICAL  PLAN 
3.1 General Overview  of Analyses 
 
3.1.1 Statistical  Methods 
Descriptive summary statistics including number of subjects, mean, median, standard 
deviation, standard error, interquartile range (25th percentile, 75th percentile), and range 
(minimum, maximum) for continuous variables, and counts and percentages for categorical 
variables will be used to summarize  most data. All statistical  tests will be conducted  using 2- 
sided tests with 5% Type I error rate unless otherwise stated. In view of the exploratory 
nature of this study, adjustments for multiplicity of testing will generally not be used.  
Both central and local lab data will be used in the analyses, including  by visit summaries, 
figures and  abnormality summary.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
10  
  
PK parameters  will be summarized  using number of Subjects, mean, standard deviation, 
coefficient  of variation  (CV), geometric  mean, geometric  %CV, median, minimum,  and 
maximum.  
General Presentation  Considerations  
 
The minimum  and maximum  will be reported to the same number of decimal places as the raw 
data recorded in the database. The mean, median, lower quartile and upper quartile will be 
reported to one more decimal place than the raw data record ed in the database. The standard 
deviation will be reported to two more decimal places than the raw data recorded in the 
database. In general, the maximum number of decimal places reported shall be four for any 
summary statistic.  
Categorical data will be s ummarized in terms of the number of subjects providing data at the 
relevant time point (n), frequency  counts and percentages.  Any planned collapsing  ofcategories 
will be detailed in the text and the data displays.  
Percentages will be presented to one decim al place and not be presented for zero counts. 
Percentages will be calculated using n as the denominator.  
P-values greater than or equal to 0.001, in general, will be presented to three decimal places. 
P-values less than 0.001 will be presented as “<0.001”.  
Confidence  intervals will be presented  to one more decimal place than the raw data. 
 
Baseline definition  
 
For platelets, Baseline will be defined as the average of all non-missing pre-dose assessments.  
 
For other assessments,  if there are 2 or more pre-dose values available,  Baseline will be defined 
as the average of the pre -dose Study Day 1 value and the last pre -dose value prior to Study 
Day 1. If there  is only 1 pre-dose measurement available, then it will be assigned as Baseline  
 
Run-in Period 
 
The run-in period is defined as  the period from screening  to first dose of study Drug 
administration.  
 
On-treatment  and Post-treatment  Periods 
• For HAE attack endpoints:  
o The on-treatment period spans the time during which the study treatment is 
administered  until earliest date from 28 days after the last dose of medication 
and last contact date  within the study.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
11  
  
o The post-treatment  period starts on the day after the on-treatment  period and 
ends on the day of the patient’s last contact date within the study.  
• For PD (cHK and PKK levels) and AE-QoL: 
o The on-treatment period spans the time during which the study treatment is 
administered  until earliest date from 42 days after the last dose of medication 
and last contact date  within the study.  
o The post-treatment  period starts on the day after the on-treatment  period and 
ends on the day of the patient’s last contact date within the study.  
 
 
Analytical  visits 
PD (cHK, plasma proenzyme  activation,  and PKK levels) and AE-QoL data will be mapped to 
analysis visit specified in the table below. The intent of these visit windows is not to align with 
those prescribed for visit scheduling in the clinical study protocol but, rather, based on the 
protocol-defined target study day, to delin eate mutually exclusive windows so that all 
assessments  proximal to a particular  study week can be integrated  to best represent the patient’s 
status during that period of the study. Visits after Week 17 are part of the post -treatment 
assessment period and,  due to the fact that most patients are expected to roll into the OLE Study 
ISIS 721744CS3, these data will only be provided in patient listings for evaluation of individual 
patient safety rather than being tabulated. Therefore, no visit windows are needed  for data 
analysis for these visits. The PD and AE -QoL assessments that occurred during the post -
treatment period (as defined above) will not be included in the PD analyses/summaries, even  
if they occurred within one of the visit windows. If  there are multiple assessments  within a visit 
window, the visit nearest the scheduled  date will be used unless 2 visits are equally near, in 
which case the average will be used.  
 
 
Assessments  Mapped  Visit 
(Week) Target Day Study Day 
Window  
PD 3 15 2-22 
5 29 23-43 
9 57 44-71 
13 85 72-99 
17 113 100-127 
AE-QoL 9 57 44-71 
17 113 100-127 
 
 
Other data will be summarized using the visit labels provided in the data. Multiple results 
with the same visit label will be averaged.  Results with visit labels as “Unscheduled”  will not 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
12  
  
be included in the by-visit summary tables and figures except for determining  baseline and 
laboratory abnormality summaries but will be presented in data listings.  
 
3.1.2 Subject Population  Analyzed 
The following  analysis populations  will be used for the analysis of data as described  within 
each analysis population.  
Safety Population  
The Safety Population  will include all enrolled patients who receive at least 1 dose of Study 
Drug (ISIS 721744 or placebo).  
Intent-to-Treat (ITT) Population  
The ITT Population  will include all enrolled or randomized  patients. 
Per Protocol Population  
The Per-Protocol (PP) Population  will include all patients in the ITT Population  who are 
treated according to the protocol without any major deviations.  
PK Population  
The PK Population  will include all patients who are enrolled and receive at least 1 dose of 
Study Drug and have at least 1 evaluable PK sample.  
 
In addition to the above analysis populations,  it is recognized  that some data displays will be 
provided for “All Screened”, “Screening Failures” and “All Randomized” subjects but no 
data analysis will be executed in these populations except for the disposition table that 
includes all screened subjects.  
 
3.1.3 Sample Size Consideration  
The primary endpoint is the time-normalized  number of HAE attacks (per month)  from Week 
1 to Week 17. From historical data, the placebo group is estimated to have 6.8 HAE attacks 
per 4-month period. If the ISIS 721744 80 mg group is assumed to have 2.8 HAE attacks per 
4-month period, then with a 0.05 significance level and using Poisson model, the sample size 
of 18 patients (12 patients administered SC injections of ISIS 721744 80 mg and 6 patients 
administered placebo) will provide at least 90% power for the primary endpoint, considering a 
10% missing data or dropout rate for both active  treatment and placebo. The sample size of  
18 patients with HAE -1/HAE-2 is also considered sufficient for safety and tolerability 
evaluation.  
 
There is no statistical  rationale for the sample size of 6 patients with HAE-nC1-INH. 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
13  
  
3.1.4 Planned Interim Analysis 
No interim analysis is planned for this study. However,  an independent  Data Safety Monitoring 
Board (DSMB) will be established  to provide ongoing, independent  review and assessment  of 
the safety data,  and to safeguard the interests and safety of the participating subjects in the  
study. Analysis of the data for DSMB review will be conducted  according  to the DSMB 
Charter. Because no formal hypothesis testing for safety assessments is planned, multiplicity 
concerns regarding r epeated analyses are not an issue.  
 
3.1.5 Incomplete  or Missing Data 
 
 
All available data will be included in the analysis. The length of observation  time will be 
included as an offset variable in the Poisson model to adjust for differences  in follow-up time. 
 
3.1.5.1  Imputing  Missing Start or End Date  and Time  for HAE Attacks 
 
In general, missing start time will be imputed as 0:00 and missing end time will be imputed as 
23:59. However,  the following  rules will be applied for the attacks satisfying  the corresponding 
conditions, in order to conservatively classify the attacks as separate, distinct attacks with at 
least 24 hours in -between: 
• For HAE attacks with a missing start time and a non -missing start date one calendar 
day after the end date of the pre vious attack, the start time will be imputed using the 
end time of the previous HAE attack to ensure there are 24 hours in between the two 
attacks. 
• For HAE attacks with a missing start time and a non -missing end date/time within 24 
hours from the end date/time of the previous attack, the attack should be considered  as 
one attack with the previous attack  
• For HAE attacks with missing end time and a non -missing end date one calendar day 
before the start date of the next attack, the end time will be imputed as the start time of 
the next HAE attack to ensure there are 24 hours in between the two attacks.  
• For HAE attacks with a missing end time and non -missing start date/time within 24 
hours from the start date/time of the next attack, the attack should be considered  as one 
attack with the next attack.  
 
For HAE attacks with a non-missing start date and time and a missing stop date and time: 
• The stop date and time will be imputed as the earlier of the following  two date and time: 
o Start date and time + 48 hours or study completion date and the stop time of  
23:59, whichever is later.  
o 24 hours before the start date and time of the next attack. 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
14  
  
 
 
3.1.6 Unique HAE Attacks 
To be counted as a unique attack distinct from the previous attack, the new symptoms must 
occur at least 24 hours after resolution of the prior attack’s symptoms.  
 
Specifically, there must be at least 24 hours between the stop date/ time of the first event and 
the start date/time of the next event, for the attacks to be considered  distinct. If there is less 
than 24 hours between the stop date/time of the first event and the start date/time of the next 
event, the events will be counted as one attack.  
 
When two or more attacks are combined for efficacy analysis, the parameters of the  attacks 
will be conservatively chosen. The start date and time of the combined attack will take the 
earliest start date and time from the individual attacks; and the end date and time of the 
combined attack will take the latest end date and time of the in dividual attacks. The severity of  
the combined attack will take  the highest severity from the  individual attacks. The primary 
location of the combined attack will be determined by the primary location of the individual 
attacks, and by following the hierarc hy of laryngeal attack, peripheral attack, and abdominal 
attack. One primary location will be taken; and all the other primary location(s)  and secondary 
locations will be considered as secondary location for the combined attack. The rescue 
medications  and supportive  treatment  for the combined  attack will include all the records from 
individual attacks. Also, the combined attack will be considered as an investigator -confirmed 
attack if any of the individual attack being combined is an investi gator-confirmed attack.  
 
3.2 Demographic  and Baseline Characteristics  and Patient Disposition  
Baseline and demographic  variables will be summarized  descriptively  by treatment  group and 
overall for Part A, overall for Part B, and for each analysis population.  
 
Demographic and baseline characteristics to be presented include age, age category (18 -<40, 
40 to 64, ≥65 years), gender, race, ethnicity, height, weight, BMI, type of genetic mutation.  
 
Age will be calculated as the difference between informe d consent date and patient birth date 
divided by 365.25 and rounded down to the associated integer value.  
 
For race summary, if multiple races are recorded in database, ‘Multiple Race’ will be used in 
the summary table but details records in the listing.  
 
A separate table will be created for HAE history and will include family history of HAE, age 
at onset of angioedema  symptoms,  HAE type, type of attack(s) experienced,  Lanadelumab  use, 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
15  
  
reason for discontinuation of Lanadelumab, number of attacks in the last 12 months, run -in 
period HAE attack rate (attacks/4 weeks), run -in period HAE attack rate group (1 to <2, 2 to  
<3, ≥3 attacks/4weeks).  
 
The run-in period HAE attack rate will be calculated  for each subject as number of HAE attacks 
occurring during the run-in period divided by the number of days the subject contributed  to the 
run-in period multiplied by 28 days.  
 
Medical history will be provided in the data listings. 
 
Subject enrollment  and disposition  will be summarized  by treatment  group and overall for Part 
A, and overall for Part B.  
 
The summaries  will include: the total number of screened subjects,  the number of randomized 
(Part A) or enrolled (Part B) subjects, the number of subjects in each analysis population  (with 
the exception  of the PK Set), the number of subjects completing  treatment,  the primary reason 
for terminating  treatment,  the number of subjects completing  post-treatment  follow-up, and the 
primary reason for terminating post-treatment follow -up. 
 
3.3 Efficacy Analyses 
All efficacy analyses will be performed on the ITT population and Per -protocol population, 
with the former being the basis for the primary efficacy analysis.  
 
3.3.1 Analysis of Primary Endpoint  
The primary efficacy endpoint is the time-normalized  number of investigator -confirmed  HAE 
attacks per month (defined as 28 days) during the on -treatment period from Week 1 to Week 
17 (28 days after last dose administration),  will be compared  between ISIS 721744  80 mg and 
placebo in Part A using a Poisson regression  model and Pearson chi-square scaling of standard 
errors to account for potential overdispersion.  The model will include fixed effect for treatment 
group (categorical), the time normalized run -in period attack rate (continuous) as a covariate, 
and the logarithm of time in month (days from first dose date to 28 days after last dose 
administration  divided by 28) that each subject was observed during the period will be used as 
an offset variable.  
 
The primary analysis of the primary endpoint will be conducted  in the ITT population. 
See Section 3.2 for the calculation of the normalized run -in period attack rate.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
16  
  
From this model, the least squares mean rate and standard error for each treatment group as 
well as, the  mean rate  ratios relative  to the placebo group and corresponding  95% confidence 
intervals will be estimated. The p -value of Wald -based chi-square test will also be reported. 
The percentage  difference  in mean investigator -confirmed HAE attack rate between ISIS 
721744 80 mg and placebo will be calculated as 100% * (mean rate ratio –1). Similarly, the 
estimated upper and lower confidence limits for the mean  rate ratio can be transformed by  
subtracting 1 and multiplying by 100% t o calculate 95% confidence intervals for the 
percentage change.  
 
Below is the SAS code for the primary analysis: 
 
PROC GENMOD;  
CLASS arm; 
MODEL no_attks = arm baserate / DIST=poisson  LINK=log  OFFSET=logmon  PSCALE; 
LSMEANS arm/ DIFF CL EXP ILINK;  
RUN; 
Where: 
arm= treatment  arm (categorical)  
no_attks = number of HAE attacks during  the analysis period 
baserate = normalized  HAE attack rate during the run-in period (continuous)  
logmon = logarithm  of time in month each patient was observed during the analysis period. 
 
 
If one treatment  group has 0 count, Fisher’s  Exact Test will be used for the analysis instead of 
Poisson regression. The odds ratio, corresponding 95% CI, and p -value will be provided.  
 
The following  sensitivity  analyses will be performed  on the primary efficacy endpoint to 
evaluate the robustness of the results.  
1. The primary analysis described above will be repeated in the PPS as a sensitivity 
analysis. 
 
2. The primary efficacy endpoint will be compared between ISIS 721744 80 mg and 
placebo in Part A using a Negative Binomial model. The model will include fixed 
effects for treatment  group (categorical),  the time normalized  run-in period attack rate 
(continuous) as a covariate, and the logarithm of time in month (days from first dose 
date to 28 days after last dose administration divided by 28) that each patient was 
observed during the on-treatment  period will be used as an offset variable. The analysis 
will be conducted in the ITT population.  
 
Below is the SAS code  for the sensitivity  analysis: 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
17  
  
PROC GENMOD;  
CLASS arm; 
MODEL no_attks = arm baserate / DIST= NEGBIN  OFFSET=logmon; 
LSMEANS arm/ DIFF CL EXP ILINK;  
RUN; 
Where: 
arm= treatment  arm (categorical)  
no_attks = number of HAE attacks during the analysis period 
baserate = normalized  HAE attack rate during the run-in period (continuous)  
logmon = logarithm of time in month each patient was observed during the analysis 
period 
 
The Part B data will be summarized using descriptive statistics. The exact  95% CI for mean 
based on the gamma distribution will be reported.  
 
In addition to the model -based analysis described above, unadjusted monthly investigator - 
confirmed  HAE attack rates from Week 1 to Week 17 (end of the on-treatment  period) as well 
as change and percent change from baseline will be summarized by treatment group and by 
Part. The monthly investigator -confirmed HAE attack rate will be calculated for each patient 
as the number of HAE attacks occurring during from Week 1 to Week 17 (end of t he on- 
treatment period) divided by number of days the patient contributed to the period multiplied 
by 28 days. The mean percent change from baseline on HAE attacks by study month and 
treatment group will be plotted.  
 
The number of investigator -confirmed  HAE attacks per month from Week 1 to Week 17 (end 
of the on -treatment period) will be also summarized descriptively by month (per 28 -day 
interval) and treatment  group and by Part. The summary will include the monthly investigator - 
confirmed HAE attack rate, change from run-in period, and percent change from run-in period 
of investigator -confirmed HAE attack rate. Investigator -confirmed HAE attacks will be 
grouped into 28 -day intervals using the start date of the HAE attack. The date of the first 
exposure to study drug will be used as the start of the first interval and end of  the interval will 
be the date of first exposure to study drug plus 28 days. Each successive  interval will start the 
last day of the prior interval plus 1 day and end 28 days later.  
 
3.3.2 Analysis of Secondary  Endpoints  
 
3.3.2.1  Time-normalized number of investigator -confirmed HAE attacks (per month) 
from Week 5 to Week 17  
It will be analyzed using the same method as described  for the primary efficacy endpoint,  will 
be conducted in both ITT and Per -protocol populations. Data summaries will parallel those 
described  for the primary analysis of the primary efficacy endpoint. Only  patients who 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
18  
  
complete Week 5 ( 29 days) HAE assessments  will be included in the analysis. The logarithm 
of time in month from Week 5 (Day 29) to Week 17 (end of the on-treatment  period) for each 
patient will be used as an offset variable in the model.  
 
3.3.2.2  Time-normalized number of moderate or severe investigator -confirmed HAE 
attacks (pe r month) from Week 5 to Week 17  
It will be analyzed using the same method as described  for the primary efficacy endpoint, will 
be conducted in both ITT and Per -protocol populations. Only patients who complete Week 5 
(29 days) of HAE assessments  will be included in the analysis. The logarithm  of time in month 
from Week 5 (Day 29) to Week 17 (end of the on -treatment period) for each patient will be 
used as an offset variable in the model.  
 
3.3.2.3  The number of patients with  a clinical response (defined as a ≥ 50%, ≥ 70%, or ≥ 
90% reduction from Baseline in HAE attack rate) by Week 17  
For each patient, a treatment  period HAE attack rate from Week 5 to Week 17 and run-in period 
HAE attack rate will be calculated.  The percentage  reduction  will be calculated  as the treatment 
period HAE attack rate from Week 5 to Week 17minus the run -in period HAE attackrate divided 
by the run-in period HAE attack rate. Patients who discontinued  treatment  early due to lack of 
efficacy or AEs will be considered  as non-responders  and included in the denominator  for the 
calculation of the proportion in the ITT population. Patients who discontinued due to other 
reason will be excluded from analysis.  
 
Risk difference comparing ISIS 721744 80 mg group to the placebo grou p in Part A, and 
corresponding exact 95% confidence interval (Santner and Snell 1980) will be provided. The 
Fisher’s Exact test p -value will also be reported. The analysis will be conducted in both ITT 
and Per-protocol populations.  
 
Below is the SAS code for this analysis: 
 
PROC FREQ; 
TABLES  arm*attack  / RISKDIFF; 
EXACT RISKDIFF;  
RUN; 
 
3.3.2.4  The number of investigator -confirmed  HAE attacks requiring  acute therapy from 
Week 5 to Week 17  
It will be analyzed using the same method as described  for the primary efficacy endpoint, will 
be conducted in both ITT and Per -protocol populations. HAE attacks requiring acute therapy 
include those attacks with medical intervention or hospitalization marked on the CRFs.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
19  
  
3.3.2.5  Change and Percent Change in cHK and PKK levels at Week 5 to Week 17 
The change and percent change  from baseline  in cHK and PKK levels at each visit during the 
treatment period will be compared between ISIS 721744 80 mg and placebo in Part A using 
the Mixed Effects Model with Repeated Measure s (MMRM) model. The response variable is 
the change or percent change from baseline at post -baseline visit up to Week 17. For patients 
who terminate treatment early, only the data collected up to 42 days after last dose 
administration will be included. The  MMRM model will include effects of treatment (ISIS 
721744 or placebo), time (categorical),  treatment -by-time interaction,  and baseline value. The 
analysis will be conducted in both ITT and Per -protocol populations. The unstructured 
covariance  model will be used to model the within patient errors, shared across treatments  and 
small sample adjustments to standard errors and tests will be made following the Kenward - 
Roger approach (Kenward,  M. G. and Roger, J. H. (1997). If there are convergence  problems 
with the repeated measures mixed model, this will be explored. For example, the SCORING=4 
option could be used in the PROC MIXED statement in SAS. This makes SAS use Fisher 
scoring for the first 4 iterations. If the convergence problem cannot be r esolved the unstructured  
covariance  matrix will be replaced by the compound  symmetry  covariance  matrix (Type=CS in 
SAS). 
Below is the SAS code for this analysis: 
 
PROC MIXED; 
CLASS arm visit subject; 
MODEL endpoint=arm  baseline visit arm*visit/  DDFM=kr; 
REPEATED visit / SUBJECT=subject TYPE=un; 
LSMEANS arm*visit / CL DIFF;  
RUN; 
 
The normality of each parameter will be examined using the Shapiro –Wilk test. The non - 
parametric Wilcoxon Rank Sum test will also be performed at each visit as the sensitivity 
analysis. Hodges -Lehmann estimates of the differences between ISIS 721744 80 mg group 
and the placebo group in Part A as well as distribution -free CIs based on the Wilcoxon  Rank 
Sum Test will also be provided.  
 
CHK and PKK levels as well as  the change and percent changes from  baseline over time will 
also be summarized using descriptive statistics by visit, treatment group and by Part.  
 
The change and percent change in plasma proenzyme  activation  levels will also be analyzed. 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
20  
  
3.3.2.6  Consumption  of on-demand medication  by Weeks 9 and 17 
The number and percentage  of patients who used on-demand medication  by Week 9 (Day 57) 
and by Week 17 (end of the  on-treatment period) will be  tabulated by treatment group and by 
Part. On-demand medicat ions will be identified based on manual review.  
 
3.3.2.7  AE-QoL score at Weeks 9 and 17 
AE-QoL will be evaluated by determining its four individual domain scores and a  total score. 
Each item answered by the patient scores between 0 and 4 points depending on the an swer 
option chosen by the patient. The first answer option gets 0 points, the second option 1 point, 
the third option 2 points, etc. The AE -QoL domain scores and total score are calculated by 
using the following formula:  
(Sum of all completed  items) / (maximum  sum of all possible items)*100 
Computation of AE -QoL Total Score  
Example 1: All items were completed (maximum  possible sum: 68 points) 
Sum of all 17 completed  items: 41 points. 
Total score = 100*(41/68)  = 60 (out of a possible 100 points) 
 
Example 2: 2 items were not completed  (maximum  possible sum: 60 points). 
Sum of all 15 completed items: 41 points.  
Total score = 100*(41/60)  = 68 (out of a possible 100 points) 
 
Computation  of Domain Scores (Example:  Fears/Shame)  
Example: Sum of all 6 completed items: 14 points 
Maximum possible sum: 24 points  
Domain Score = 100*(14/24)  = 58 (out of a possible 100 points) 
Remarks 
Since only answered items are included in the computation (and the calculated domain and 
total scores are not raw scores but linear transformations to a 0 -to-100 scale), the calculated 
scores are not or only little influenced by missing items.  
 
An AE-QoL domain score should not be calculated if more than one item is left unanswered 
in that domain. T he AE-QoL total score should not be calculated if more than 25% of items 
(>4 items) are left unanswered.  
The minimal and highest possible domain and total scores are 0 and 100, respectively.  
 
The AE-QoL total score and domain score will be analyzed using the same method as described 
for cHK, will be conducted in both ITT and Per -protocol population.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
21  
  
3.3.3 Analysis of Exploratory  Endpoints  
 
3.3.3.1  The number of HAE attack-free patient by Week 17 
The number and percentage of patients who achieve invest igator-confirmed HAE attack free 
(no investigator  confirmed  HAE attacks) by Week 17 (end of the on-treatment  period) will be 
tabulated by treatment group and by Part. Patients who discontinued treatment early due to 
lack of efficacy or AEs will be considered  as non-responders  and included in the denominator 
for the calculation of the proportion in the ITT population. Patients who discontinued due to 
other reason will be excluded from analysis. The risk difference between ISIS 721744 80 mg 
group to t he placebo group in Part A, and the corresponding exact 95% confidence interval 
will be provided. The Fisher’s Exact test p -value will also be reported. The analysis will be 
conducted in both ITT and Per -protocol population.  
 
The number and percentage of p atients who achieve investigator -confirmed HAE attack free 
(no investigator  confirmed  HAE attacks) between Week 5 to the end of the on-treatment  period, 
between Week  9 to the end of the on-treatment  period, and between Week 13 to the end of the 
on-treatment period will also be tabulated and analyzed in a similar manner.  
 
 
3.3.4 Analysis of Additional  Endpoint  
 
3.3.4.1  Time-normalized  number of moderate  or severe investigator -confirmed  HAE 
attacks (per month) from Week 1 to Week 17  
It will be analyzed using the same method as described  for the primary efficacy endpoint,  will 
be conducted in both ITT and Per -protocol populations.  
 
 
3.4 Safety Analyses 
Safety analyses will be performed  on the safety population.  
 
3.4.1 Exposure  
 
Treatment duration, number of doses and amount of Study Drug will be summarized by Part 
and treatment group.  
 
The treatment  duration (days) for each patient is defined as last dose date - first dose date +1. 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
22  
  
3.4.2 Adverse Events 
An adverse event will be regarded as treatment emergent if it is present prior to receiving the 
first dose of study drug and subsequently  worsens, or is not present prior to receiving  the first 
dose of study drug but subsequently appears.  
To determine  the AE as treatment -emergent or  not, if there is no “Formlink”  link, and the  AE 
(start date/time)  occurs on or after the patient’s first dosing date/time,  then the AE is treatment - 
emergent. Otherwise, if the AE (start date/time) occurs prior to the patient’s first dosing 
date/time, then the AE is not treatment -emergent.  
 
If there is a “Formlink” link between two AE records, then we compare them pairwise, and 
consider two cases, where we compare the AE severity (mild/moderate/severe) betw een the 
two records in the pair. We chronologically  order the 2 records (by AE start date) and refer to 
the “first” and “second” AE.  
 
Case 1: The first AE record in the pair occurs before first dosing, and the second AE 
record occurs after first dosing.  
If the AE severity of  the second record is worse than that of  the first record, then only 
the second AE is deemed as a TEAE. Otherwise,  neither record is considered  as TEAE. 
 
Case 2: Both AE records in  the pair occur after first dosing. 
If the AE severity on the second record is worse than the severity on the first record, 
then count both records as treatment -emergent.  But, if the severity improves,  then only 
count the first record as treatment -emergent.  
When counting the total number of treatment -emergent events, events linked together 
through change in severity will still be counted as separate events.  
 
All TEAEs identified  based on the rules above will be summarized  in the event number 
analysis. 
The most conservative approach will be used to determine if the event occurs after the 
treatment. For example, if the onset date or resolution date of an AE is prior to the first study 
treatment date, it will be considered to have occurred prior to the study  period. If the onset or 
resolution date of an AE is a partial date with only month or year available or complete 
missing, then the event is assumed to be within the study period unless the year is prior to the 
year of the first study treatment  date, or if in the same year, the month is prior to the month of 
the first study treatment date.  
The incidence  of AEs will be summarized  by Medical Dictionary  for Regulatory  Activities 
(MedDRA) preferred term and system organ class for:  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
23  
  
• Any treatment  emergent adverse events 
• Related treatment  emergent adverse events. Related is defined as “Related”, 
“Possible”, or missing relationship to study drug  
• Any treatment emergent adverse events by severity. At each level of patient 
summarization, a pat ient is classified according to the highest severity if the 
patient reported one or more events. Adverse events with missing severity will 
categorized as “Missing” for this summary  
• Related treatment  emergent adverse  events by severity 
• Serious treatment  emergent adverse events 
• Serious and related treatment  emergent adverse events 
AEs that lead to study discontinuation or investigational drug discontinuation will be listed. 
Non-treatment emergent adverse event will be flagged in the data listing.  
 
Local Cutaneous  Reactions  at the Injection  Site 
 
Local cutaneous  reaction at injection site (LCRIS) is defined as (A) moderate or severe adverse 
events with the preferred terms (PTs) Injection site erythema,  Injection site swelling, Injection 
site pruritus, or Injection site pain that started on the day of injection, persisted for at least two 
days or ongoing; or (B) any AE at the Study Drug injection site, regardless of severity, that 
leads to discontinuation of study drug, where AE at the Study Dr ug injection site is the principal 
reason for discontinuation. LCRIS will be summarized using the MedDRA coding system,  by 
PT and by treatment  group and Part. Patients with moderate,  severe and any LCRIS will also be 
summarized. Discontinuations due to  AE at the injection site will be summarized separately.  
Percentage of injections leading  to those events will be summarized by PT and overall using 
the descriptive statistics. Additionally, percentage of injections leading to events will be 
summarized  by moderate,  severe severity and overall discontinuation  of study drug due to AE 
at injectio n site. 
Percentage  of injections  leading to LCRIS at the injection site will be calculated  as follows for 
each patient: (A/B)*100,  where A=number  of injections  with a LCRIS, and B=total number of 
injections. Doses that are split across multiple injections are counted as a single injection.  
 
LCRIS will also be listed. 
 
Flu-like Reactions  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
24  
  
Flu-like reactions are defined as adverse events with PTs including either (A) Influenza like 
illness or (B) Pyrexia or Feeling hot or Body temperature increased, plus at least two of the 
following symptoms  with the PTs:  Chills, Myalgia, or Arthralgia, starting on day of injection 
or the next day.  
Flu-like reactions will also be summarized using the MedDRA coding system, by preferred 
term and by treatment group and part.  
Percentage of injections leading to flu -like reactions will be summarized by treatment group 
and by Part using the descriptive statistics.  
Percentage  of the injections  leading to flu-like reactions will be calculated  as follows for each 
patient: (A/B)*100, where A=number of injections leading to flu -like reactions, and B=total 
number of injections.  
Flu-like reactions will also be listed. 
Bleeding Adverse Events 
 
Bleeding AEs will be identified based on the Haemorrhages (S MQ) Export from MedDRA 
and summarized by MedDRA system organ class and preferred term and by treatment group 
and part. 
 
3.4.3 Laboratory  Measurements  
The following  is the list of lab analytes that will be collected throughout  the study: 
• Chemistry: sodium, potassium, chloride, bicarbonate, total protein, albumin, 
calcium, magnesium,  phosphorus,  glucose, BUN, creatinine,  cholesterol,  uric 
acid, total bilirubin, direct (conjugated) bilirubin, indirect (unconjugated) 
bilirubin, ALT, AST, alkaline phosphatase, c reatine kinase, GGT,  
• Hematology: red blood cells, hemoglobin, hematocrit, platelets, MCV, MCH, 
MCHC, platelets, white blood cells (WBC), and WBC differential  (percentage 
and absolute count) (basophils, eosinophils, lymphocytes, monocytes and 
neutrophils)  
• Coagulation:  aPTT (sec): PT (sec), INR, Plasmin-antiplasmin  complexes,  D-dimer 
• Complement:  Bb, C5a, C4 split products, C4 
• Inflammatory:  Hs-CRP 
• Screening tests: hepatitis B surface antigen, hepatitis C antibody, HIV antibody, 
FSH (women only, if applicable), and serum βhCG (women only) The data will 
only be displayed in subject listings.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
25  
  
• Urinalysis  (other): color, appearance,  specific gravity, pH, P/C ratio, protein, blood, 
ketones, urobilinogen, glucose, bilirubin, , leukocyte estera se, nitrate, eGFR, 
microscopic examination. The data will only be displayed in subject listings.  
 
Missing WBC differential  absolute counts and percentages  will be derived: 
If WBC differential absolute counts are missing, and percentages are available, then absolute 
counts will be calculated by multiplying the percentage by total WBC count. Conversely, if 
absolute count is available, and percentage is missing, then percentage will be calculated by 
dividing absolute count by the total WBC count . If WBC differential absolute counts are 
missing, and manual count values are available, then manual count values will be used. If 
neutrophils  count and percentages  are missing, and segmented  neutrophil  and band neutrophil 
results are available,  then neutrophils will be calculated  by adding segmented  neutrophils  and 
band neutrophils, if only  segmented neutrophil result is available, then neutrophils will be set 
to segmented neutrophils result.  
All lab data will be displayed  in subject listings. 
Chemistry,  hematology,  coagulation,  and complement,  (result, change and percent change 
from baseline) will be summarized using descriptive statistics (n, mean, median, standard 
error, standard deviation,  Q1, Q3, minimum,  and maximum)  by treatment  group and study 
visit. 
For ALT and AST, the number and percent of subjects falling in each of the following 
categories based on the confirmed results will be tabulated by treatment group  
• ALT/AST  > 3 x ULN, which is confirmed  
• ALT/AST  > 5 x ULN, which is confirmed  
For platelet, the number and  percentage  of patients falling  in each of the following  categories 
based on the confirmed  results will be tabulated by treatment  group for 100,000/mm3 to 
<140,000/mm3, 75,000 to <100,000/mm3, 50,000 to <75,000/mm3, 25,000 to <50,000/mm3, 0 
to <25,000/mm3. 
 
A confirmed value is based on a consecutive lab value within 7 days. If that value is in the 
same or worse category the initial value is confirmed. If the consecutive value is in a better 
category, then the initial value is confirmed using the consecutive value category. If there is no  
retest within 7 days, then the initial value is presumed  confirmed.  If there are multiple results on 
the same day, no matter from the same lab vendor or different lab vendors, then the worst value 
will be utilized in the anal ysis. 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
26  
  
3.4.4 Vital Signs, Weight, and BMI 
Vital signs will include heart rate, respiratory rate, body temperature, systolic and diastolic 
blood pressure and pulse pressure. Summary tables will be created to present the descriptive 
statistics (n, mean , standard error, standard deviation, median, Q1, Q3, minimum, and 
maximum) for vital sign values, weight, and BMI as well as the change and percent change 
from baseline at each study visits.  
 
3.4.5 Physical Examinations  
Adverse changes in physical examinations  that are deemed clinically significant  by the 
Investigator will be classified as adverse events. All physical examination data will be 
provided in a data listing.  
 
3.4.6 12-Lead Electrocardiograms  (ECG) 
Safety 12-lead ECG will be performed  at the visits Screening,  Day 1 (Pre-Dose), Day 57, Day 
113 and Day 176. The ECG data will include Ventricular Rate, PR Interval, QRS Duration, 
QTc, QTcF (QT corrected using the Fridericia’s formula), QTcB (QT corrected using the 
Bazett’s formula), and Overall interpretation.  QTcF and QTcB will be calculated  based on the 
patient’s reportable ECG data at each time point using the formula described below:  
QTcF = QT / (RR) 1/3, where RR= 60/VR 
QTcB = QT / (RR) 1/2, where RR= 60/VR 
For the continuous variables above, descriptive statistics (n, mean, standard error, standard 
deviation, median, 25th percentile, 75th percentile, minimum and maximum) of the results at 
each study visit, as well as the changes and percent changes  from Baseline to each study visit, 
will be presented  in summary tables; for the categorical  responses  to overall interpretation,  the 
results and the associated  findings at each visit will be summarized  by counts and percentages.  
 
All the safety ECG data collected will be listed. 
 
3.4.7 Prior and Concomitant  Medications  
Prior medications include medications started prior to the first dose of study medication 
regardless whether continued while on treatment or not. Concomitant medications include 
medications that patients are expo sed to on or after the first dose of study medication. Partial 
or missing medication  start date or end date will be imputed by the following  imputation  rules: 
 
Start date: 
• If year, month and  day are all missing then assign the  date of first dose of Study Drug 
• If month and day are missing and year is: 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
27  
  
o earlier than the year of the first dose of Study Drug then assign December 31 
o otherwise,  assign January 1 
• If only day is missing and month-year is: 
o earlier than the month-year of the first dose of Study Drug then assign the last day 
of the month  
o otherwise,  assign the first day of the month 
End date: imputation will be performed for the end date only if the day or month is missing 
(i.e., year is present):  
• If month and day are missing, then assign December  31 
• If only day is missing,  then assign  the last day of the month 
If the imputed start date is later than the imputed end date, then set the imputed start date to 
the imputed end date.  
Prior and concomitant  medications  will be coded using WHO Drug dictionary  and 
summarized by ATC class, preferred name and by treatment group and Part.  
 
3.4.8 Angioedema  Activity Score 
The AAS consists of 5 questions as well as an opening question. A score between 0 and 3 is 
assigned to every answer field. The question scores are summed up to an AAS day sum score, 
7 AAS day sum scores to an AAS week  sum score (AAS7), and 4 ASS week sum scores may 
be summed up to an AAS 4 -week sum score (AAS28). Accordingly, the minimum and 
maximum possible AAS scores are 0 -15 (AAS day sum score), 0 -105 (AAS7), and 0 -420 
(AAS28). Missing scores will be imputed using the LOCF method.  
 
The opening question may be used to count the number of angioedema affected days during 
the AAS documentation period b ut has no score.  
The AAS scores will be listed. The AAS 4 -week sum score will also be summarized by 
treatment group and by Part over time. In addition, the AAS 4 -week sum score will be 
analyzed using an ANCOVA  model, including  treatment  group as effect, and baseline AAS 
score as covariate.  
 
3.5 Pharmacokinetic  Analysis  
The plasma pharmacokinetics  of ISIS 721744 (as total full -length oligonucleotides or  ISIS 
721744-equivalent, ISIS 721744 -eq.) will be assessed following SC administration(s).  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
28  
  
3.5.1 Plasma Concentration  Data of Total Full Length Oligonucleotides  
Plasma concentrations  of ISIS 721744  (ISIS 721744  eq.), along with the scheduled  (nominal) 
and actual samples times (i.e., time  from SC dosing)  will be listed (when applicable)  for each 
patient, by treatment group, nominal dose, and day. In addition, percent differences between 
scheduled and actual sampling times will also be listed for all patients. Percent differences 
between actual administered dose and nominal dose will also be listed.  
 
Plasma concentrations below the lower limit of quantification (LLOQ) will be indicated by 
“BLQ”. For the purpose of calculating typical descriptive statistics (n, mean, SD, %CV, 
geometric mean, geometric %CV, median, minimum, and maximum) for plasma 
concentrations, all BLQ values will be set to zero. Mean plasma concentrations that are BLQ 
will be presented  as “BLQ”, and the SD and %CV will be reported as not applicable.  Summary 
statistics of the ISIS 721744 plasma concentrations will be tabulated by treatment group, 
nominal dose, day, and scheduled  time point. At the discretion  of the pharmacokineticist  and/or 
biostatistician,  samples may be excluded from descriptive  statistics if there are large deviations 
between scheduled and actual sampling times,  or large deviations between actual dose and 
nominal dose.  
 
ISIS 721744 eq. plasma concentration versus time (actual) profiles for each patient that 
received ISIS 721744 active treatment, as well as the mean (± SD or SE) plasma 
concentrations  versus time (scheduled)  profiles, will be presented  graphically  on linear and 
semilogarithmic scales. At the discretion of the pharmacokineticist and/or biostatistician, 
samples may be excluded from the mean plots if there are large deviations between 
scheduled and ac tual sampling times.  
 
3.5.2 Plasma Pharmacokinetic  Parameters  
The plasma PK of ISIS 721744 (as total full -length oligonucleotides) will be assessed 
following SC administration. Non -compartmental PK analysis of ISIS 721744 (total full - 
length oligonucleotides)  will be carried out on each individual  subject data set using Phoenix 
WinNonlin version 8.0 or higher (Pharsight Corporation, Mountain View, CA). For 
calculation of PK parameters, all BLQ values will be set to zero. The plasma PK parameters 
for ISIS 721744 -eq. will be calculated based on actual sampling times. The plasma PK 
parameters to be calculated or determined (when applicable) are listed in Table 1. Other 
plasma PK parameters, as appropriate, may be determined or calculated at the discretion of 
the PK scientist. 
 
Table 1 Plasma Pharmacokinetic  Parameters  to be Calculated  or Determined  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
29  
  
Parameter  Definition/Method  Day 1 D85 
Cmax Maximum  observed concentration  X X 
Tmax Observed  time at which Cmax occurs X X 
Tlast Time of last measurable  (positive)  concentration  X X 
AUClast Area under the concentration -time curve  from time zero  to Tlast, calculated 
using linear -up log-down method.  X  
AUC0-t Partial AUC: Area under the concentration -time curve from time zero to time 
t (e.g., t may be 24, 48, 72, 168 hrs or 28 days, as applicable),  calculated using 
linear-up log-down method  X X 
AUCτ Area under the concentration -time curve within the dosing interval (τ) at 
steady-state, calculated using linear -up log-down method   X 
t1/2λz Terminal elimination  half-life determined from  the equation: ln 2/λ z, where λz 
is the first -order rate constant associated with the terminal (log -linear) 
elimination phase. This is estimated via linear regression of time vs. log 
concentration.  A minimum of three data points in the elimination  phase will be 
used to define λz and the correlation  of determination  values (r2) had to be at or 
greater than 0.8 for the estimate to be accepted.   X 
CLss/F Steady-state clearance  divided by F (fraction of the dose absorbed)  determined 
by Dose/AUC τ  X 
CL0-t/F Clearance after first dose divided by F (fraction of the dose absorbed) 
determined by Dose/AUC 0-t X  
Vz/F Volume of distribution  (based on the terminal phase) divided by F (fraction of 
the dose absorbed)   X 
Note: X designates  parameters  to be calculated  or determined  assuming  sufficient  data 
 
Plasma pharmacokinetic  parameters  will be summarized  using descriptive  statistics (n, mean, 
SD, %CV, geometric mean, geometric %CV, median, minimum, and maximum) by 
treatment group, nominal dose, and day. Additionally, the relationship between dose and 
plasma exposure parameters (C max and AUC) of total full -length ASOs (ISIS 721744 -eq.) 
will be evaluated using linear -regression analysis of the  log-transformed mean data. Lastly, 
the relationship between individual subject trough data at selected time points and plasma 
exposure parameters (C max and AUC) will also be evaluated.  
 
3.5.3 Pharmacokinetic/Pharmacodynamic  Exposure -Response  Analysis 
 
Exposure -response correlations  may be explored graphically  between plasma exposure (AUC, 
Cmax, Ctrough, as appropriate), and selected PD measures and outcomes, as well as other 
relevant biomarkers (such as plasma prekallikrein (PKK), etc.). In addition, the relatio nship 
between relevant PD markers and outcomes  and plasma trough concentrations  of ISIS 721744 
will be further evaluated with an inhibitory effect E max model or another exposure -response 
model as appropriate.  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
30  
  
Population  PK and PKPD analysis may be performed  using the PK and PD data from this 
Study, and/or combined  with other ISIS 721744  clinical PK data later in the development 
timeline. 
 
3.4.5 Immunogenicity  (IM) Analysis 
 
Immunogenicity (IM) analyses will be conducted in the Safety Population.  Samples 
collected pre -dose on Days 1, 29 and 57 and anytime on Days 15, 113, and 176, including 
early termination samples for IM assessment, may be analyzed for anti -ISIS 721744 
antibodies (ADA). In addition, plasma samples collected at other t ime points (for PK 
purposes) may also potentially be evaluated if deemed of further interest and warranted by  
the pharmacokinetic scientist.  An evaluable sample will be designated ‘IM positive’ based 
on both positive screening  and confirmation  assay results (i.e., confirmed  positive result), and 
otherwise will be deemed ‘IM negative’. Sample IM results (screen positive/negative, 
confirmed positive/negative or unevaluable, and when applicable, titer of anti -ISIS 721744 
antibodies) before, during, and after t reatment with study drug (ISIS 721744 or placebo) 
(sample IM status) will be listed by treatment and dose. The sample ADA incidence  
(number) and incidence rate (percent) at each evaluated study time point will be determined 
and appropriately summarized by treatment and dose as the total number of and percentage  
of evaluated subjects with sample ADA negative, positive, and unknown status.  
Furthermore,  titer over time will be also appropriately  summarized  (using descriptive 
statistics) as median, quartiles (25% and 75%), and range by treatment and dose.  
 
Study subjects’ overall ADA status will be assigned ‘IM positive’ status if they have at least 
one confirmed positive sample result at any time during the treatment or post -treatment 
evaluation per iods. Study subjects will be assigned ‘IM negative’ status if all evaluated IM 
sample results during the treatment  and post-treatment  evaluation  periods are IM negative and 
they have at least one evaluable IM result collected post study drug treatment. Oth erwise, a 
study subject will be assigned ‘unknown’ IM status. Furthermore, subjects with positive overall  
ADA status will be further classified  into different ADA  types based on their baseline ADA  
status and change in ADA titer post treatment  as described  below (Shankar et al., 2014): 
• Treatment -Emergent  ADA: sum of treatment -induced ADA and treatment -boosted 
ADA as described below:  
o Treatment -Induced ADA: ADA developed de novo (seroconversion) 
following  biologic drug administration  (i.e., formation  of ADA any time after 
the initial drug administration in a subject without pre -existing ADA, i.e., 
baseline negative ADA)  
o Treatment -Boosted ADA: pre -existing ADA that were boosted to a higher 
level following biologic drug administration (i.e., any time after the initial 
drug administration  the ADA titer is greater than the baseline titer by a factor 
of 8-fold or more  
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
31  
  
• Treatment -Unaffected  ADA: pre-existing ADA that were not affected (boosted) 
following biologic drug administration (i.e., any time after the initial drug 
administration the ADA titer is 4 -fold or less)  
• ADA type would be not applicable  (NA) if the subject overall ADA status is 
negative. 
•  
Other subject level IM parameters  to be calculated/defined  may include but not limited to: 
• Subject ADA Status at Baseline: "Positive"  if the subject has Week 1 Day 1 pre-dose 
sample (baseline) tested as confirmed positive; "Negative" if the subject has Week 1 
Day 1 pre -dose sample (baseline) tested as confirmed negative; "Unknown" if the 
subject has Week 1 Day 1 pre -dose sample (baseline) unevaluable.  
• Onset of ADA: i.e., the first day ADA positive sample observed,  will be calculated 
by: the date of first sample has “positive” sample  IM status - first dose date +1  
• Last Positive ADA Study Day: the last positive ADA sample observed from the start 
of study drug treatment and will be calculated by: the date of last sample has 
“positive” sample IM status - first dose date +1  
• Last IM Sampling Study Day :the last ADA sample collected from the start of study 
drug treatment  and will be calculated  by: the date of last sample collected - first dose 
date +1 
• Peak titer: the highest titer observed for the subject 
• Time to peak titer: the time to reach peak titer will be calculated  by: 
the date of first peak titer observed - first dose date +1  
• Total number of ADA Positive Samples: the total number of ADA samples being 
confirmed positive for the subject  
• Total number of ADA Samples evaluated:  the total number of ADA samples being 
collected and analyzed successfully with reportable results for the subject  
 
Other immunogenicity data analysis may be conducted (e.g. classification as transient or 
persistent  status for IM positive subjects) if there are a sufficient  number of subjects with 
transient IM status. Transient and Persistent ADA definitions are defined below: 
Transient ADA response will be defined as:  
• Treatment -induced ADA detected only at one sampling time point during the 
treatment or follow -up observation period (excluding the last sampling time point, 
which will be considered  persistent  unless shown to be undetectable  at a later time) or 
• Treatment -induced ADA detected at two or more sampling time points during the 
treatment (including  follow-up period if any), where the ﬁrst and last ADA-positive 
samples (irrespective  of any negative samples in between) are separated  by a period 
less than 16 weeks, and the subject’s last sampling time point is ADA -negative. 
Ionis Pharmaceuticals,  Inc. 
Statistical Analysis Plan  Feb 17, 2021 
ISIS 721744-CS2 CONFIDENTIAL  
32  
  
Persistent  ADA response will be defined as: 
• Treatment -induced ADA detected at two or more sampling time points during the 
treatment  (including  follow-up period if any), where the ﬁrst and last ADA-positive 
samples (irrespective  of any negative samples in between) are separated  by a period 
of 16 weeks or longer or  
• Treatment -induced ADA detected only at the last sampling time point of the study 
treatment  period or at a sampling time point with less than 16 weeks before an ADA- 
negative last sample.  
 
 
 
The subject level ADA prevalence, incidence, and positive ADA response being transient or 
persistent (if applicable) will be calculated as the number and the proportion (percent) of the 
study population during the study period by treatment and dose. Subjec t level IM parameters 
(as described above) will be listed by treatment and dose for all evaluable subjects, and also 
appropriately summarized (using descriptive statistics) as median, quartiles (25% and 75%) 
and range, by treatment and dose.  
 
In addition t o PK assessments (Section 3.5.2), selected safety (Section 3.4) and PD 
assessments (Section 3.6) may be further stratified by subject IM status (i.e., subject IM 
status being positive, negative or unknown) and presented in tables and/or graphically, as 
deemed appropriate or warranted by the designated study pharmacokineticist, medical 
monitor, and/or biostatistician. Other stratifications (e.g., based on antibody titer, onset of 
ADA, etc.) of selected PK, efficacy and safety assessments  may also be performed  if deemed 
warranted  at the discretion  of the pharmacokineticist,  medical monitor, and/or biostatistician.  